Mylan II B.V. 10-Q 6 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - € / shares	9 Months Ended
	Sep. 30, 2018	Oct. 31, 2018	Dec. 31, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	MYLAN N.V.
Entity Central Index Key	1,623,613
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filler Category	Large Accelerated Filer
Entity Ordinary Shares, Shares Outstanding		515,631,491
Common Stock, Par or Stated Value Per Share	€ 0.01		€ 0.01

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Net sales	$ 2,827.3	$ 2,956.3	$ 8,233.2	$ 8,570.2
Total revenues	2,862.4	2,987.1	8,355.2	8,668.8
Cost of sales	1,823.2	1,809	5,369.2	5,180.3
Gross profit	1,039.2	1,178.1	2,986	3,488.5
Operating expenses:
Research and development	144.1	182.3	555.7	580.9
Selling, general and administrative	577.3	664.1	1,808.1	1,915.4
Litigation settlements and other contingencies, net	(20.4)	15.2	(50.6)	(25.8)
Total operating expenses	701	861.6	2,313.2	2,470.5
Earnings from operations	338.2	316.5	672.8	1,018
Interest expense	136.2	131.8	407.1	406.3
Other expense, net	9.8	5.1	44.3	35.8
Earnings before income taxes	192.2	179.6	221.4	575.9
Income tax provision (benefit)	15.5	91.3	(79.9)	124.2
Net earnings (loss)			301.3	451.7
Net earnings	$ 176.7	$ 88.3	$ 301.3	$ 451.7
Earnings per ordinary share:
Basic (in USD per share)	$ 0.34	$ 0.17	$ 0.59	$ 0.84
Diluted (in USD per share)	$ 0.34	$ 0.16	$ 0.58	$ 0.84
Weighted average ordinary shares outstanding:
Basic	514.5	535.2	514.4	534.9
Diluted	516.5	537	516.5	537
Other Revenues
Revenues:
Total revenues	$ 35.1	$ 30.8	$ 122	$ 98.6

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Comprehensive Earnings - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Document Fiscal Year Focus			2,018
Net earnings	$ 176.7	$ 88.3	$ 301.3	$ 451.7
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment	(270.8)	423	(1,097.6)	1,831.9
Change in unrecognized (loss) gain and prior service cost related to defined benefit plans	(6.8)	1.1	(8.3)	2.4
Net unrealized (loss) gain on marketable securities	0	(8.9)	(0.1)	3.5
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Income tax (benefit) provision	(19.1)	(5.8)	(51.2)	11.3
Other comprehensive (loss) earnings, net of tax	(291.6)	344.4	(1,122.2)	1,652.5
Comprehensive (loss) earnings	(114.9)	432.7	(820.9)	2,104.2
Cash Flow Hedging
Other comprehensive (loss) earnings, before tax:
Net unrecognized gain (loss) on derivatives	(51.9)	(4.5)	(146.1)	29.2
Net Investment Hedging
Other comprehensive (loss) earnings, before tax:
Net unrecognized gain (loss) on derivatives	$ 18.8	$ (72.1)	$ 78.7	$ (203.2)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 449.2	$ 292.1
Accounts receivable, net	2,948.7	3,612.4
Inventories	2,560.6	2,542.7
Prepaid expenses and other current assets	583.2	766.1
Total current assets	6,541.7	7,213.3
Property, plant and equipment, net	2,119.6	2,339.1
Intangible assets, net	14,239	15,245.8
Goodwill	9,796.6	10,205.7
Deferred income tax benefit	514	496.8
Other assets	244.7	305.6
Total assets	33,455.6	35,806.3
Current liabilities:
Accounts payable	1,401.1	1,452.5
Short-term borrowings	0.4	46.5
Income taxes payable	75.7	112.9
Current portion of long-term debt and other long-term obligations	1,176.4	1,808.9
Other current liabilities	2,528.4	2,964.5
Total current liabilities	5,182	6,385.3
Long-term debt	13,291.4	12,865.3
Deferred income tax liability	1,764.4	2,012.4
Other long-term obligations	1,151.6	1,235.7
Total liabilities	21,389.4	22,498.7
Mylan N.V. shareholders’ equity
Ordinary shares — nominal value €0.01 per ordinary share	6	6
Additional paid-in capital	8,585	8,586
Retained earnings	5,965.8	5,644.5
Accumulated other comprehensive loss	(1,490.9)	(361.2)
Total Mylan N.V. equity, before treasury stock	13,065.9	13,875.3
Less: Treasury stock — at cost	999.7	567.7
Total equity	12,066.2	13,307.6
Total liabilities and equity	$ 33,455.6	$ 35,806.3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - € / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Ordinary shares, nominal value	€ 0.01	€ 0.01
Ordinary shares, shares authorized	1,200,000,000	1,200,000,000
Ordinary shares, shares issued	0	536,639,291
Treasury stock, shares	1,311,193	1,311,193

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net earnings	$ 301.3	$ 451.7
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	1,501	1,279.8
Share-based Compensation	(8.6)	64.2
Deferred income tax (benefit) expense	(149.9)	17.4
Loss from equity method investments	58.6	77.2
Other non-cash items	238.3	265.4
Litigation settlements and other contingencies, net	(40.9)	(45.2)
Changes in operating assets and liabilities:
Accounts receivable	262.2	216.2
Inventories	(425.5)	(87.9)
Accounts payable	(14.1)	(187.4)
Income taxes	(97.4)	(149.3)
Other operating assets and liabilities, net	80.6	(332.8)
Net cash provided by operating activities	1,705.6	1,569.3
Cash flows from investing activities:
Cash paid for acquisitions, net	(65.9)	(71.6)
Capital expenditures	(137.4)	(156.4)
Proceeds from the sale of assets	0	31.1
Purchase of available for sale securities and other investments	(49.4)	(8.9)
Proceeds from the sale of marketable securities	72.1	8.9
Payments for product rights and other, net	(854.2)	(558.8)
Net cash used in investing activities	(1,034.8)	(755.7)
Cash flows from financing activities:
Payments of long-term debt	(2,598.6)	(1,747.3)
Purchase of ordinary shares	(432)	0
Change in short-term borrowings, net	(45.9)	(48.3)
Taxes paid related to net share settlement of equity awards	(10.1)	(7.4)
Contingent consideration payments	(0.2)	(10.1)
Payments of financing fees	(20.8)	(8.7)
Proceeds from issuance of long-term debt	2,577.7	555.8
Proceeds from exercise of stock options	15.6	12.8
Other items, net	(0.4)	(0.7)
Net cash used in financing activities	(514.7)	(1,253.9)
Effect on cash of changes in exchange rates	(22.9)	44.1
Net increase (decrease) in cash, cash equivalents and restricted cash	133.2	(396.2)
Cash, cash equivalents and restricted cash — end of period	449.2	614.9
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 503.1	$ 750.8

General

General	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited Condensed Consolidated Financial Statements (“ interim financial statements ”) of Mylan N.V. and subsidiaries (“Mylan” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive earnings, financial position and cash flows for the periods presented. These interim financial statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto in Mylan N.V. ’s Annual Report on Form 10-K for the year ended December 31, 2017 , as amended (the “ 2017 Form 10-K”). The December 31, 2017 Condensed Consolidated Balance Sheet was derived from audited financial statements. The interim results of operations and comprehensive earnings for the three and nine months ended September 30, 2018 , and cash flows for the nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year or any other future period. Certain prior year amounts have been reclassified to conform to the current year presentation.

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606 Revenue from Contracts with Customers (“ASC 606”) using the modified retrospective method applied to those contracts which were not completed as of the date of adoption. Results for reporting periods beginning on January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605 Revenue Recognition (“ASC 605”). Under ASC 605, the Company recognized net sales when title and risk of loss passed to its customers and when provisions for estimates, as described below, were reasonably determinable. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the interim financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). The following briefly describes the nature of our provisions for variable consideration and how such provisions are estimated: • Chargebacks : the Company has agreements with certain indirect customers, such as independent pharmacies, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Mylan will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels. • Rebates, promotional programs and other sales allowances : this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. • Returns : consistent with industry practice, Mylan maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. • Governmental rebate programs : government reimbursement programs include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. Also, includes price reductions that are mandated by law outside of the U.S. Wholesaler and distributor inventory levels of our products can fluctuate throughout the year due to the seasonality of certain products, the timing of product demand and other factors. Such fluctuations may impact the comparability of our net sales between periods. Consideration received from licenses of intellectual property is recorded as revenue. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenue in the Consolidated Statements of Operations. The Company elected to apply the following practical expedients and elections in connection with the adoption of ASC 606: i) taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products, primarily in Europe, are excluded from revenues, and ii) shipping and handling activities are accounted for as fulfillment costs and are recorded in selling, general and administrative expense (“SG&A”). Payment terms related to product sales vary by jurisdiction and customer, but revenue for product sales has not been adjusted for the effects of a financing component as we expect that the period between when we transfer control of the product and when we receive payment to be one year or less. Revenue Disaggregation The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the three and nine months ended September 30, 2018 : (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2018 Central Nervous System & Anesthesia $ 154.7 $ 219.6 $ 92.4 $ 466.7 Infectious Disease 63.1 157.8 223.2 444.1 Respiratory & Allergy 161.8 94.8 47.4 304.0 Cardiovascular 95.9 147.3 40.9 284.1 Gastroenterology 24.5 150.0 91.1 265.6 Diabetes & Metabolism 94.9 73.9 43.8 212.6 Dermatology 86.7 62.8 18.0 167.5 Women’s Healthcare 83.1 61.3 28.1 172.5 Oncology 171.0 18.2 31.9 221.1 Immunology 8.0 2.3 10.0 20.3 Other (1) 68.6 53.3 146.9 268.8 Total $ 1,012.3 $ 1,041.3 $ 773.7 $ 2,827.3 Nine Months Ended September 30, 2018 Central Nervous System & Anesthesia $ 554.2 $ 665.7 $ 251.7 $ 1,471.6 Infectious Disease 172.1 280.5 643.8 1,096.4 Respiratory & Allergy 457.3 351.8 147.7 956.8 Cardiovascular 262.4 443.2 126.6 832.2 Gastroenterology 102.5 448.3 249.3 800.1 Diabetes & Metabolism 318.6 227.9 102.1 648.6 Dermatology 265.7 217.4 70.1 553.2 Women’s Healthcare 261.4 198.1 69.5 529.0 Oncology 382.5 55.4 95.6 533.5 Immunology 36.1 7.3 29.1 72.5 Other (1) 185.6 174.7 379.0 739.3 Total $ 2,998.4 $ 3,070.3 $ 2,164.5 $ 8,233.2 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2018 : (In millions) Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Gross sales $ 4,861.4 $ 14,419.0 Gross to net adjustments: Chargebacks (835.7 ) (2,524.2 ) Rebates, promotional programs and other sales allowances (1,025.6 ) (3,144.2 ) Returns (59.4 ) (160.5 ) Governmental rebate programs (113.4 ) (356.9 ) Total gross to net adjustments $ (2,034.1 ) $ (6,185.8 ) Net sales $ 2,827.3 $ 8,233.2 No significant revisions were made to the methodology used in determining these provisions or the nature of the provisions during the three and nine months ended September 30, 2018 . Such allowances were comprised of the following at September 30, 2018 and December 31, 2017 , respectively: (In millions) September 30, December 31, Accounts receivable, net $ 1,642.2 $ 1,977.2 Other current liabilities 631.9 818.0 Total $ 2,274.1 $ 2,795.2 Accounts receivable, net was comprised of the following at September 30, 2018 and December 31, 2017 , respectively: (In millions) September 30, December 31, Trade receivables, net $ 2,591.0 $ 3,173.1 Other receivables 357.7 439.3 Accounts receivable, net $ 2,948.7 $ 3,612.4 Through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (“MPI”), the Company has access to a $400 million accounts receivable securitization facility (the “Receivables Facility”). The receivables underlying any borrowings are included in accounts receivable, net, in the Condensed Consolidated Balance Sheets . There were $464.0 million and $1.04 billion of securitized accounts receivable at September 30, 2018 and December 31, 2017 , respectively.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Recent Accounting Pronouncements Accounting Standards Issued Not Yet Adopted In August 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2018-14 (“ASU 2018-14”), Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 removes certain disclosures that are not considered cost beneficial, clarifies certain required disclosures and added additional disclosures. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2020 with early adoption in any interim period permitted. The amendments in ASU 2018-14 would need to be applied on a retrospective basis. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , which modifies the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any removed or modified disclosures. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In February 2018, the FASB issued Accounting Standards Update 2018-02, Income Statement - Reporting Comprehensive Income , (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the newly enacted federal corporate income tax rate under the comprehensive tax legislation enacted by the U.S. government on December 22, 2017 commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The amount of the reclassification would be the difference between the historical corporate income tax rate and the newly enacted 21% corporate income tax rate. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2018 with early adoption in any interim period permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (Topic 842) which supersedes FASB Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. In July 2018, the FASB issued Accounting Standards Update 2018-10, Codification Improvements to Topic 842 (Leases) , and Accounting Standards Update 2018-11, Leases (Topic 842), Targeted Improvements , which provide (i) narrow amendments to clarify how to apply certain aspects of the new lease standard, (ii) entities with an additional transition method to adopt the new standard, and (iii) lessors with a practical expedient for separating components of a contract. All Accounting Standards Updates related to Topic 842 will be effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. While the Company is continuing to assess the impact of the adoption of this guidance on its consolidated financial statements and disclosures, we expect that the adoption will result in an increase in total assets and total liabilities. For reference, as disclosed in the 2017 Form 10-K, total undiscounted minimum lease payments remaining at December 31, 2017 were approximately $280 million. In addition, we expect to present additional qualitative and quantitative disclosures. The Company is in the process of analyzing its lease portfolio, implementing systems and processes and updating its accounting policies to comply with Topic 842. Adoption of New Accounting Standards In August 2017, the FASB issued Accounting Standards Update 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The objective of this update is to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The amendments in this update also make certain targeted improvements to simplify the application of the hedge accounting guidance in current U.S. GAAP based on feedback received from preparers, auditors, users, and other stakeholders. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted, including adoption in any interim period. The Company has elected to early adopt this guidance as of January 1, 2018 and is applying it on a prospective basis. Upon adoption, the Company recorded a cumulative effect adjustment. In May 2017, the FASB issued Accounting Standards Update 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”), which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions and classification of the awards are the same immediately before and after the modification. As required, the Company applied the provisions of ASU 2017-09 on a prospective basis as of January 1, 2018 and the adoption did not have a material impact on its condensed consolidated financial statements. In March 2017, the FASB issued Accounting Standards Update 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (“ASU 2017-07”), which requires companies to disaggregate the service cost component from the other components of net benefit cost and disclose the amount of net benefit cost that is included in the income statement or capitalized in assets, by line item. This guidance requires companies to report the service cost component in the same line item(s) as other compensation costs and to report other pension-related costs (which include interest costs, amortization of pension-related costs from prior periods and gains or losses on plan assets) separately and exclude them from the subtotal of operating income. This guidance also allows only the service cost component to be eligible for capitalization when applicable. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. This guidance should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic postretirement benefit cost in the income statement and prospectively, on and after the effective date, for the capitalization of the service cost component of net periodic pension cost and net periodic postretirement benefit in assets. The update allows a practical expedient that permits a company to use the amounts disclosed in its pension and other postretirement plan note for the prior comparative periods as the estimation basis for applying the retrospective presentation requirements. As required, the Company applied the provisions of ASU 2017-07 as of January 1, 2018 and the adoption did not have a material impact on its condensed consolidated financial statements. In November 2016, the FASB issued Accounting Standards Update 2016-18, Statement of Cash Flows (Topic 230) Restricted Cash (“ASU 2016-18”), which requires that the reconciliation of the beginning of period and end of period amounts shown in the statement of cash flows include restricted cash and restricted cash equivalents. If restricted cash is presented separately from cash and cash equivalents on the balance sheet, companies will be required to reconcile the amounts presented on the statement of cash flows to the amounts on the balance sheet. This guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. As required, the Company applied the provisions of ASU 2016-18 as of January 1, 2018. As a result, the change in restricted cash has been excluded from investing activities and included in the change in cash, cash equivalents and restricted cash and the prior year period has been recast to reflect the new presentation. In January 2016, the FASB issued Accounting Standards Update 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”), which supersedes the current guidance to classify equity securities with readily determinable fair values into different categories and requires equity securities to be measured at fair value with changes in the fair value recognized through net income (loss). In February 2018, the FASB issued Accounting Standards Update 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities , which clarifies the guidance in ASU 2016-01. The standards are effective for annual and interim periods beginning after December 15, 2017. As required, the Company applied the provisions of ASU 2016-01 as of January 1, 2018. Upon adoption, the Company recorded a cumulative effect adjustment. In May 2014, the FASB issued Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers (updated with Accounting Standards Update 2015-14, 2016-08, 2016-10, 2016-12 and 2016-20), which revises accounting guidance on revenue recognition that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of this guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This guidance is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years, and can be applied using a full retrospective or modified retrospective approach. The Company adopted this standard and its updates as of January 1, 2018 and elected to apply the modified retrospective transition approach. As a result, the Company is recognizing revenue on certain arrangements upon the transfer of control of product shipments rather than upon sell-through by the customer, and is recording certain costs historically in cost of sales as contra revenue. The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09, ASU 2016-01 and ASU 2017-12 were as follows: (In millions) Balance as of December 31, 2017 Adjustments Due to ASU 2014-09 Adjustments Due to ASU 2016-01 Adjustments Due to ASU 2017-12 Balance as of January 1, 2018 Condensed Consolidated Balance Sheet Assets Prepaid expenses and other current assets $ 766.1 $ 18.5 $ — $ — $ 784.6 Liabilities Deferred income tax liability 2,012.4 5.7 — — 2,018.1 Equity Retained earnings 5,644.5 12.8 10.0 (2.5 ) 5,664.8 Accumulated other comprehensive loss (361.2 ) — (10.0 ) 2.5 (368.7 ) In accordance with ASU 2014-09, the disclosure of the impact of adoption on our condensed consolidated statements of operations and balance sheet was as follows: For the Three Months Ended September 30, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Condensed Consolidated Statement of Operations Revenues $ 2,862.4 $ 2,914.0 $ (51.6 ) Cost of sales 1,823.2 1,876.4 (53.2 ) Income tax provision 15.5 15.0 0.5 Net earnings 176.7 175.6 1.1 For the Nine Months Ended September 30, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Condensed Consolidated Statement of Operations Revenues $ 8,355.2 $ 8,454.0 $ (98.8 ) Cost of sales 5,369.2 5,475.5 (106.3 ) Income tax benefit (79.9 ) (82.3 ) 2.4 Net earnings 301.3 296.2 5.1 September 30, 2018 (In millions) As Reported Balances Without Adoption of ASC 606 Effect of Change Increase (Decrease) Condensed Consolidated Balance Sheet Prepaid expenses and other current assets $ 583.2 $ 575.7 $ 7.5 Income taxes payable 75.7 73.3 2.4 Retained earnings 5,965.8 5,960.7 5.1

Acquisitions and Other Transact

Acquisitions and Other Transactions	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Acquisitions and Other Transactions	Acquisitions and Other Transactions Apicore Inc. On October 3, 2017, the Company completed the acquisition of Apicore, Inc. (“Apicore”), a U.S. based developer and manufacturer of active pharmaceutical ingredient (“API”) for approximately $174.9 million , net of cash acquired, which included estimated contingent consideration of approximately $4.0 million related to the potential $15.0 million payment contingent on the achievement of certain 2017 financial results of the acquired business. As of December 31, 2017 , the contingent consideration liability was zero as Apicore did not achieve the financial results that would have triggered the contingent consideration payment. The allocation of the $174.9 million purchase price to the assets acquired and liabilities assumed for this business is as follows: (In millions) Current assets (net of cash acquired) $ 6.5 Identified intangible assets 121.0 Goodwill 92.2 Other assets 1.9 Total assets acquired 221.6 Current liabilities (4.1 ) Deferred tax liabilities (40.9 ) Other non-current liabilities (1.7 ) Net assets acquired $ 174.9 The acquisition of Apicore added a diversified portfolio of API products to the Company’s existing portfolio. The identified intangible assets of $121.0 million are comprised of product rights and licenses with a weighted average useful life of seven years and includes in-process research and development (“IPR&D”) with a fair value of $9.0 million at the date of the acquisition. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $92.2 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was allocated to the North America segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the three and nine months ended September 30, 2018 and 2017 . Other Transactions On December 25, 2017, the Company entered into an agreement to reacquire certain intellectual property rights and marketing authorizations related to a product commercialized in Japan for $90.0 million , which was paid during the second quarter of 2018. The Company recognized a liability in its Condensed Consolidated Balance Sheet as of December 31, 2017 for the reacquisition of these rights. The Company accounted for this transaction as an asset acquisition and the asset is being amortized over a useful life of five years. On February 28, 2018, the Company and Revance Therapeutics, Inc. (“Revance”) entered into a collaboration agreement (the “Revance Collaboration Agreement”) pursuant to which the Company and Revance will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. Under the Revance Collaboration Agreement, the Company will be primarily responsible for (a) clinical development activities outside of North America (excluding Japan) (the “ex-U.S. Mylan territories”), (b) regulatory activities, and (c) commercialization for any approved product. Revance will be primarily responsible for (a) non-clinical development activities, (b) clinical development activities in North America, and (c) manufacturing and supply of clinical drug substance and drug product; Revance will be solely responsible for an initial portion of non-clinical development costs. The remaining portion of any non-clinical development costs and clinical development costs for obtaining approval in the U.S. and Europe will be shared equally between the parties, and the Company will be responsible for all other clinical development costs and commercialization expenses. Upon closing, Revance received a non-refundable upfront payment of $25.0 million . In addition, under the Revance Collaboration Agreement, Revance can receive potential development milestone payments of up to $100.0 million , in the aggregate, upon the achievement of specified clinical and regulatory milestones and potential tiered sales milestones of up to $225.0 million . In addition, Mylan will pay Revance royalties on sales of the biosimilar in the ex-U.S. Mylan territories. The Company accounted for this transaction as an asset acquisition of IPR&D and the total upfront payment was expensed as a component of research and development (“R&D”) expense. On August 31, 2018, the Company completed an agreement with certain subsidiaries of Novartis AG (“Novartis”) to purchase the worldwide rights to their global cystic fibrosis products consisting of the TOBI Podhaler® and TOBI® solution. Tobramycin is the standard of care for treatment of pseudomonas aeruginosa, a leading driver of infection in cystic fibrosis. These products further strengthen our existing presence in cystic fibrosis, especially with our Creon Franchise in Europe, Australia, Japan and Canada. The asset acquisition allows us to further extend our respiratory franchise into rare/orphan disease indications and broaden our portfolio into dry powdered inhalers and nebulized products. Tobi Podhaler™ is manufactured using a proprietary Pulmosphere technology for which we have acquired exclusive rights for use, hence we expect a high barrier for generic entry. Under the terms of the agreement, Novartis is owed fixed consideration of $463.0 million which consists of $240.0 million which was paid at closing and deferred payments of $130.0 million included in other current liabilities and $93.0 million included in other long-term obligations, due in 2019 and 2020, respectively. Novartis is also eligible to receive a contingent payment of up to $20 million . The Company also entered into a supply agreement with Novartis to purchase the products for up to three years from the date of closing. The Company has recorded a liability of approximately $91 million related to supply obligations. The Company accounted for this transaction as an asset acquisition and recognized an intangible asset for the product rights of $574.8 million . The intangible asset is being amortized over a useful life of ten years . During the nine months ended September 30, 2018, the Company completed four agreements to acquire certain intellectual property rights and marketing authorizations for products that were in the development stage, including agreements with Fujifilm Kyowa Kirin Biologics Co., Ltd., Mapi Pharma Ltd., and Lupin Limited. The Company also completed the acquisition of intellectual property rights and marketing authorizations related to a commercialized product in certain rest of world markets for $220.0 million , of which $160.0 million was paid at closing with the remaining amount due within twelve months of the closing of the transaction and included in other current liabilities. The Company is accounting for these transactions as asset acquisitions and a useful life of five years is being used to amortize the asset related to the commercialized product. The Company recorded expense of approximately $53.7 million as a component of R&D expense related to non-refundable upfront payments for agreements for products in development during the nine months ended September 30, 2018 . Certain of the agreements include additional development and commercial milestones.

Share-Based Incentive Plan

Share-Based Incentive Plan	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Incentive Plan	Share-Based Incentive Plan The Company’s shareholders have approved the 2003 Long-Term Incentive Plan (as amended, the “ 2003 Plan ”). Under the 2003 Plan , 55,300,000 ordinary shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, stock appreciation rights (“SAR”), restricted ordinary shares, restricted stock units, performance awards (“PSU”), other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the ordinary shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three to four years , and generally expire in ten years . Since approval of the 2003 Plan, no further grants of stock options have been made under any other previous plan. The following table summarizes stock option and SAR (together, “stock awards”) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2017 7,198,684 $ 35.17 Granted 847,590 40.92 Exercised (720,226 ) 21.77 Forfeited (286,473 ) 48.37 Outstanding at September 30, 2018 7,039,575 $ 36.69 Vested and expected to vest at September 30, 2018 6,821,737 $ 36.48 Exercisable at September 30, 2018 5,335,545 $ 34.76 As of September 30, 2018 , stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 5.5 years , 5.4 years and 4.4 years , respectively. Also, at September 30, 2018 , stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable each had an aggregate intrinsic value of $41.1 million , $41.1 million and $40.9 million , respectively. A summary of the status of the Company’s nonvested restricted ordinary shares and restricted stock unit awards, including PSUs (collectively, “restricted stock awards”), as of September 30, 2018 and the changes during the nine months ended September 30, 2018 are presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value per Share Nonvested at December 31, 2017 5,964,207 $ 41.92 Granted 1,542,727 41.03 Released (682,557 ) 50.06 Forfeited (257,208 ) 44.88 Nonvested at September 30, 2018 6,567,169 $ 40.79 As of September 30, 2018 , the Company had $99.1 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.6 years . The total intrinsic value of stock awards exercised and restricted stock units released during the nine months ended September 30, 2018 and 2017 was $42.8 million and $34.7 million , respectively. In February 2014, Mylan’s Compensation Committee and the independent members of the Board of Directors adopted the One-Time Special Performance-Based Five-Year Realizable Value Incentive Program (the “2014 Program”) under the 2003 Plan. Under the 2014 Program, certain key employees received a one-time, performance-based incentive award (the “Awards”) either in the form of a grant of SARs or PSUs. The initial Awards were granted in February 2014 and contain a five-year cliff-vesting feature based on the achievement of various performance targets, external market conditions and the employee’s continued services. Additional Awards were granted in 2016 and 2017 and are subject to the same performance conditions as the Awards granted in February 2014 and with a service vesting condition of between two and six years. The market condition was met on June 10, 2015 and is therefore no longer applicable to any of the Awards. During the three months ended June 30, 2018, the Company revised its estimates for the amount of Awards that it expects will ultimately vest under the 2014 Program and recognized a reduction in share-based compensation expense of approximately $23.5 million . During the three months ended September 30, 2018 , the Company determined that it was no longer probable that the minimum performance condition would be met and therefore reversed all of the remaining cumulative expense related to the Awards resulting in a reduction in share-based compensation expense of approximately $47.1 million . In addition, during the three months ended September 30, 2018, the Company recorded $20.0 million of compensation expense as an additional discretionary bonus for a certain group of employees. None of the employees who will receive this bonus are named executive officers. As of September 30, 2018 , there are approximately 2.6 million Awards outstanding under the 2014 Program. Each Award is equal to one ordinary share with the maximum value of each Award upon vesting subject to varying limitations.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	9 Months Ended
	Sep. 30, 2018
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits Disclosure	Pensions and Other Postretirement Benefits Defined Benefit Plans The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. The Company maintains two fully frozen defined benefit pension plans in the U.S., and employees in the U.S. and Puerto Rico are generally provided retirement benefits through defined contribution plans. The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees. Net Periodic Benefit Cost Components of net periodic benefit cost for the three and nine months ended September 30, 2018 and 2017 were as follows: Pension and Other Postretirement Benefits Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Service cost $ 5.0 $ 5.0 $ 15.1 $ 15.1 Interest cost 3.6 3.7 10.9 11.2 Expected return on plan assets (3.6 ) (3.5 ) (10.9 ) (10.6 ) Amortization of prior service costs 0.1 0.1 0.3 0.2 Recognized net actuarial losses 0.1 0.2 0.1 0.5 Net periodic benefit cost $ 5.2 $ 5.5 $ 15.5 $ 16.4 The Company is making the minimum mandatory contributions to its U.S. defined benefit pension plans in the 2018 plan year. The Company expects to make total benefit payments of approximately $31.1 million from pension and other postretirement benefit plans in 2018 . The Company anticipates making contributions to pension and other postretirement benefit plans of approximately $29.9 million in 2018 .

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2018
Balance Sheet Components [Abstract]
Balance Sheet Components	Balance Sheet Components Selected balance sheet components consist of the following: Cash and restricted cash (In millions) September 30, December 31, September 30, Cash and cash equivalents $ 449.2 $ 292.1 $ 614.9 Restricted cash, included in prepaid expenses and other current assets 53.9 77.8 135.9 Cash, cash equivalents and restricted cash $ 503.1 $ 369.9 $ 750.8 Inventories (In millions) September 30, December 31, Raw materials $ 926.0 $ 895.5 Work in process 369.5 384.7 Finished goods 1,265.1 1,262.5 Inventories $ 2,560.6 $ 2,542.7 Prepaid and other current assets (In millions) September 30, December 31, 2017 Prepaid expenses $ 117.1 $ 119.8 Restricted cash 53.9 77.8 Available-for-sale fixed income securities 25.3 31.5 Fair value of financial instruments 7.1 88.9 Equity securities 36.6 79.1 Other current assets 343.2 369.0 Prepaid expenses and other current assets $ 583.2 $ 766.1 Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items. Property, plant and equipment, net (In millions) September 30, December 31, 2017 Machinery and equipment $ 2,365.2 $ 2,414.5 Buildings and improvements 1,170.4 1,191.7 Construction in progress 221.1 252.9 Land and improvements 133.8 143.1 Gross property, plant and equipment 3,890.5 4,002.2 Accumulated depreciation 1,770.9 1,663.1 Property, plant and equipment, net $ 2,119.6 $ 2,339.1 Other assets (In millions) September 30, December 31, 2017 Equity method investments, clean energy investments $ 149.5 $ 226.0 Other long-term assets 95.2 79.6 Other assets $ 244.7 $ 305.6 Accounts payable (In millions) September 30, December 31, Trade accounts payable $ 963.7 $ 976.0 Other payables 437.4 476.5 Accounts payable $ 1,401.1 $ 1,452.5 Other current liabilities (In millions) September 30, December 31, 2017 Accrued sales allowances $ 631.9 $ 818.0 Legal and professional accruals, including litigation accruals 131.4 241.1 Payroll and employee benefit liabilities 372.4 404.6 Contingent consideration 223.3 167.8 Accrued interest 193.8 42.3 Restructuring 80.9 91.5 Equity method investments, clean energy investments 38.1 56.7 Fair value of financial instruments 114.4 31.1 Other 742.2 1,111.4 Other current liabilities $ 2,528.4 $ 2,964.5 In April 2018, the State of New York passed a budget which included the Opioid Stewardship Fund (the “Fund”) pursuant to a law that became effective July 1, 2018. The Fund created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Each licensed manufacturer and distributor will be required to pay a portion of the assessment based on its ratable share, as determined by the state, of the total morphine milligram equivalents first sold or distributed within, or into, New York during the applicable calendar year. The initial payment is due on January 1, 2019 for opioids sold or distributed during calendar year 2017. Based upon initial correspondence received from the State of New York, the Company believes its amount related to the Fund for calendar year 2017 will be immaterial. On March 31, 2017, the Company announced that Meridian Medical Technologies (“Meridian”), a Pfizer company that manufactures the EpiPen® Auto-Injector , expanded a voluntary recall of select lots of EpiPen® Auto-Injector and EpiPen Jr® Auto-Injector to include additional lots distributed in the U.S. and other markets in consultation with the U.S. Food and Drug Administration (“FDA”) (the “ EpiPen® Auto-Injector Recall”). This recall was conducted as a result of the receipt of two previously disclosed reports outside of the U.S. of the failure to activate the device due to a potential defect in a supplier component. Both reports were related to the single lot that was previously recalled. The expanded voluntary recall was initiated in the U.S. and also extends to additional markets in Europe, Asia, North and South America. The Company is replacing recalled devices at no cost to the consumer. Estimated costs to Mylan related to product recalls are based on a formal campaign soliciting return of the product and are accrued when they are deemed to be probable and can be reasonably estimated. As of September 30, 2018 , the Company recorded an accrual for certain costs of the recall but there can be no assurance that future costs related to the recall will not exceed amounts recorded. In addition, Meridian is contractually obligated to reimburse Mylan for costs related to the EpiPen® Auto-Injector Recall, and the Company has recorded an asset for the recovery of such costs. Other long-term obligations (In millions) September 30, December 31, 2017 Employee benefit liabilities $ 411.7 $ 408.2 Contingent consideration 195.5 285.9 Equity method investments, clean energy investments 151.4 171.8 Tax related items, including contingencies 155.6 237.7 Other 237.4 132.1 Other long-term obligations $ 1,151.6 $ 1,235.7

Equity Method Investments

Equity Method Investments	9 Months Ended
	Sep. 30, 2018
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	Equity Method Investments The Company currently has three equity method investments in limited liability companies that own refined coal production plants (the “clean energy investments”) whose activities qualify for income tax credits under Section 45 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Company does not consolidate these entities as we have determined that we are not the primary beneficiary of these entities and do not have the power to individually direct the activities of these entities. Accordingly, these investments are accounted for under the equity method of accounting. For each of the clean energy investments, the Company has entered into notes payable with the respective project sponsor, which in part will be paid to the sponsor as certain production levels are met. During the third quarter of 2018, the Company and a project sponsor agreed to terminate two previous investments. Under the termination agreements, the Company returned its ownership interest in the projects to the sponsor and in exchange the Company will have no further obligations with respect to the notes payable for these projects. Also, during the third quarter of 2018, the Company entered into amended agreements related to the three remaining investments. These amendments effectively reduce the amount of expected future variable debt payments to the respective project sponsor. As a result of these transactions, during the third quarter of 2018, the Company impaired its investment balance and other assets by approximately $39 million and reduced the related long-term obligations for these investments by approximately $40 million resulting in a net gain of approximately $1 million , which was recognized as a component of the net loss of the equity method investments in the Condensed Consolidated Statement of Operations. Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis for the three and nine months ended September 30, 2018 and 2017 are as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Total revenues $ 128.6 $ 129.3 $ 376.8 $ 352.0 Gross loss (1.3 ) (2.4 ) (20.0 ) (8.8 ) Operating and non-operating expense 5.9 6.5 16.5 16.9 Net loss $ (7.2 ) $ (8.9 ) $ (36.5 ) $ (25.7 ) The Company’s net losses from its equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the three months ended September 30, 2018 and 2017 , the Company recognized net losses from equity method investments of $12.6 million and $22.4 million , respectively. For the nine months ended September 30, 2018 and 2017 , the Company recognized net losses from equity method investments of $58.6 million and $77.2 million , respectively, which were recognized as a component of other expense, net in the Condensed Consolidated Statements of Operations . The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.

Earnings per Ordinary Share

Earnings per Ordinary Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings per Ordinary Share	Earnings per Ordinary Share Basic earnings per ordinary share is computed by dividing net earnings by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share is computed by dividing net earnings by the weighted average number of ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive. Basic and diluted earnings per ordinary share are calculated as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions, except per share amounts) 2018 2017 2018 2017 Basic earnings (numerator): Net earnings $ 176.7 $ 88.3 $ 301.3 $ 451.7 Shares (denominator): Weighted average ordinary shares outstanding 514.5 535.2 514.4 534.9 Basic earnings per ordinary share $ 0.34 $ 0.17 $ 0.59 $ 0.84 Diluted earnings (numerator): Net earnings $ 176.7 $ 88.3 $ 301.3 $ 451.7 Shares (denominator): Weighted average ordinary shares outstanding 514.5 535.2 514.4 534.9 Share-based awards 2.0 1.8 2.1 2.1 Total dilutive shares outstanding 516.5 537.0 516.5 537.0 Diluted earnings per ordinary share $ 0.34 $ 0.16 $ 0.58 $ 0.84 Additional stock awards and restricted stock awards were outstanding during the three and nine months ended September 30, 2018 and 2017 , but were not included in the computation of diluted earnings per ordinary share for each respective period because the effect would be anti-dilutive. Excluded shares at September 30, 2018 include certain share-based compensation awards and restricted ordinary shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 9.3 million shares and 8.9 million shares for the three and nine months ended September 30, 2018 , respectively and 8.9 million shares and 8.6 million shares for the three and nine months ended September 30, 2017 , respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the nine months ended September 30, 2018 are as follows: (In millions) North America Segment Europe Segment Rest of World Segment Total Balance at December 31, 2017: Goodwill $ 3,934.6 $ 4,967.1 $ 1,689.0 $ 10,590.7 Accumulated impairment losses (385.0 ) — — (385.0 ) 3,549.6 4,967.1 1,689.0 10,205.7 Foreign currency translation (16.8 ) (255.1 ) (137.2 ) (409.1 ) $ 3,532.8 $ 4,712.0 $ 1,551.8 $ 9,796.6 Balance at September 30, 2018: Goodwill $ 3,917.8 $ 4,712.0 $ 1,551.8 $ 10,181.6 Accumulated impairment losses (385.0 ) — — (385.0 ) $ 3,532.8 $ 4,712.0 $ 1,551.8 $ 9,796.6 Intangible assets consist of the following components at September 30, 2018 and December 31, 2017 : (In millions) Weighted Average Life (Years) Original Cost Accumulated Amortization Net Book Value September 30, 2018 Product rights, licenses and other (1) 15 $ 20,407.7 $ 6,857.5 $ 13,550.2 In-process research and development 688.8 — 688.8 $ 21,096.5 $ 6,857.5 $ 14,239.0 December 31, 2017 Product rights, licenses and other (1) 15 $ 20,338.7 $ 5,906.1 $ 14,432.6 In-process research and development 813.2 — 813.2 $ 21,151.9 $ 5,906.1 $ 15,245.8 ____________ (1) Represents amortizable intangible assets. Other intangible assets consists principally of customer lists and contractual rights. In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus and Seretide® Diskus incorporating Pfizer Inc.’s proprietary dry powder inhaler delivery platform (the “respiratory delivery platform”). The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. As of September 30, 2018 , the Company has an IPR&D asset of $347.2 million and a related contingent consideration liability of $326.6 million . The Company performed an analysis and valuation of the IPR&D asset and the fair value of the related contingent consideration liability using a discounted cash flow model. The model contained certain key assumptions including: the expected product launch date, the number of competitors, the timing of competition and a discount factor based on an industry specific weighted average cost of capital. Based on the analysis performed, the Company determined that the fair value of the IPR&D asset was substantially in excess of its carrying value, and the asset was not impaired at September 30, 2018 . Additionally, fair value adjustments of $19.3 million and $49.3 million were recorded for the three and nine months ended September 30, 2018 , respectively, to reduce the contingent consideration liability. The fair value of the contingent consideration liability was determined based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 11 - Financial Instruments and Risk Management . Resolution of the matters with the FDA, market conditions and other factors may result in significant future changes in the projections and assumptions utilized in the discounted cash flow model, which could lead to material adjustments to the amounts recorded for IPR&D and contingent consideration. During the three and nine months ended September 30, 2018 , the Company recognized impairment charges of $15.5 million and $87.5 million , respectively, which has been recorded as a component of amortization expense, for the impairment of certain IPR&D assets. The impairment charge recorded during the third quarter of 2018 related to certain assets acquired as part of the acquisition of Agila Specialties Private Limited (“Agila”). The remaining impairment charges during the nine months ended September 30, 2018 related to certain assets acquired as part of the acquisition of the non-sterile, topicals-focused business (the “Topicals Business”) of Renaissance Acquisition Holdings, LLC. The impairment charges resulted from the Company’s updated estimate of the fair value of certain assets, which were based upon revised forecasts and future development plans. The Company performed its annual impairment testing of IPR&D assets acquired as part of the Topicals Business acquisition during the three months ended June 30, 2018. The impairment testing involved calculating the fair value of the assets based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 11 - Financial Instruments and Risk Management . These valuations reflect, among other things, the impact of changes to the development programs, the projected development and regulatory time frames and the current competitive environment. Changes in any of the Company’s assumptions may result in a further reduction to the estimated fair values of these IPR&D assets and could result in additional future impairment charges. The Company has performed its annual goodwill impairment test as of April 1, 2018 on a quantitative basis for its four reporting units, North America Generics, North America Brands, Europe and Rest of World. In estimating each reporting unit’s fair value, the Company performed an extensive valuation analysis, utilizing both income and market-based approaches, except for the North America Brands reporting unit where the fair value was estimated utilizing the income approach. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 inputs, primarily include, but are not limited to, market multiples, control premiums, the discount rate, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts. Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as it relates to the key assumptions detailed, could have a significant impact on the fair value of the reporting units. As of the date of our annual impairment test, the allocation of the Company’s total goodwill was as follows: North America Generics $2.89 billion , North America Brands $0.66 billion , Europe $4.97 billion and Rest of World $1.80 billion . The fair value of the North America Generics, North America Brands and Rest of World reporting units was substantially in excess of the respective unit’s carrying value. For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $800 million or 6.0% . The excess fair value for the Europe reporting unit is consistent with the result of the Company’s 2017 annual impairment test. As it relates to the income approach for the Europe reporting unit at April 1, 2018 , the Company forecasted cash flows for the next 5 years. During the forecast period, the revenue compound annual growth rate was approximately 3.5% . A terminal value year was calculated with a 2% revenue growth rate applied. The discount rate utilized was 9.0% and the estimated tax rate was 24.0% . Under the market-based approach, we utilized an estimated range of market multiples of 9.0 to 10.5 times EBITDA plus a control premium of 15.0% . If all other assumptions are held constant, a reduction in the terminal value growth rate by 2.0% or an increase in discount rate by 1.5% would result in an impairment charge for the Europe reporting unit. Amortization expense, which is classified primarily within cost of sales in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017 totaled: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Intangible asset amortization expense $ 412.2 $ 369.4 $ 1,191.9 $ 1,052.6 Intangible asset impairment charges 15.5 — 87.5 13.0 Total Intangible asset amortization expense (including impairment charges) $ 427.7 $ 369.4 $ 1,279.4 $ 1,065.6 Intangible asset amortization expense over the remainder of 2018 and for the years ended December 31, 2019 through 2022 is estimated to be as follows: (In millions) 2018 $ 383 2019 1,446 2020 1,283 2021 1,203 2022 1,137

Financial Instruments and Risk

Financial Instruments and Risk Management	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Financial Instruments and Risk Management The Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk. Foreign Currency Risk Management In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities on the Condensed Consolidated Balance Sheets . Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the Condensed Consolidated Statements of Operations . The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities on the Condensed Consolidated Balance Sheets . Any changes in the fair value of designated cash flow hedges are deferred in accumulated other comprehensive earnings (“AOCE”) and are reclassified into earnings when the hedged item impacts earnings. Net Investment Hedges The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments. The Company has designated certain Euro borrowings as a hedge of its investment in certain Euro-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro borrowings not designated as net investment hedges through certain Euro denominated financial assets and forward currency swaps. The following table summarizes the principal amounts of the Company’s outstanding Euro borrowings and the notional amounts of the Euro borrowings designated as net investment hedges: Notional Amount Designated as a Net Investment Hedge (in millions) Principal Amount September 30, December 31, 2.250% Euro Senior Notes due 2024 € 1,000.0 € 1,000.0 € 1,000.0 3.125% Euro Senior Notes due 2028 750.0 750.0 750.0 1.250% Euro Senior Notes due 2020 750.0 104.0 104.0 2.125% Euro Senior Notes due 2025 500.0 500.0 — Floating Rate Euro Notes due 2018 500.0 — — Floating Rate Euro Notes due 2020 500.0 — — Total € 4,000.0 € 2,354.0 € 1,854.0 Interest Rate Risk Management The Company enters into interest rate swaps in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the Condensed Consolidated Balance Sheets . For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings. Credit Risk Management The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the Condensed Consolidated Balance Sheets . Accordingly, there are no offsetting amounts that net assets against liabilities. The Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Designated as Hedging Instruments Asset Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Prepaid expenses and other current assets $ — Prepaid expenses and other current assets $ 16.2 Foreign currency forward contracts Prepaid expenses and other current assets — Prepaid expenses and other current assets 63.4 Total $ — $ 79.6 Liability Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Other current liabilities $ 11.1 Other current liabilities $ — Foreign currency forward contracts Other current liabilities 76.8 Other current liabilities — Total $ 87.9 $ — The Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated as Hedging Instruments Asset Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Prepaid expenses and other current assets $ 7.1 Prepaid expenses and other current assets $ 9.3 Total $ 7.1 $ 9.3 Liability Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 26.5 Other current liabilities $ 31.1 Total $ 26.5 $ 31.1 The Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships Location of Gain (Loss) Recognized in Earnings on Derivatives Amount of Gain (Loss) Recognized in Earnings on Derivatives (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Interest rate swaps Interest expense $ (5.0 ) $ (2.5 ) $ (27.3 ) $ (1.0 ) Total $ (5.0 ) $ (2.5 ) $ (27.3 ) $ (1.0 ) Location of Gain (Loss) Recognized in Earnings on Hedged Items Amount of Gain (Loss) Recognized in Earnings on Hedged Items (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 2023 Senior Notes (3.125% coupon) Interest expense $ 5.0 $ 2.5 $ 27.3 $ 1.0 Total $ 5.0 $ 2.5 $ 27.3 $ 1.0 The Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency forward contracts $ (33.9 ) $ (8.8 ) $ (87.7 ) $ 7.5 Interest rate swaps — (3.3 ) — (2.0 ) Total $ (33.9 ) $ (12.1 ) $ (87.7 ) $ 5.5 The Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationships Amount of Gain (Loss) Recognized in AOCE Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency borrowings and forward contracts $ 17.9 $ (72.1 ) $ 77.7 $ (203.2 ) Total $ 17.9 $ (72.1 ) $ 77.7 $ (203.2 ) The Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships Location of Gain (Loss) Reclassified from AOCE into Earnings (Effective Portion) Amount of Gain (Loss) Reclassified from AOCE into Earnings Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency forward contracts Net sales $ 0.9 $ 2.0 $ 8.1 $ (3.8 ) Interest rate swaps Interest expense (1.9 ) (1.9 ) (5.7 ) (5.5 ) Total $ (1.0 ) $ 0.1 $ 2.4 $ (9.3 ) Location of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness Amount of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency forward contracts Other expense, net $ — $ 3.3 $ — $ 6.9 Total $ — $ 3.3 $ — $ 6.9 At September 30, 2018 , the Company expects that approximately $85 million of pre-tax net losses on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months . The Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments Location of Gain (Loss) Recognized in Earnings on Derivatives Amount of Gain (Loss) Recognized in Earnings on Derivatives Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency option and forward contracts Other expense, net $ (25.1 ) $ (43.0 ) $ 2.5 $ (60.1 ) Total $ (25.1 ) $ (43.0 ) $ 2.5 $ (60.1 ) Fair Value Measurement Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. The Company recognized unrealized gains of $1.3 million and unrealized losses of $7.8 million during the three months ended September 30, 2018 and September 30, 2017 , respectively, and unrealized gains of $2.0 million and $6.6 million during the nine months ended September 30, 2018 and September 30, 2017 , respectively, attributable to the changes in fair value of equity securities. Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: September 30, 2018 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 27.5 $ — $ — $ 27.5 Total cash equivalents 27.5 — — 27.5 Equity securities: Exchange traded funds 35.7 — — 35.7 Marketable securities 0.9 — — 0.9 Total equity securities 36.6 — — 36.6 Available-for-sale fixed income investments: Corporate bonds — 10.4 — 10.4 U.S. Treasuries — 8.7 — 8.7 Agency mortgage-backed securities — 1.7 — 1.7 Asset backed securities — 3.2 — 3.2 Other — 1.3 — 1.3 Total available-for-sale fixed income investments — 25.3 — 25.3 Foreign exchange derivative assets — 7.1 — 7.1 Total assets at recurring fair value measurement $ 64.1 $ 32.4 $ — $ 96.5 Financial Liabilities Interest rate swap derivative liabilities $ — $ 11.1 $ — $ 11.1 Foreign exchange derivative liabilities — 103.3 — 103.3 Contingent consideration — — 418.8 418.8 Total liabilities at recurring fair value measurement $ — $ 114.4 $ 418.8 $ 533.2 December 31, 2017 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 8.4 $ — $ — $ 8.4 Total cash equivalents 8.4 — — 8.4 Equity securities: Exchange traded funds 33.9 — — 33.9 Marketable securities 45.2 — — 45.2 Total equity securities 79.1 — — 79.1 Available-for-sale fixed income investments: Corporate bonds — 16.5 — 16.5 U.S. Treasuries — 7.4 — 7.4 Agency mortgage-backed securities — 4.1 — 4.1 Asset backed securities — 2.1 — 2.1 Other — 1.4 — 1.4 Total available-for-sale fixed income investments — 31.5 — 31.5 Foreign exchange derivative assets — 72.7 — 72.7 Interest rate swap derivative assets — 16.2 — 16.2 Total assets at recurring fair value measurement $ 87.5 $ 120.4 $ — $ 207.9 Financial Liabilities Foreign exchange derivative liabilities $ — $ 31.1 $ — $ 31.1 Contingent consideration — — 453.7 453.7 Total liabilities at recurring fair value measurement $ — $ 31.1 $ 453.7 $ 484.8 For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities: • Cash equivalents — valued at observable net asset value prices. • Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the Condensed Consolidated Statements of Operations . • Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the Condensed Consolidated Statements of Operations . • Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity. • Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions. • Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions. Contingent Consideration The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for the respiratory delivery platform, the acquisition of Agila , the acquisition of certain female healthcare businesses from Famy Care Limited (such businesses “Jai Pharma Limited”) and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions. For the respiratory delivery platform, Jai Pharma Limited and certain other acquisitions, significant unobservable inputs in the valuation include the probability and timing of future development and commercial milestones and future profit sharing payments. When valuing the contingent consideration related to the respiratory delivery platform and Jai Pharma Limited, the value of the obligations is derived from a probability assessment based on expectations of when certain milestones or profit share payments occur which are discounted using a market rate of return. At September 30, 2018 and December 31, 2017 , discount rates ranging from 2.1% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability. A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2017 to September 30, 2018 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2017 $ 167.8 $ 285.9 $ 453.7 Payments (1.1 ) — (1.1 ) Reclassifications 53.6 (53.6 ) — Accretion — 15.1 15.1 Fair value adjustments (3) 3.0 (51.9 ) (48.9 ) Balance at September 30, 2018 $ 223.3 $ 195.5 $ 418.8 ____________ (1) Included in other current liabilities on the Condensed Consolidated Balance Sheets. (2) Included in other long-term obligations on the Condensed Consolidated Balance Sheets. (3) Included in litigation settlements and other contingencies, net in the Condensed Consolidated Statements of Operations. 2018 Significant Changes to Contingent Consideration: During the three and nine months ended September 30, 2018 , the Company recorded fair value gains of $19.3 million and $49.3 million , respectively, related to the respiratory delivery platform contingent consideration. Although the Company has not elected the fair value option for other financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election.

Debt

Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt	Debt Short-Term Borrowings (In millions) September 30, December 31, Receivables Facility $ — $ 45.0 Other 0.4 1.5 Short-term borrowings $ 0.4 $ 46.5 The Receivables Facility matures in January 2019. On July 27, 2018, the Company established an unsecured commercial paper program (the “Commercial Paper Program”) pursuant to which Mylan Inc. may issue short-term, unsecured commercial paper notes (the “CP Notes”) that are guaranteed by the Company pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), which replaced Mylan N.V.’s existing commercial paper program established June 8, 2017 (the “Existing Commercial Paper Program”) on substantially identical terms to the Existing Commercial Paper Program. Amounts available under the Commercial Paper Program may be borrowed, repaid and re-borrowed from time to time, with the aggregate principal amount of the commercial paper notes outstanding under the Commercial Paper Program at any time not to exceed $1.65 billion . The net proceeds of issuances of the CP Notes are expected to be used for general corporate purposes. The Company’s 2018 Revolving Facility (as defined below) will be available to pay the CP Notes, if necessary. The maturities of the CP Notes will vary but will not exceed 364 days from the date of issue. The Company uses net proceeds from its Commercial Paper Program and the Receivables Facility as a source of liquidity for general corporate purposes, including for business development transactions, working capital and share repurchases. Commercial paper borrowings and the Receivables Facility may vary during a particular period, as a result of fluctuations in working capital requirements and timing of cash receipts. Long-Term Debt A summary of long-term debt is as follows: (In millions) Interest Rate as of September 30, 2018 September 30, December 31, Current portion of long-term debt: 2018 Senior Notes * 2.600 % $ — $ 649.9 2018 Floating Rate Euro Notes (a) ** 580.2 600.2 2018 Senior Notes ** 3.000 % — 499.8 2019 Senior Notes ** 2.500 % 549.9 — Other 6.3 2.4 Deferred financing fees (0.8 ) (3.1 ) Current portion of long-term debt $ 1,135.6 $ 1,749.2 Non-current portion of long-term debt: 2016 Term Facility (b) ** 3.617 % 100.0 100.0 2019 Senior Notes ** 2.500 % — 999.5 2019 Senior Notes * 2.550 % — 499.7 2020 Floating Rate Euro Notes (c) ** 580.2 600.2 2020 Euro Senior Notes ** 1.250 % 868.4 897.6 2020 Senior Notes ** 3.750 % 499.9 499.9 2021 Senior Notes ** 3.150 % 2,248.5 2,248.2 2023 Senior Notes * 3.125 % 738.2 765.4 2023 Senior Notes * 4.200 % 498.9 498.8 2024 Euro Senior Notes ** 2.250 % 1,158.1 1,197.7 2025 Euro Senior Notes * 2.125 % 578.9 — 2026 Senior Notes ** 3.950 % 2,236.1 2,235.0 2028 Euro Senior Notes ** 3.125 % 862.7 892.0 2028 Senior Notes * 4.550 % 748.2 — 2043 Senior Notes * 5.400 % 497.1 497.1 2046 Senior Notes ** 5.250 % 999.8 999.8 2048 Senior Notes * 5.200 % 747.6 — Other 5.9 6.3 Deferred financing fees (77.1 ) (71.9 ) Long-term debt $ 13,291.4 $ 12,865.3 ____________ (a) Instrument bears interest at a rate of three-month EURIBOR plus 0.870% per annum, reset quarterly. (b) The 2016 Term Facility bears interest at LIBOR plus a base rate, which margins can fluctuate based on the Company’s credit ratings. (c) Instrument bears interest at a rate of three-month EURIBOR plus 0.50% per annum, reset quarterly. * Instrument was issued by Mylan Inc. ** Instrument was issued by Mylan N.V. For additional information, see Note 8 Debt in Mylan N.V. ’s 2017 Form 10-K. 2016 Revolving Facility, 2018 Revolving Facility and 2016 Term Facility On November 22, 2016, the Company entered into a revolving credit facility among the Company, as borrower, Mylan Inc., as a guarantor, certain lenders and issuing banks and Bank of America, N.A., as the administrative agent, pursuant to which the Company may obtain extensions of credit in an aggregate principal amount not to exceed $2.0 billion (the “2016 Revolving Facility”). On the same day, the Company entered into a term credit facility among the Company, as borrower, Mylan Inc., as a guarantor, certain lenders and Goldman Sachs Bank USA, as administrative agent, pursuant to which the Company has outstanding $100.0 million in term loans (the “2016 Term Facility”) at September 30, 2018 . On July 27, 2018, the Company entered into a revolving credit facility among Mylan Inc., as borrower, the Company, as a guarantor, certain lenders and issuing banks and Bank of America, N.A., as the administrative agent, which replaced the 2016 Revolving Facility on substantially identical terms to the 2016 Revolving Facility and pursuant to which Mylan Inc. may obtain extensions of credit in an aggregate principal amount not to exceed $2.0 billion (the “2018 Revolving Facility”). The 2016 Term Facility and 2016 Revolving Facility contain a maximum consolidated leverage ratio financial covenant requiring maintenance of a maximum ratio of 3.75 to 1.00 for consolidated total indebtedness as of the end of any quarter to consolidated EBITDA for the trailing four quarters as defined in the related credit agreements (“leverage ratio”). Following the acquisition of Meda AB (publ.) (“Meda”) (a qualifying acquisition), the leverage ratio changed to 4.25 to 1.00 through June 30, 2017. On November 3, 2017 , the Company entered into an amendment to the agreements for the 2016 Term Facility and 2016 Revolving Facility to extend the leverage ratio covenant of 4.25 to 1.00 through the December 31, 2018 reporting period. The 2018 Revolving Facility similarly provides for a leverage ratio covenant of 4.25 to 1.00 through the December 31, 2018 reporting period and a leverage ratio of 3.75 to 1.00 thereafter. The Company is in compliance at September 30, 2018 and expects to remain in compliance for the next twelve months. April 2018 Senior Notes Offering The following table provides the amounts of senior unsecured debt issued by Mylan Inc., and guaranteed by Mylan N.V., on April 9, 2018 (the “April 2018 Senior Notes”). The April 2018 Senior Notes were issued pursuant to an indenture dated April 9, 2018. The April 2018 Senior Notes were issued in a private offering exempt from the registration requirements of the Securities Act to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to persons outside of the U.S. pursuant to Regulation S under the Securities Act. The Company has entered into a registration rights agreement, dated as of April 9, 2018 pursuant to which Mylan Inc. and Mylan N.V. are required to use commercially reasonable efforts to file a registration statement with respect to an offer to exchange each series of the April 2018 Senior Notes for new notes with the same aggregate principal amount and terms substantially identical in all material respects. (In millions) Interest Rate Principal Amount 2028 Senior Notes (1) 4.550 % $ 750.0 2048 Senior Notes (1) 5.200 % 750.0 Total April 2018 Senior Notes $ 1,500.0 ____________ (1) Redeemable, in whole or in part, at our option at any time prior to three months (in the case of the 2028 Senior Notes) or six months (in the case of the 2048 Senior Notes) of the maturity date at the greater of 100% of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus an incremental spread of 0.30% (in the case of the 2028 Senior Notes) or 0.35% (in the case of the 2048 Senior Notes), plus, in each case, accrued and unpaid interest. On April 28, 2018, the Company redeemed all of the outstanding $650 million principal amount of Mylan Inc.’s 2.600% senior notes due 2018, all of the outstanding $500 million principal amount of Mylan N.V.’s 3.000% senior notes due 2018 and $350 million of the outstanding $500 million principal amount of Mylan Inc.’s 2.550% senior notes due 2019. The redemption of these notes was funded with the net proceeds from the April 2018 Senior Notes offering. May 2018 Euro Senior Notes Offering On May 23, 2018, Mylan Inc. completed the offering of €500 million aggregate principal amount of its 2.125% Euro Senior Notes due 2025 (the “May 2018 Euro Senior Notes”). The May 2018 Euro Senior Notes were issued pursuant to an indenture dated May 23, 2018. The May 2018 Euro Senior Notes are guaranteed by Mylan N.V. and were issued in a private offering exempt from the registration requirements of the Securities Act, to persons outside of the United States pursuant to Regulation S under the Securities Act. The May 2018 Euro Notes are redeemable, in whole or in part, at our option at any time prior to three months of the maturity date at the greater of 100% of the principal amount or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the applicable Bund Rate plus an incremental spread of 0.30% , plus, in each case, accrued and unpaid interest. On June 15, 2018, the Company redeemed the remaining $150 million outstanding principal amount of Mylan Inc.’s 2.550% Senior Notes due 2019 and $450 million of the outstanding $1.0 billion principal amount of Mylan N.V.’s 2.500% Senior Notes due 2019. The redemption of these notes was funded with the net proceeds from the May 2018 Euro Senior Notes offering. Fair Value At September 30, 2018 and December 31, 2017 , the fair value of the Company’s 2.500% Senior Notes due 2019, 3.750% Senior Notes due 2020, 3.150% Senior Notes due 2021, 3.125% Senior Notes due 2023, 4.200% Senior Notes due 2023, 3.950% Senior Notes due 2026, 4.550% Senior Notes due 2028, 5.400% Senior Notes due 2043, 5.250% Senior Notes due 2046 and 5.200% Senior Notes due 2048 (collectively, the “Senior Notes”), 1.250% Euro Senior Notes due 2020, 2.250% Euro Senior Notes due in 2024, 2.125% Euro Senior Notes due in 2025, 3.125% Euro Senior Notes due in 2028, 2018 Floating Rate Euro Notes and 2020 Floating Rate Euro Notes (collectively, the “Euro Notes”) was approximately $14.1 billion and $14.9 billion , respectively. The fair values of the Senior Notes and Euro Notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value hierarchy. Based on quoted market rates of interest and maturity schedules of similar debt issues, the fair value of the Company’s 2016 Term Facility determined based on Level 2 inputs, approximates its carrying value at September 30, 2018 and December 31, 2017 . Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at September 30, 2018 were as follows for each of the periods ending December 31: (In millions) Total 2018 $ 580 2019 650 2020 1,951 2021 2,250 2022 — Thereafter 9,111 Total $ 14,542

Comprehensive Earnings

Comprehensive Earnings	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Comprehensive Earnings	Comprehensive Earnings Accumulated other comprehensive loss, as reflected on the Condensed Consolidated Balance Sheets , is comprised of the following: (In millions) September 30, December 31, Accumulated other comprehensive loss: Net unrealized gain on marketable securities, net of tax $ — $ 10.1 Net unrecognized (losses) gains and prior service cost related to defined benefit plans, net of tax (0.5 ) 6.0 Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax (96.9 ) (3.7 ) Net unrecognized losses on derivatives in net investment hedging relationships, net of tax (162.1 ) (239.8 ) Foreign currency translation adjustment (1,231.4 ) (133.8 ) $ (1,490.9 ) $ (361.2 ) Components of accumulated other comprehensive loss, before tax, consist of the following, for the three and nine months ended September 30, 2018 and 2017 : Three Months Ended September 30, 2018 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2018, net of tax $ (63.0 ) $ (180.0 ) $ — $ 4.3 $ (960.6 ) $ (1,199.3 ) Other comprehensive (loss) earnings before reclassifications, before tax (52.9 ) 18.8 — (7.0 ) (270.8 ) (311.9 ) Amounts reclassified from accumulated other comprehensive loss, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (0.9 ) (0.9 ) (0.9 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.9 1.9 1.9 Amortization of prior service costs included in SG&A 0.1 0.1 Amortization of actuarial loss included in SG&A 0.1 0.1 Net other comprehensive (loss) earnings, before tax (51.9 ) 18.8 — (6.8 ) (270.8 ) (310.7 ) Income tax (benefit) provision (18.0 ) 0.9 — (2.0 ) — (19.1 ) Balance at September 30, 2018, net of tax $ (96.9 ) $ (162.1 ) $ — $ (0.5 ) $ (1,231.4 ) $ (1,490.9 ) Nine Months Ended September 30, 2018 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2017, net of tax $ (3.7 ) $ (239.8 ) $ 10.1 $ 6.0 $ (133.8 ) $ (361.2 ) Other comprehensive (loss) earnings before reclassifications, before tax (143.7 ) 78.7 (0.1 ) (8.7 ) (1,097.6 ) (1,171.4 ) Amounts reclassified from accumulated other comprehensive loss, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (8.1 ) (8.1 ) (8.1 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 5.7 5.7 5.7 Amortization of prior service costs included in SG&A 0.3 0.3 Amortization of actuarial loss included in SG&A 0.1 0.1 Net other comprehensive (loss) earnings, before tax (146.1 ) 78.7 (0.1 ) (8.3 ) (1,097.6 ) (1,173.4 ) Income tax (benefit) provision (50.4 ) 1.0 — (1.8 ) — (51.2 ) Cumulative effect of the adoption of new accounting standards 2.5 — (10.0 ) — — (7.5 ) Balance at September 30, 2018, net of tax $ (96.9 ) $ (162.1 ) $ — $ (0.5 ) $ (1,231.4 ) $ (1,490.9 ) Three Months Ended September 30, 2017 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2017, net of tax $ (17.1 ) $ (132.5 ) $ 22.3 $ 0.5 $ (828.8 ) $ (955.6 ) Other comprehensive (loss) earnings before reclassifications, before tax (4.4 ) (72.1 ) (8.9 ) 0.8 423.0 338.4 Amounts reclassified from accumulated other comprehensive loss, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (2.0 ) (2.0 ) (2.0 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.9 1.9 1.9 Amortization of prior service costs included in SG&A 0.1 0.1 Amortization of actuarial loss included in SG&A 0.2 0.2 Net other comprehensive (loss) earnings, before tax (4.5 ) (72.1 ) (8.9 ) 1.1 423.0 338.6 Income tax (benefit) provision (2.8 ) — (3.2 ) 0.2 — (5.8 ) Balance at September 30, 2017, net of tax $ (18.8 ) $ (204.6 ) $ 16.6 $ 1.4 $ (405.8 ) $ (611.2 ) Nine Months Ended September 30, 2017 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2016, net of tax $ (38.6 ) $ (1.4 ) $ 14.5 $ (0.5 ) $ (2,237.7 ) $ (2,263.7 ) Other comprehensive earnings (loss) before reclassifications, before tax 19.9 (203.2 ) 3.5 1.7 1,831.9 1,653.8 Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales 3.8 3.8 3.8 Loss on interest rate swaps classified as cash flow hedges, included in interest expense 5.5 5.5 5.5 Amortization of prior service costs included in SG&A 0.2 0.2 Amortization of actuarial gain included in SG&A 0.5 0.5 Net other comprehensive earnings (loss), before tax 29.2 (203.2 ) 3.5 2.4 1,831.9 1,663.8 Income tax provision 9.4 — 1.4 0.5 — 11.3 Balance at September 30, 2017, net of tax $ (18.8 ) $ (204.6 ) $ 16.6 $ 1.4 $ (405.8 ) $ (611.2 )

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity A summary of the changes in shareholders’ equity for the nine months ended September 30, 2018 and 2017 is as follows: (In millions) Total December 31, 2017 $ 13,307.6 Net earnings 301.3 Other comprehensive loss, net of tax (1,122.2 ) Stock option activity 15.4 Ordinary share repurchase (432.0 ) Share-based compensation expense (8.6 ) Issuance of restricted stock, net of shares withheld (8.1 ) Cumulative effect of the adoption of new accounting standards 12.8 September 30, 2018 $ 12,066.2 (In millions) Total Noncontrolling Interest Total December 31, 2016 $ 11,116.2 $ 1.4 $ 11,117.6 Net earnings 451.7 — 451.7 Other comprehensive earnings, net of tax 1,652.5 — 1,652.5 Stock option activity 12.8 — 12.8 Share-based compensation expense 64.2 — 64.2 Issuance of restricted stock, net of shares withheld (5.8 ) — (5.8 ) Other — (1.4 ) (1.4 ) September 30, 2017 $ 13,291.6 $ — $ 13,291.6

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Information	Segment Information Mylan reports segment information on a geographic basis. This approach reflects the company’s focus on bringing its broad and diversified portfolio of generic, branded generic, brand-name and over-the-counter products to people in markets everywhere. Our North America segment comprises our operations in the U.S. and Canada. Our Europe segment comprises our operations in more than 35 countries, including France, Italy, Germany, the U.K. and Spain. Our Rest of World segment reflects our operations in more than 120 countries, including Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle East and Southeast Asia. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct R&D and direct SG&A. Certain general and administrative and R&D expenses not allocated to the segments, including certain special items, net charges for litigation settlements and other contingencies, amortization of intangible assets, impairment charges and other expenses not directly attributable to the segments are reported separately or outside of segment profitability. Items below the earnings from operations line on the Company’s Condensed Consolidated Statements of Operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company has revised segment profitability for Rest of World to conform with the current presentation by reclassifying approximately $78.2 million of net gains to litigation settlements and other contingencies for the nine months ended September 30, 2017 . The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Revenue Recognition and Accounts Receivable above and the “Summary of Significant Accounting Policies” included in the 2017 Form 10-K. Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level. Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2018 Net sales $ 1,012.3 $ 1,041.3 $ 773.7 $ — $ 2,827.3 Other revenue 20.9 7.4 6.8 — 35.1 Intersegment revenue 19.5 23.2 97.3 (140.0 ) — Total $ 1,052.7 $ 1,071.9 $ 877.8 $ (140.0 ) $ 2,862.4 Segment profitability $ 446.0 $ 310.5 $ 194.6 $ — $ 951.1 Intangible asset amortization expense (412.2 ) Intangible asset impairment charges (15.5 ) Globally managed research and development costs (61.9 ) Corporate costs and special items (143.7 ) Litigation settlements & other contingencies 20.4 Earnings from operations $ 338.2 Nine Months Ended September 30, 2018 Net sales $ 2,998.4 $ 3,070.3 $ 2,164.5 $ — $ 8,233.2 Other revenue 84.5 19.8 17.7 — 122.0 Intersegment revenue 55.5 74.2 287.1 (416.8 ) — Total $ 3,138.4 $ 3,164.3 $ 2,469.3 $ (416.8 ) $ 8,355.2 Segment profitability $ 1,281.3 $ 806.8 $ 475.2 $ — $ 2,563.3 Intangible asset amortization expense (1,191.9 ) Intangible asset impairment charges (87.5 ) Globally managed research and development costs (213.6 ) Corporate costs and special items (448.1 ) Litigation settlements & other contingencies 50.6 Earnings from operations $ 672.8 (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2017 Net sales $ 1,172.2 $ 1,040.8 $ 743.3 $ — $ 2,956.3 Other revenue 20.0 8.9 1.9 — 30.8 Intersegment revenue 15.5 18.4 87.7 (121.6 ) — Total $ 1,207.7 $ 1,068.1 $ 832.9 $ (121.6 ) $ 2,987.1 Segment profitability $ 575.8 $ 290.3 $ 133.9 $ — $ 1,000.0 Intangible asset amortization expense (369.4 ) Globally managed research and development costs (76.8 ) Corporate costs and special items (222.1 ) Litigation settlements & other contingencies (15.2 ) Earnings from operations $ 316.5 Nine Months Ended September 30, 2017 Net sales $ 3,666.7 $ 2,887.1 $ 2,016.4 $ — $ 8,570.2 Other revenue 67.3 25.0 6.3 — 98.6 Intersegment revenue 60.5 87.6 275.4 (423.5 ) — Total $ 3,794.5 $ 2,999.7 $ 2,298.1 $ (423.5 ) $ 8,668.8 Segment profitability $ 1,810.5 $ 776.8 $ 358.9 $ — $ 2,946.2 Intangible asset amortization expense (1,052.6 ) Intangible asset impairment charges (13.0 ) Globally managed research and development costs (269.0 ) Corporate costs and special items (619.4 ) Litigation settlements & other contingencies 25.8 Earnings from operations $ 1,018.0

Subsidiary Guarantors

Subsidiary Guarantors	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Statements	Subsidiary Guarantors The following tables present condensed consolidating financial information for (a) Mylan N.V., the issuer of the 2.500% Senior Notes due 2019, 3.750% Senior Notes due 2020, 3.150% Senior Notes due 2021, 3.950% Senior Notes due 2026 and 5.250% Senior Notes due 2046 (collectively, the “Mylan N.V. Senior Notes”), which are guaranteed on a senior unsecured basis by Mylan Inc.; (b) Mylan Inc., the issuer of the 3.125% Senior Notes due 2023, 4.200% Senior Notes due 2023, 4.550% Senior Notes due 2028, 5.400% Senior Notes due 2043 and 5.200% Senior Notes due 2048 (collectively, the “Mylan Inc. Senior Notes”), which are guaranteed on a senior unsecured basis by Mylan N.V.; and (c) all other subsidiaries of the Company on a combined basis, none of which guarantee the Mylan N.V. Senior Notes or guarantee the Mylan Inc. Senior Notes (“Non-Guarantor Subsidiaries”). The consolidating adjustments primarily relate to eliminations of investments in subsidiaries and intercompany balances and transactions. The condensed consolidating financial statements present investments in subsidiaries using the equity method of accounting. The following financial information presents the unaudited Condensed Consolidating Statements of Operations for the three and nine months ended September 30, 2018 and 2017 , the unaudited Condensed Consolidating Statements of Comprehensive Earnings for the three and nine months ended September 30, 2018 and 2017 , the unaudited Condensed Consolidating Balance Sheets as of September 30, 2018 and December 31, 2017 and the unaudited Condensed Consolidating Statements of Cash Flows for the nine months ended September 30, 2018 and 2017 . This unaudited condensed consolidating financial information has been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The Company has revised its condensed consolidating balance sheet as previously presented in the 2017 Form 10-K to appropriately present intercompany activity relating to certain subsidiaries which were included in the Mylan Inc. column. The Company overstated the line items investment in subsidiaries and total equity within the Mylan Inc. column with a corresponding offset to the elimination column. Specifically, the balance sheet caption investment in subsidiaries has been revised from the previously reported amount of $15.3 billion as of December 31, 2017 to $13.7 billion with an offset to total equity. There is no impact to the consolidated financial statements of Mylan N.V. as previously filed in the 2017 Form 10-K. UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 2,827.3 $ — $ 2,827.3 Other revenues — — — 35.1 — 35.1 Total revenues — — — 2,862.4 — 2,862.4 Cost of sales — — — 1,823.2 — 1,823.2 Gross profit — — — 1,039.2 — 1,039.2 Operating expenses: Research and development — — — 144.1 — 144.1 Selling, general and administrative 11.5 117.6 — 448.2 — 577.3 Litigation settlements and other contingencies, net — 0.1 — (20.5 ) — (20.4 ) Total operating expenses 11.5 117.7 — 571.8 — 701.0 (Loss) earnings from operations (11.5 ) (117.7 ) — 467.4 — 338.2 Interest expense 84.0 42.9 — 9.3 — 136.2 Other (income) expense, net (47.9 ) (79.0 ) — 136.7 — 9.8 (Loss) earnings before income taxes (47.6 ) (81.6 ) — 321.4 — 192.2 Income tax (benefit) provision (8.0 ) 18.1 — 5.4 — 15.5 Earnings of equity interest subsidiaries 216.3 143.3 — — (359.6 ) — Net earnings $ 176.7 $ 43.6 $ — $ 316.0 $ (359.6 ) $ 176.7 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 8,233.2 $ — $ 8,233.2 Other revenues — — — 122.0 — 122.0 Total revenues — — — 8,355.2 — 8,355.2 Cost of sales — — — 5,369.2 — 5,369.2 Gross profit — — — 2,986.0 — 2,986.0 Operating expenses: Research and development — — — 555.7 — 555.7 Selling, general and administrative 31.0 367.7 — 1,409.4 — 1,808.1 Litigation settlements and other contingencies, net — 7.1 — (57.7 ) — (50.6 ) Total operating expenses 31.0 374.8 — 1,907.4 — 2,313.2 (Loss) earnings from operations (31.0 ) (374.8 ) — 1,078.6 — 672.8 Interest expense 266.1 110.9 — 30.1 — 407.1 Other (income) expense, net (211.5 ) (205.0 ) — 460.8 — 44.3 (Loss) earnings before income taxes (85.6 ) (280.7 ) — 587.7 — 221.4 Income tax (benefit) provision (23.3 ) 13.5 — (70.1 ) — (79.9 ) Earnings of equity interest subsidiaries 363.6 217.2 — — (580.8 ) — Net earnings (loss) $ 301.3 $ (77.0 ) $ — $ 657.8 $ (580.8 ) $ 301.3 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 2,956.3 $ — $ 2,956.3 Other revenues — — — 30.8 — 30.8 Total revenues — — — 2,987.1 — 2,987.1 Cost of sales — — — 1,809.0 — 1,809.0 Gross profit — — — 1,178.1 — 1,178.1 Operating expenses: Research and development — — — 182.3 — 182.3 Selling, general and administrative 6.5 184.3 — 473.3 — 664.1 Litigation settlements and other contingencies, net — 17.0 — (1.8 ) — 15.2 Total operating expenses 6.5 201.3 — 653.8 — 861.6 (Loss) earnings from operations (6.5 ) (201.3 ) — 524.3 — 316.5 Interest expense 93.3 26.7 — 11.8 — 131.8 Other (income) expense, net (122.3 ) (44.7 ) — 172.1 — 5.1 Earnings (loss) before income taxes 22.5 (183.3 ) — 340.4 — 179.6 Income tax provision (benefit) 2.4 (0.6 ) — 89.5 — 91.3 Earnings of equity interest subsidiaries 68.2 129.9 — — (198.1 ) — Net earnings (loss) $ 88.3 $ (52.8 ) $ — $ 250.9 $ (198.1 ) $ 88.3 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 8,570.2 $ — $ 8,570.2 Other revenues — — — 98.6 — 98.6 Total revenues — — — 8,668.8 — 8,668.8 Cost of sales — — — 5,180.3 — 5,180.3 Gross profit — — — 3,488.5 — 3,488.5 Operating expenses: Research and development — — — 580.9 — 580.9 Selling, general and administrative 32.4 477.6 — 1,405.4 — 1,915.4 Litigation settlements and other contingencies, net — 17.0 — (42.8 ) — (25.8 ) Total operating expenses 32.4 494.6 — 1,943.5 — 2,470.5 (Loss) earnings from operations (32.4 ) (494.6 ) — 1,545.0 — 1,018.0 Interest expense 285.6 77.8 — 42.9 — 406.3 Other (income) expense, net (331.3 ) (161.5 ) — 528.6 — 35.8 Earnings (loss) before income taxes 13.3 (410.9 ) — 973.5 — 575.9 Income tax provision 1.4 5.1 — 117.7 — 124.2 Earnings of equity interest subsidiaries 439.8 788.8 — — (1,228.6 ) — Net earnings $ 451.7 $ 372.8 $ — $ 855.8 $ (1,228.6 ) $ 451.7 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Three Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 176.7 $ 43.6 $ — $ 316.0 $ (359.6 ) $ 176.7 Other comprehensive (loss) earnings, before tax: Foreign currency translation adjustment (270.8 ) — — (270.8 ) 270.8 (270.8 ) Change in unrecognized (loss) gain and prior service cost related to defined benefit plans (6.8 ) 0.1 — (6.9 ) 6.8 (6.8 ) Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (51.9 ) 1.9 — (53.8 ) 51.9 (51.9 ) Net unrecognized gain on derivatives in net investment hedging relationships 18.8 4.0 — — (4.0 ) 18.8 Other comprehensive (loss) earnings, before tax (310.7 ) 6.0 — (331.5 ) 325.5 (310.7 ) Income tax benefit (19.1 ) (1.6 ) — (17.5 ) 19.1 (19.1 ) Other comprehensive (loss) earnings, net of tax (291.6 ) 7.6 — (314.0 ) 306.4 (291.6 ) Comprehensive (loss) earnings $ (114.9 ) $ 51.2 $ — $ 2.0 $ (53.2 ) $ (114.9 ) UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Nine Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings (loss) $ 301.3 $ (77.0 ) $ — $ 657.8 $ (580.8 ) $ 301.3 Other comprehensive (loss) earnings, before tax: Foreign currency translation adjustment (1,097.6 ) — — (1,097.6 ) 1,097.6 (1,097.6 ) Change in unrecognized (loss) gain and prior service cost related to defined benefit plans (8.3 ) 0.2 — (8.5 ) 8.3 (8.3 ) Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (146.1 ) 5.7 — (151.8 ) 146.1 (146.1 ) Net unrecognized gain on derivatives in net investment hedging relationships 78.7 4.6 — — (4.6 ) 78.7 Net unrealized loss on marketable securities (0.1 ) — — (0.1 ) 0.1 (0.1 ) Other comprehensive (loss) earnings, before tax (1,173.4 ) 10.5 — (1,258.0 ) 1,247.5 (1,173.4 ) Income tax benefit (51.2 ) (2.4 ) — (48.8 ) 51.2 (51.2 ) Other comprehensive (loss) earnings, net of tax (1,122.2 ) 12.9 — (1,209.2 ) 1,196.3 (1,122.2 ) Comprehensive loss $ (820.9 ) $ (64.1 ) $ — $ (551.4 ) $ 615.5 $ (820.9 ) UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Three Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings (loss) $ 88.3 $ (52.8 ) $ — $ 250.9 $ (198.1 ) $ 88.3 Other comprehensive earnings (loss), before tax: Foreign currency translation adjustment 423.0 — — 423.0 (423.0 ) 423.0 Change in unrecognized gain and prior service cost related to defined benefit plans 1.1 0.1 — 1.2 (1.3 ) 1.1 Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (4.5 ) 1.9 — (6.4 ) 4.5 (4.5 ) Net unrecognized loss on derivatives in net investment hedging relationships (72.1 ) — — — — (72.1 ) Net unrealized loss on marketable securities (8.9 ) (8.9 ) — — 8.9 (8.9 ) Other comprehensive earnings (loss), before tax 338.6 (6.9 ) — 417.8 (410.9 ) 338.6 Income tax (benefit) provision (5.8 ) 2.5 — (8.0 ) 5.5 (5.8 ) Other comprehensive earnings (loss), net of tax 344.4 (9.4 ) — 425.8 (416.4 ) 344.4 Comprehensive earnings (loss) $ 432.7 $ (62.2 ) $ — $ 676.7 $ (614.5 ) $ 432.7 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Nine Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 451.7 $ 372.8 $ — $ 855.8 $ (1,228.6 ) $ 451.7 Other comprehensive earnings, before tax: Foreign currency translation adjustment 1,831.9 — — 1,831.9 (1,831.9 ) 1,831.9 Change in unrecognized gain and prior service cost related to defined benefit plans 2.4 0.3 — 2.1 (2.4 ) 2.4 Net unrecognized gain on derivatives in cash flow hedging relationships 29.2 5.5 — 23.7 (29.2 ) 29.2 Net unrecognized loss on derivatives in net investment hedging relationships (203.2 ) — — — — (203.2 ) Net unrealized gain (loss) on marketable securities 3.5 3.7 — (0.2 ) (3.5 ) 3.5 Other comprehensive earnings, before tax 1,663.8 9.5 — 1,857.5 (1,867.0 ) 1,663.8 Income tax provision (benefit) 11.3 (3.5 ) — 14.8 (11.3 ) 11.3 Other comprehensive earnings, net of tax 1,652.5 13.0 — 1,842.7 (1,855.7 ) 1,652.5 Comprehensive earnings $ 2,104.2 $ 385.8 $ — $ 2,698.5 $ (3,084.3 ) $ 2,104.2 UNAUDITED CONDENSED CONSOLIDATING BALANCE SHEET As of September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 27.1 $ — $ 422.1 $ — $ 449.2 Accounts receivable, net — 5.0 — 2,943.7 — 2,948.7 Inventories — — — 2,560.6 — 2,560.6 Intercompany receivables 446.0 572.8 — 11,946.6 (12,965.4 ) — Prepaid expenses and other current assets 4.9 67.9 — 510.4 — 583.2 Total current assets 450.9 672.8 — 18,383.4 (12,965.4 ) 6,541.7 Property, plant and equipment, net — 263.7 — 1,855.9 — 2,119.6 Investments in subsidiaries 18,939.5 12,829.4 — — (31,768.9 ) — Intercompany notes and interest receivable 6,479.2 10,615.5 — 2,932.3 (20,027.0 ) — Intangible assets, net — — — 14,239.0 — 14,239.0 Goodwill — 17.1 — 9,779.5 — 9,796.6 Other assets 0.3 58.3 — 700.1 — 758.7 Total assets $ 25,869.9 $ 24,456.8 $ — $ 47,890.2 $ (64,761.3 ) $ 33,455.6 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 55.8 $ — $ 1,345.3 $ — $ 1,401.1 Short-term borrowings — — — 0.4 — 0.4 Income taxes payable — 4.5 — 71.2 — 75.7 Current portion of long-term debt and other long-term obligations 1,129.3 0.2 — 46.9 — 1,176.4 Intercompany payables 875.5 12,019.3 — 70.6 (12,965.4 ) — Other current liabilities 138.1 315.2 — 2,075.1 — 2,528.4 Total current liabilities 2,142.9 12,395.0 — 3,609.5 (12,965.4 ) 5,182.0 Long-term debt 9,507.9 3,777.8 — 5.7 — 13,291.4 Intercompany notes payable 2,152.9 3,127.2 — 14,746.9 (20,027.0 ) — Other long-term obligations — 50.7 — 2,865.3 — 2,916.0 Total liabilities 13,803.7 19,350.7 — 21,227.4 (32,992.4 ) 21,389.4 Total equity 12,066.2 5,106.1 — 26,662.8 (31,768.9 ) 12,066.2 Total liabilities and equity $ 25,869.9 $ 24,456.8 $ — $ 47,890.2 $ (64,761.3 ) $ 33,455.6 UNAUDITED CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Accounts receivable, net — 1.0 — 3,611.4 — 3,612.4 Inventories — — — 2,542.7 — 2,542.7 Intercompany receivables 317.2 462.1 — 11,828.5 (12,607.8 ) — Prepaid expenses and other current assets 5.6 171.1 — 589.4 — 766.1 Total current assets 322.8 634.4 — 18,863.9 (12,607.8 ) 7,213.3 Property, plant and equipment, net — 294.1 — 2,045.0 — 2,339.1 Investments in subsidiaries 19,736.5 13,683.3 — — (33,419.8 ) — Intercompany notes and interest receivable 7,822.6 10,271.2 — 2,186.3 (20,280.1 ) — Intangible assets, net — — — 15,245.8 — 15,245.8 Goodwill — 17.1 — 10,188.6 — 10,205.7 Other assets 4.9 56.5 — 741.0 — 802.4 Total assets $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 45.3 $ — $ 1,407.2 $ — $ 1,452.5 Short-term borrowings — — — 46.5 — 46.5 Income taxes payable — — — 112.9 — 112.9 Current portion of long-term debt and other long-term obligations 1,097.8 649.1 — 62.0 — 1,808.9 Intercompany payables 664.7 11,911.5 — 31.6 (12,607.8 ) — Other current liabilities 35.5 397.0 — 2,532.0 — 2,964.5 Total current liabilities 1,798.0 13,002.9 — 4,192.2 (12,607.8 ) 6,385.3 Long-term debt 10,614.3 2,244.5 — 6.5 — 12,865.3 Intercompany notes payable 2,166.9 3,312.7 — 14,800.5 (20,280.1 ) — Other long-term obligations — 57.3 — 3,190.8 — 3,248.1 Total liabilities 14,579.2 18,617.4 — 22,190.0 (32,887.9 ) 22,498.7 Total equity 13,307.6 6,339.2 — 27,080.6 (33,419.8 ) 13,307.6 Total liabilities and equity $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Nine Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (68.6 ) $ (1,201.6 ) $ — $ 2,975.8 $ — $ 1,705.6 Cash flows from investing activities: Capital expenditures — (17.8 ) — (119.6 ) — (137.4 ) Purchase of available for sale securities and other investments — — — (49.4 ) — (49.4 ) Proceeds from the sale of marketable securities — 36.3 — 35.8 — 72.1 Cash paid for acquisitions, net — — — (65.9 ) — (65.9 ) Investments in affiliates — (22.0 ) — — 22.0 — Dividends from affiliates 65.3 — — — (65.3 ) — Loans to affiliates (470.6 ) — — (4,577.1 ) 5,047.7 — Repayments of loans from affiliates 1,810.8 — — 3,205.0 (5,015.8 ) — Payments for product rights and other, net — (0.4 ) — (853.8 ) — (854.2 ) Net cash provided by (used in) investing activities 1,405.5 (3.9 ) — (2,425.0 ) (11.4 ) (1,034.8 ) Cash flows from financing activities: Payments of financing fees (0.5 ) (20.2 ) — (0.1 ) — (20.8 ) Purchase of ordinary shares (432.0 ) — — — — (432.0 ) Change in short-term borrowings, net — — — (45.9 ) — (45.9 ) Proceeds from issuance of long-term debt 496.5 2,079.2 — 2.0 — 2,577.7 Payments of long-term debt (1,446.5 ) (1,150.0 ) — (2.1 ) — (2,598.6 ) Proceeds from exercise of stock options 15.6 — — — — 15.6 Taxes paid related to net share settlement of equity awards (10.1 ) — — — — (10.1 ) Contingent consideration payments — — — (0.2 ) — (0.2 ) Capital contribution from affiliates — — — 22.0 (22.0 ) — Capital payments to affiliates — — — (65.3 ) 65.3 — Payments on borrowings from affiliates (1,273.9 ) (3,010.1 ) — (731.8 ) 5,015.8 — Proceeds from borrowings from affiliates 1,314.0 3,309.9 — 423.8 (5,047.7 ) — Other items, net — — — (0.4 ) — (0.4 ) Net cash (used in) provided by financing activities (1,336.9 ) 1,208.8 — (398.0 ) 11.4 (514.7 ) Effect on cash of changes in exchange rates — — — (22.9 ) — (22.9 ) Net increase in cash, cash equivalents and restricted cash — 3.3 — 129.9 — 133.2 Cash, cash equivalents and restricted cash — beginning of period — 23.8 — 346.1 — 369.9 Cash, cash equivalents and restricted cash — end of period $ — $ 27.1 $ — $ 476.0 $ — $ 503.1 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Nine Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (175.1 ) $ (338.8 ) $ — $ 2,083.2 $ — $ 1,569.3 Cash flows from investing activities: Capital expenditures — (31.4 ) — (125.0 ) — (156.4 ) Purchase of available for sale securities and other investments — — — (8.9 ) — (8.9 ) Proceeds from the sale of assets — — — 31.1 — 31.1 Proceeds from the sale of marketable securities — — — 8.9 — 8.9 Cash paid for acquisitions, net (71.6 ) — — — — (71.6 ) Investments in affiliates — (21.1 ) — — 21.1 — Dividends from affiliates 168.1 — — — (168.1 ) — Loans to affiliates (143.7 ) (364.1 ) — (2,558.0 ) 3,065.8 — Repayments of loans from affiliates 1,066.4 0.3 — 943.6 (2,010.3 ) — Payments for product rights and other, net — (0.3 ) — (558.5 ) — (558.8 ) Net cash provided by (used in) investing activities 1,019.2 (416.6 ) — (2,266.8 ) 908.5 (755.7 ) Cash flows from financing activities: Payments of financing fees (8.3 ) (0.4 ) — — — (8.7 ) Change in short-term borrowings, net — — — (48.3 ) — (48.3 ) Proceeds from issuance of long-term debt 554.5 — — 1.3 — 555.8 Payments of long-term debt (1,500.0 ) — — (247.3 ) — (1,747.3 ) Proceeds from exercise of stock options 12.8 — — — — 12.8 Taxes paid related to net share settlement of equity awards (7.4 ) — — — — (7.4 ) Contingent consideration payments — — — (10.1 ) — (10.1 ) Capital contribution from affiliates — — — 21.1 (21.1 ) — Capital payments to affiliates — — — (168.1 ) 168.1 — Payments on borrowings from affiliates — (1,664.4 ) — (345.9 ) 2,010.3 — Proceeds from borrowings from affiliates 104.0 2,497.5 — 464.3 (3,065.8 ) — Other items, net — (7.4 ) — 6.7 — (0.7 ) Net cash (used in) provided by financing activities (844.4 ) 825.3 — (326.3 ) (908.5 ) (1,253.9 ) Effect on cash of changes in exchange rates — — — 44.1 — 44.1 Net (decrease) increase in cash, cash equivalents and restricted cash (0.3 ) 69.9 — (465.8 ) — (396.2 ) Cash, cash equivalents and restricted cash — beginning of period 0.3 85.4 — 1,061.3 — 1,147.0 Cash, cash equivalents and restricted cash — end of period $ — $ 155.3 $ — $ 595.5 $ — $ 750.8 The following tables provide a reconciliation of cash and cash equivalents, as reported on our unaudited condensed consolidating balance sheets, to cash, cash equivalents and restricted cash, as reported on our unaudited condensed consolidating statements of cash flows (in millions): September 30, 2018 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 27.1 $ — $ 422.1 $ — $ 449.2 Restricted cash, included in prepaid expenses and other current assets — — — 53.9 — 53.9 Cash, cash equivalents and restricted cash $ — $ 27.1 $ — $ 476.0 $ — $ 503.1 December 31, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Restricted cash, included in prepaid expenses and other current assets — 23.6 — 54.2 — 77.8 Cash, cash equivalents and restricted cash $ — $ 23.8 $ — $ 346.1 $ — $ 369.9 September 30, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 82.2 $ — $ 532.7 $ — $ 614.9 Restricted cash, included in prepaid expenses and other current assets — 73.1 — 62.8 — 135.9 Cash, cash equivalents and restricted cash $ — $ 155.3 $ — $ 595.5 $ — $ 750.8

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring On December 5, 2016, the Company announced restructuring programs in certain locations representing initial steps in a series of actions that are anticipated to further streamline its operations globally. Since 2015, the Company has made a number of significant acquisitions, and as part of the holistic, global integration of these acquisitions, the Company is focused on how to best optimize and maximize all of its assets across the organization and across all geographies. Charges for restructuring and ongoing cost reduction initiatives are recorded in the period the Company commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. The Company continues to develop the details of the cost reduction initiatives, including workforce actions and other potential restructuring activities beyond the programs announced, including potential shutdown or consolidation of certain operations. During the second quarter of 2018, the Company commenced a restructuring and remediation program at its Morgantown, West Virginia facility, for which activities and initiatives are ongoing. The continued restructuring actions other than for this facility are expected to be implemented through fiscal year 2018. The Company anticipates total aggregate pre-tax charges for committed restructuring activities ranging between $500.0 million and $600.0 million , inclusive of all restructuring charges incurred through September 30, 2018 . As additional restructuring activities are undertaken, the Company expects to incur additional costs including employee related costs, such as severance and continuation of healthcare and other benefits; asset impairments; accelerated depreciation; costs associated with contract terminations; and other closure costs. At this time, the expenses related to the additional restructuring activities cannot be reasonably estimated. The following table summarizes the restructuring charges and the reserve activity from December 31, 2017 to September 30, 2018 : (In millions) Employee Related Costs Other Exit Costs Total Balance at December 31, 2017: $ 92.9 $ 14.1 $ 107.0 Charges (1) 15.1 30.3 45.4 Cash payment (28.7 ) (2.8 ) (31.5 ) Utilization — (30.8 ) (30.8 ) Foreign currency translation 0.6 — 0.6 Balance at March 31, 2018: $ 79.9 $ 10.8 $ 90.7 Charges (1) 35.1 41.0 76.1 Cash payment (31.1 ) (8.2 ) (39.3 ) Utilization — (28.0 ) (28.0 ) Foreign currency translation (2.7 ) (0.6 ) (3.3 ) Balance at June 30, 2018: $ 81.2 $ 15.0 $ 96.2 Charges (1) 16.2 64.6 80.8 Cash payment (19.3 ) (7.5 ) (26.8 ) Utilization — (54.6 ) (54.6 ) Foreign currency translation (0.3 ) 0.2 (0.1 ) Balance at September 30, 2018: $ 77.8 $ 17.7 $ 95.5 ____________ (1) For the three months ended September 30, 2018 , total restructuring charges in North America, Europe, and Rest of World were approximately $49.7 million , $28.5 million , and $2.6 million , respectively. For the nine months ended September 30, 2018 , total restructuring charges in North America, Europe, Rest of World and corporate were approximately $108.1 million , $79.9 million , $13.3 million and $1.0 million , respectively. At September 30, 2018 and December 31, 2017 , accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities on the Condensed Consolidated Balance Sheets .

Collaboration and Licensing Agr

Collaboration and Licensing Agreements (Notes)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	18. Collaboration and Licensing Agreements We periodically enter into collaboration and licensing agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant collaboration agreements are focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds, insulin analog products and respiratory products, among other complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the Condensed Consolidated Balance Sheets, except for milestone and royalty obligations reflected as acquisition related contingent consideration. Refer to Note 11 Financial Instruments and Risk Management for contingent consideration amounts recorded. Our potential maximum development milestones not accrued for at September 30, 2018 totaled approximately $430 million , which includes the new agreements entered into as described in Note 4 Acquisitions and Other Transactions, and excludes potential milestone payments to Momenta Pharmaceuticals, Inc. (“Momenta”). We estimate the amounts that may be paid within the next year to be approximately $70 million . These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty obligations may be significant depending upon the level of commercial sales for each product. On October 1, 2018, Momenta announced that it had initiated discussions with Mylan, to exit its participation in the development of five biosimilar programs including M834, a proposed biosimilar to ORENCIA®. Momenta also announced that it intends to continue the development of M710, a proposed biosimilar to EYLEA® (aflibercept) injection. While the Company is in the process of discussing the transition of collaboration activities with Momenta, it remains committed to invest strategically in biosimilar programs through the evaluation of regulatory data and market dynamics. There have been no other significant changes to our collaboration and licensing agreements as disclosed in our 2017 Form 10-K.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Litigation The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. The Company is also party to certain proceedings and litigation matters for which it may be entitled to indemnification under the respective sale and purchase agreements relating to the acquisitions of the former Merck Generics business, Agila, Abbott Laboratories’ (“Abbott”) non-U.S. developed markets specialty and branded generics business, and certain other acquisitions. While the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters or the inability or denial of Merck KGaA, Strides Arcolab, Abbott, or another indemnitor or insurer to pay an indemnified claim, could have a material effect on the Company’s business, financial condition, results of operations, cash flows and/or ordinary share price. Some of these governmental inquiries, investigations, proceedings and litigation matters with which the Company is involved are described below, and unless otherwise disclosed, the Company is unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. The Company records accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is also involved in other pending proceedings for which, in the opinion of the Company based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s business, financial position, results of operations, cash flows and/or ordinary share price. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in the opinion of the Company, become material, the Company will disclose such matters. Legal costs are recorded as incurred and are classified in SG&A in the Company’s Condensed Consolidated Statements of Operations. Lorazepam and Clorazepate On June 1, 2005, a jury verdict was rendered against Mylan, MPI, and co-defendants Cambrex Corporation and Gyma Laboratories in the U.S. District Court for the District of Columbia in the amount of approximately $12.0 million in an antitrust case brought by four health insurers who opted out of earlier class action settlements agreed to by the Company in 2001. The Court entered final judgment on August 30, 2017 in the amount of approximately $67.0 million (not including post-judgment interest and fees and costs). Mylan filed a notice of appeal on September 15, 2017 with the United States Court of Appeals for the District of Columbia Circuit. This matter has been resolved by way of settlement and the case is closed. The Company paid approximately $34.5 million during 2018 related to this matter. The Company maintained a surety bond underwritten by a third-party insurance company in the amount of $66.6 million which has been released. Pricing and Medicaid Litigation Dey L.P. (now known as Mylan Specialty L.P. and herein as “Mylan Specialty”), a wholly owned subsidiary of the Company, was named in 1997 as a defendant in a case brought by the United States as well as in later filed class actions brought by consumers and third-party payors. All of the cases and claims brought against Mylan Specialty have been fully resolved and dismissed. Under the terms of the purchase agreement with Merck KGaA, Mylan is fully indemnified for the claims in the preceding paragraph and Merck KGaA is entitled to any income tax benefit the Company realizes for any deductions of amounts paid for such pricing litigation. In the second quarter, the Company paid approximately $23.5 million , and in October 2018, the Company paid approximately $42.2 million . No further amounts are owed by the Company. Modafinil Antitrust Litigation Beginning in April 2006, Mylan and four other drug manufacturers were named as defendants in civil lawsuits filed in or transferred to the U.S. District Court for the Eastern District of Pennsylvania (“EDPA”) by a variety of plaintiffs purportedly representing direct and indirect purchasers of the drug modafinil and in a lawsuit filed by Apotex, Inc., a manufacturer of generic drugs. These actions alleged violations of federal antitrust and state laws in connection with the generic defendants’ settlement of patent litigation with Cephalon relating to modafinil. Mylan entered into a settlement agreement with the putative indirect purchasers for approximately $16.0 million , which is subject to court approval. Mylan has settled with the putative direct purchaser class and the retailer opt-out plaintiffs for $165 million , a portion of which was paid by the Company prior to 2018, and a final amount of approximately $89.2 million was paid in April 2018. Mylan and Apotex have also settled Apotex’s claims. The Company has also received subpoenas from certain state attorneys general requesting documents related to the modafinil patent litigation. On July 10, 2015, the Louisiana Attorney General filed in the 19th Judicial District Court in Louisiana a petition against Mylan and three other drug manufacturers asserting state law claims based on the same underlying allegations as those made in the litigation then pending in the EDPA. On December 8, 2016, Mylan’s peremptory exceptions of no cause of action with respect to the supplemental and amended petition were granted in their entirety and with prejudice. The State of Louisiana appealed this decision. The First Circuit Court of Appeal subsequently returned the case to the District Court with instructions to include certain decretal language in order to make the District Court’s decision final and appealable. On July 28, 2016, United Healthcare filed a complaint against Mylan Inc. and four other drug manufacturers in the United States District Court for the District of Minnesota, asserting state law claims based on the same underlying allegations as those made in the litigation then pending in the EDPA. On January 6, 2017, the case was transferred to the EDPA and is still pending. MPI has since been included as an additional party. A trial date has been scheduled for July 2019. The Company believes that it has strong defenses to these remaining cases. Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. The Company has a total accrual of approximately $16.0 million related to this matter at September 30, 2018 , which is included in other current liabilities in the Condensed Consolidated Balance Sheets. Pioglitazone Beginning in December 2013, Mylan, Takeda, and several other drug manufacturers have been named as defendants in civil lawsuits consolidated in the U.S. District Court for the Southern District of New York by plaintiffs which purport to represent direct and indirect purchasers of branded or generic Actos® and Actoplus Met®. These actions allege violations of state and federal competition laws in connection with the defendants’ settlements of patent litigation in 2010 related to Actos® and Actoplus Met®. Mylan’s motion to dismiss the indirect purchasers’ complaint was granted and no appeal was filed as to Mylan. Following the appellate decision relating to other defendants, the direct purchasers filed an amended complaint against Mylan and the other manufacturers. Mylan’s motion to dismiss the amended complaint is pending. SEC Investigation On September 10, 2015, Mylan N.V. received a subpoena from the SEC seeking documents with regard to certain related party matters. Mylan has received additional requests for information and will continue to fully cooperate with the SEC. Trade Agreements Act (“TAA”) On April 9, 2018, a subsidiary of Mylan N.V. received a civil investigative demand from the Commercial Litigation Branch of the U.S. Department of Justice (“DOJ”) concerning its TAA compliance for certain products. The company fully cooperated with DOJ. On September 14, 2018, the United States District Court for the Southern District of Ohio unsealed a qui tam lawsuit filed against the Mylan N.V. subsidiary concerning its TAA compliance for the same products identified in DOJ’s civil investigative demand. DOJ has declined to intervene in the lawsuit and has closed its investigation. We believe that the claims in this lawsuit are without merit and intend to defend against them vigorously. EpiPen® Auto-Injector and Certain Congressional Matters Classification of EpiPen® Auto-Injector and EpiPen Jr® Auto-Injector In November 2014, the Company received a subpoena from the DOJ related to the classification of the EpiPen® Auto-Injector for purposes of the Medicaid Drug Rebate Program (“MDRP”). On August 17, 2017, two of Mylan’s subsidiaries - Mylan Inc. and Mylan Specialty - signed an agreement for a $465 million settlement, plus interest, with the DOJ, state government agencies and two relators (the “ MDRP Settlement ”). The settlement with the DOJ, two relators and all 50 states plus the District of Columbia has been completed and both the federal and state matters have been dismissed through stipulations of dismissal. In connection with the settlement, Mylan Inc. and Mylan Specialty entered into a Corporate Integrity Agreement (the “CIA”) with the Office of Inspector General of the Department of Health and Human Services. The CIA has a five-year term and requires, among other things, that an independent review organization annually review various matters relating to the MDRP. Neither the settlement agreement nor the CIA contains an admission or finding of wrongdoing. In connection with the settlement, Mylan Specialty has reclassified EpiPen® Auto-Injector as an innovator product for purposes of the MDRP effective April 1, 2017. The Company recorded an accrual for the full settlement amount during the year ended December 31, 2016 and recorded an additional accrual for interest related to the settlement amount prior to the payment made in 2017. Department of Veterans Affairs Request for Information On June 30, 2017, the Company responded to a request for information from the Department of Veterans Affairs (“VA”) (acting on behalf of itself and other government agencies) requesting certain historical pricing data related to the EpiPen® Auto-Injector. The Company and the VA are engaged in a continuing dialogue regarding the classification of the EpiPen® Auto-Injector as a covered drug under Section 603 of the Veterans Health Care Act of 1992, Public Law 102-585. The EpiPen® Auto-Injector has been classified as a non covered drug with the VA based upon long standing written guidance from the federal government. The Company is fully cooperating with the VA. SEC Request for Information/Subpoenas On October 7, 2016, Mylan received a document request from the SEC’s Division of Enforcement seeking communications with the Centers for Medicare and Medicaid Services and documents concerning Mylan products sold and related to the MDRP, and any related complaints. On November 15, 2016, Mylan received a follow-up letter, modifying the initial document request, seeking information on and public disclosures regarding the MDRP Settlement and the classification of the EpiPen® Auto-Injector under the MDRP. Mylan has received subpoenas and additional requests for information in this matter and will continue to fully cooperate with the SEC. On April 25, 2017, Mylan received a comment letter from the staff of the SEC’s Division of Corporation Finance (“Corporation Finance”) with respect to Mylan’s Annual Report on Form 10-K for the year ended December 31, 2016, requesting information regarding Mylan’s accounting treatment of the MDRP Settlement, including with respect to the determinations that the settlement amount should be recorded as a charge against earnings in the third quarter of 2016 rather than against any earlier periods, and that the settlement amount should be classified as an expense rather than a reduction of revenue. The Company responded to the comment letter in May 2017 and we will continue to respond to any additional correspondence from Corporation Finance. We believe that our accounting treatment for the aforementioned settlement is appropriate and consistent with all applicable accounting standards. FTC Request for Information On November 18, 2016, Mylan received a request from the U.S. Federal Trade Commission (“FTC”) Bureau of Competition seeking documents and information relating to its preliminary investigation into potential anticompetitive practices relating to epinephrine auto-injectors. Mylan is fully cooperating with the FTC. Federal Securities Litigation Purported class action complaints were filed in October 2016 against Mylan N.V., Mylan Inc. and certain of their current and former directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the United States District Court for the Southern District of New York on behalf of certain purchasers of securities of Mylan N.V. and/or Mylan Inc. on the NASDAQ. The complaints alleged that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to Mylan N.V. and Mylan Inc.’s classification of their EpiPen® Auto-Injector as a non-innovator drug for purposes of the MDRP. The complaints sought damages, as well as the plaintiffs’ fees and costs. On March 20, 2017, after the actions were consolidated, a consolidated amended complaint was filed, alleging substantially similar claims and seeking substantially similar relief, but adding allegations that defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs, and alleging violations of both federal securities laws (on behalf of a purported class of certain purchasers of securities of Mylan N.V. and/or Mylan Inc. on the NASDAQ) and Israeli securities laws (on behalf of a purported class of certain purchasers of securities of Mylan N.V. on the Tel Aviv Stock Exchange). On March 28, 2018, defendants’ motion to dismiss the consolidated amended complaint was granted in part (including the dismissal of claims arising under Israeli securities laws) and denied in part. On July 6, 2018, the Plaintiffs filed a second amended complaint, including certain current and former directors and officers and additional allegations in connection with purportedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs. On August 6, 2018, defendants filed a motion to dismiss the second amended complaint, which is currently pending. We believe that the claims in this lawsuit are without merit and intend to defend against them vigorously. Israeli Securities Litigation On October 13, 2016, a purported shareholder of Mylan N.V. filed a lawsuit, together with a motion to certify the lawsuit as a class action on behalf of certain Mylan N.V. shareholders on the Tel Aviv Stock Exchange, against Mylan N.V. and four of its directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the Tel Aviv District Court (Economic Division) (the “Friedman Action”). The plaintiff alleges that the defendants made false or misleading statements and omissions of purportedly material fact in Mylan N.V.’s reports to the Tel Aviv Stock Exchange regarding Mylan N.V.’s classification of its EpiPen® Auto-Injector for purposes of the MDRP, in violation of both U.S. and Israeli securities laws, the Israeli Companies Law and the Israeli Torts Ordinance. The plaintiff seeks damages, among other remedies. On April 30, 2017, another purported shareholder of Mylan N.V. filed a separate lawsuit, together with a motion to certify the lawsuit as a class action on behalf of certain Mylan N.V. shareholders on the Tel Aviv Stock Exchange, in the Tel Aviv District Court (Economic Division), alleging substantially similar claims and seeking substantially similar relief against the defendants and other directors and officers of Mylan N.V., but alleging also that this group of defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs, and alleging violations of both U.S. federal securities laws and Israeli law (the “IEC Fund Action”). On April 10, 2018, the Tel Aviv District Court granted the motion filed by plaintiffs in both the Friedman Action and the IEC Fund Action, voluntarily dismissing the Friedman Action and staying the IEC Fund Action until a judgment is issued in the securities litigation pending in the United States. We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously. EpiPen® Auto-Injector Civil Litigation Mylan Specialty and other Mylan-affiliated entities have been named as defendants in putative class actions relating to the pricing and/or marketing of the EpiPen® Auto-Injector . The plaintiffs in these cases assert violations of various federal and state antitrust and consumer protection laws, the Racketeer Influenced and Corrupt Organizations Act, as well as common law claims. Plaintiffs’ claims include purported challenges to the prices charged for the EpiPen® Auto-Injector and/or the marketing of the product in packages containing two auto-injectors, as well as allegedly anti-competitive conduct. A Mylan officer and other non-Mylan affiliated companies were also named as defendants in some of the class actions. These lawsuits were filed in the various federal and state courts and have either been dismissed or transferred into a multidistrict litigation (“MDL”) in the U.S. District Court for the District of Kansas and have been consolidated. Mylan filed a motion to dismiss the consolidated amended complaint, which was granted in part and denied in part. A trial date has been scheduled for July 2020. We believe that the remaining claims in these lawsuits are without merit and intend to defend against them vigorously. On April 24, 2017, Sanofi-Aventis U.S., LLC (“Sanofi”) filed a lawsuit against Mylan Inc. and Mylan Specialty in the U.S. District Court for the District of New Jersey. This lawsuit has been transferred into the aforementioned MDL. In this lawsuit, Sanofi alleges exclusive dealings and anti-competitive marketing practices in violation of the antitrust laws in connection with the sale and marketing of the EpiPen® Auto-Injector. On November 1, 2018, Sanofi filed a Motion for a Suggestion of Remand of the case to the U.S. District Court for the District of New Jersey. This Motion remains pending. We believe that Sanofi’s claims in this lawsuit are without merit and intend to defend against them vigorously. EpiPen® Auto-Injector State AG Investigations The Company and certain of its affiliated entities received subpoenas and informal requests from various state attorneys general seeking information and documents relating to the pricing and/or marketing of the EpiPen® Auto-Injector . The Company has cooperated and is fully cooperating with the various state attorneys general. U.S. Congress/State Requests for Information and Documents Mylan received several requests for information and documents from various Committees of the U.S. Congress and federal and state lawmakers concerning the marketing, distribution and sales of Mylan products. Mylan cooperated with federal and state lawmakers as appropriate in response to their requests. The Company has a total accrual of approximately $10.0 million related to this matter at September 30, 2018 , which is included in other current liabilities in the Condensed Consolidated Balance Sheets. During the year ended December 31, 2017, the Company made payments of approximately $472.7 million related to this matter. The Company believes that it has strong defenses to current and future potential civil litigation, as well as governmental investigations and enforcement proceedings, discussed in this “ EpiPen® Auto-Injector and Certain Congressional Matters” section of this Note 20 Litigation . Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. In addition, the Company expects to incur additional legal and other professional service expenses associated with such matters in future periods and will recognize these expenses as services are received. The Company believes that the ultimate amount paid for these services and claims could have a material effect on the Company's business, financial condition, results of operations, cash flows and/or ordinary share price in future periods. Opioids On July 27, 2017, Mylan N.V. received a subpoena from the DOJ seeking information relating to opioids manufactured, marketed or sold by Mylan during the period from January 1, 2013 to December 31, 2016. On August 29, 2017, Mylan N.V. received a civil investigative demand from the Attorney General of the State of Missouri seeking information relating to opioids manufactured, marketed or sold by Mylan during the period from January 1, 2010 to the present and related subject matter. Mylan is fully cooperating with these subpoena requests. Mylan also has responded to a letter from the ranking member of the U.S. Senate Committee on Homeland Security and Governmental Affairs seeking information relating to sales, marketing and educational strategies for opioid products manufactured by Mylan. In connection with this matter, Senator Claire McCaskill issued a report on February 15, 2018 relating to payments by five drug manufacturers to third-party advocacy groups and professional societies. This report positively differentiated Mylan, finding that Mylan is “[a]t the other end of the spectrum” from the other companies whose payments were examined because Mylan made only de minimis payments, and to only one of the fourteen third-parties cited in the report. Mylan has been named in the United States and Canada, along with numerous other manufacturers, distributors, pharmacies, pharmacy benefit managers, and/or individual healthcare professionals, in certain civil lawsuits brought by plaintiffs, including local governmental entities, generally asserting statutory and/or common law claims arising from the manufacture, distribution, marketing, promotion, and sale of purported prescription opioids. The lawsuits seek damages, including punitive and/or exemplary damages, injunctive relief, attorneys’ fees and costs, and other relief. Mylan believes that the claims in these lawsuits are without merit and intends to defend against them vigorously. Drug Pricing Matters Department of Justice On December 3, 2015, a subsidiary of Mylan N.V. received a subpoena from the Antitrust Division of the DOJ seeking information relating to the marketing, pricing, and sale of our generic Doxycycline products and any communications with competitors about such products. On September 8, 2016, a subsidiary of Mylan N.V., as well as certain employees and a member of senior management, received subpoenas from the DOJ seeking additional information relating to the marketing, pricing and sale of our generic Cidofovir, Glipizide-metformin, Propranolol and Verapamil products and any communications with competitors about such products. Related search warrants also were executed. On May 10, 2018, a subsidiary of Mylan N.V. received a civil investigative demand from the Civil Division of the DOJ seeking information relating to the pricing and sale of its generic drug products. The Company is fully cooperating with the DOJ. Civil Litigation The Company, along with other manufacturers, has been named as a defendant in putative class action lawsuits filed in 2016 and 2017 generally alleging anticompetitive conduct with respect to doxycycline hyclate (regular and delayed release), digoxin, divalproex, levothyroxine, propranolol, clomipramine, albuterol, benazepril and amitriptyline products (as well as a number of non-Mylan products). The lawsuits have been filed by putative classes of direct purchasers, indirect purchasers and indirect resellers and allege harm under federal and state antitrust laws, state consumer protection laws and unjust enrichment. These lawsuits have been consolidated in an MDL proceeding in the EDPA. The Court has sequenced these lawsuits into three separate product groups. Defendants filed motions to dismiss complaints in the first product group. On October 16, 2018, the Court denied the motions with respect to the federal law claims and a decision on the state law claims remains pending. On January 22, 2018, three direct purchaser retailers filed a complaint against Mylan and other manufacturers asserting similar allegations with respect to the products identified above, as well as doxycycline monohydrate, glipizide-metformin, and verapamil (as well as other non-Mylan products). Subsequently, putative classes of direct purchasers, indirect purchasers, and indirect resellers filed complaints against Mylan and other manufacturers alleging harm under federal and state antitrust laws, state consumer protection laws and unjust enrichment and asserting similar allegations with respect to a number of products, including Mylan’s doxycycline products, glipizide-metformin, and verapamil (as well as other non-Mylan products). These complaints also name Mylan’s President as a defendant and include allegations against him with respect to doxycycline hyclate delayed release. On August 3, 2018, a complaint was filed by a plaintiff claiming to be a direct and indirect purchaser against Mylan and other defendants alleging anti-competitive conduct with respect to certain of the products identified above as well as pravastatin. On September 25, 2018, a complaint was filed by plaintiffs on behalf of putative classes of direct and indirect purchasers against Mylan and other defendants alleging anti-competitive conduct with respect to generic drugs. The Company believes that the claims in these lawsuits are without merit and intends to defend against them vigorously. Attorneys General Litigation On December 21, 2015, the Company received a subpoena and interrogatories from the Connecticut Office of the Attorney General seeking information relating to the marketing, pricing and sale of certain of the Company’s generic products (including generic doxycycline) and communications with competitors about such products. On December 14, 2016, attorneys general of twenty states filed a complaint in the United States District Court for the District of Connecticut against several generic pharmaceutical drug manufacturers, including Mylan, alleging anticompetitive conduct with respect to, among other things, Doxycycline Hyclate Delayed Release. The complaint was subsequently amended to add certain attorneys general alleging violations of federal and state antitrust laws, as well as violations of various states’ consumer protection laws. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA. On October 31, 2017, attorneys general of forty-five states, the District of Columbia and the Commonwealth of Puerto Rico filed a motion for leave to file a consolidated amended complaint (“proposed amended complaint”) against various drug manufacturers, including Mylan. The proposed amended complaint was permitted and was filed on June 18, 2018 and included two additional states. Mylan is alleged to have engaged in anticompetitive conduct with respect to Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin, and Verapamil. The amended complaint also includes claims asserted by attorneys general of thirty-seven states and the Commonwealth of Puerto Rico against certain individuals, including Mylan’s President, with respect to Doxycycline Hyclate Delayed Release. The allegations in the amended complaint are similar to those in the previously filed complaints. We believe that the claims in this lawsuit are without merit and intend to defend against them vigorously. European Commission Proceedings Perindopril On July 9, 2014 , the European Commission (the “Commission”) issued a decision finding that Mylan Laboratories Limited and Mylan, as well as several other companies, had violated European Union (“EU”) competition rules relating to the product Perindopril and fined Mylan Laboratories Limited approximately €17.2 million , including approximately €8.0 million jointly and severally with Mylan Inc. The Company paid approximately $21.7 million related to this matter during the fourth quarter of 2014. In September 2014, the Company filed an appeal of the Commission’s decision to the General Court of the EU. A hearing on the appeal before the General Court of the EU was held in June 2017 and a decision is pending. Citalopram On June 19, 2013, the Commission issued a decision finding that Generics [U.K.] Limited, as well as several other companies, had violated EU competition rules relating to the product Citalopram and fined Generics [U.K.] Limited approximately €7.8 million , jointly and severally with Merck KGaA. Generics [U.K.] Limited appealed the Commission’s decision to the General Court of the EU. The case is currently on appeal to the European Court of Justice. The United Kingdom applied and was granted permission to intervene in this proceeding. The Company has accrued approximately €7.4 million as of September 30, 2018 and December 31, 2017 , respectively, related to this matter. Generics [U.K.] Limited has received notices from European NHS Departments and health insurers stating an intention to commence follow-on litigation and asserting damages. Generics [U.K.] Limited has also sought indemnification from Merck KGaA with respect to the €7.8 million portion of the fine for which Merck KGaA and Generics [U.K.] Limited were held jointly and severally liable. Merck KGaA has counterclaimed against Generics [U.K.] Limited seeking the same indemnification. In June 2018, the Frankfurt Regional Court issued a judgment dismissing Generics [U.K.] Limited’s claims against Merck KGaA and ordered Generics [U.K.] Limited to indemnify Merck KGaA with respect to the amount for which the parties were held jointly and severally liable. Generics [U.K.] Limited has appealed this decision, which remains pending. It is reasonably possible that we will incur additional losses above the amount accrued but we cannot estimate a range of such reasonably possible losses at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued. U.K. Competition and Markets Authority Paroxetine On August 12, 2011, Generics [U.K.] Limited received notice that the Office of Fair Trading (subsequently changed to the Competition and Markets Authority (the “CMA”)) opened an investigation to explore the possible infringement of the Competition Act 1998 and Articles 101 and 102 of the Treaty on the Functioning of the EU, with respect to alleged agreements related to Paroxetine. The CMA issued a decision on February 12, 2016, finding that, Generics [U.K.] Limited, Merck KGaA and other companies were liable for infringing EU and U.K. competition rules. With respect to Merck KGaA and Generics [U.K.] Limited, the CMA issued a penalty of approximately £5.8 million , for which Merck KGaA is liable for the entire amount; and of that amount Generics [U.K.] Limited is jointly and severally liable for approximately £2.7 million , which has been accrued for as of September 30, 2018 . The matter is currently on appeal to the Competition Appeals Tribunal, which on March 8, 2018, referred certain questions of law to the European C

General (Policies)

General (Policies)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting Policy	The accompanying unaudited Condensed Consolidated Financial Statements (“ interim financial statements ”) of Mylan N.V. and subsidiaries (“Mylan” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, comprehensive earnings, financial position and cash flows for the periods presented.

Earnings per Ordinary Share (Po

Earnings per Ordinary Share (Policies)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings per Share Policy	Basic earnings per ordinary share is computed by dividing net earnings by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per ordinary share is computed by dividing net earnings by the weighted average number of ordinary shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Policies)	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value of Financial Instruments Policy	Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Segment Information (Policies)

Segment Information (Policies)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Reporting Policy	Mylan reports segment information on a geographic basis. This approach reflects the company’s focus on bringing its broad and diversified portfolio of generic, branded generic, brand-name and over-the-counter products to people in markets everywhere. Our North America segment comprises our operations in the U.S. and Canada. Our Europe segment comprises our operations in more than 35 countries, including France, Italy, Germany, the U.K. and Spain. Our Rest of World segment reflects our operations in more than 120 countries, including Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle East and Southeast Asia. The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability. Segment profitability represents segment gross profit less direct R&D and direct SG&A. Certain general and administrative and R&D expenses not allocated to the segments, including certain special items, net charges for litigation settlements and other contingencies, amortization of intangible assets, impairment charges and other expenses not directly attributable to the segments are reported separately or outside of segment profitability. Items below the earnings from operations line on the Company’s Condensed Consolidated Statements of Operations are not presented by segment, since they are excluded from the measure of segment profitability. The Company has revised segment profitability for Rest of World to conform with the current presentation by reclassifying approximately $78.2 million of net gains to litigation settlements and other contingencies for the nine months ended September 30, 2017 . The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. The accounting policies of the segments are the same as those described in Note 2 Revenue Recognition and Accounts Receivable above and the “Summary of Significant Accounting Policies” included in the 2017 Form 10-K. Intersegment revenues are accounted for at current market values and are eliminated at the consolidated level.

Restructuring (Policies)

Restructuring (Policies)	9 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]	Charges for restructuring and ongoing cost reduction initiatives are recorded in the period the Company commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met.

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Revenue Disaggregation The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the three and nine months ended September 30, 2018 : (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2018 Central Nervous System & Anesthesia $ 154.7 $ 219.6 $ 92.4 $ 466.7 Infectious Disease 63.1 157.8 223.2 444.1 Respiratory & Allergy 161.8 94.8 47.4 304.0 Cardiovascular 95.9 147.3 40.9 284.1 Gastroenterology 24.5 150.0 91.1 265.6 Diabetes & Metabolism 94.9 73.9 43.8 212.6 Dermatology 86.7 62.8 18.0 167.5 Women’s Healthcare 83.1 61.3 28.1 172.5 Oncology 171.0 18.2 31.9 221.1 Immunology 8.0 2.3 10.0 20.3 Other (1) 68.6 53.3 146.9 268.8 Total $ 1,012.3 $ 1,041.3 $ 773.7 $ 2,827.3 Nine Months Ended September 30, 2018 Central Nervous System & Anesthesia $ 554.2 $ 665.7 $ 251.7 $ 1,471.6 Infectious Disease 172.1 280.5 643.8 1,096.4 Respiratory & Allergy 457.3 351.8 147.7 956.8 Cardiovascular 262.4 443.2 126.6 832.2 Gastroenterology 102.5 448.3 249.3 800.1 Diabetes & Metabolism 318.6 227.9 102.1 648.6 Dermatology 265.7 217.4 70.1 553.2 Women’s Healthcare 261.4 198.1 69.5 529.0 Oncology 382.5 55.4 95.6 533.5 Immunology 36.1 7.3 29.1 72.5 Other (1) 185.6 174.7 379.0 739.3 Total $ 2,998.4 $ 3,070.3 $ 2,164.5 $ 8,233.2 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales. Variable Consideration and Accounts Receivable The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2018 : (In millions) Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Gross sales $ 4,861.4 $ 14,419.0 Gross to net adjustments: Chargebacks (835.7 ) (2,524.2 ) Rebates, promotional programs and other sales allowances (1,025.6 ) (3,144.2 ) Returns (59.4 ) (160.5 ) Governmental rebate programs (113.4 ) (356.9 ) Total gross to net adjustments $ (2,034.1 ) $ (6,185.8 ) Net sales $ 2,827.3 $ 8,233.2 No significant revisions were made to the methodology used in determining these provisions or the nature of the provisions during the three and nine months ended September 30, 2018 . Such allowances were comprised of the following at September 30, 2018 and December 31, 2017 , respectively: The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the three and nine months ended September 30, 2018 : (In millions) North America Europe Rest of World Total Three Months Ended September 30, 2018 Central Nervous System & Anesthesia $ 154.7 $ 219.6 $ 92.4 $ 466.7 Infectious Disease 63.1 157.8 223.2 444.1 Respiratory & Allergy 161.8 94.8 47.4 304.0 Cardiovascular 95.9 147.3 40.9 284.1 Gastroenterology 24.5 150.0 91.1 265.6 Diabetes & Metabolism 94.9 73.9 43.8 212.6 Dermatology 86.7 62.8 18.0 167.5 Women’s Healthcare 83.1 61.3 28.1 172.5 Oncology 171.0 18.2 31.9 221.1 Immunology 8.0 2.3 10.0 20.3 Other (1) 68.6 53.3 146.9 268.8 Total $ 1,012.3 $ 1,041.3 $ 773.7 $ 2,827.3 Nine Months Ended September 30, 2018 Central Nervous System & Anesthesia $ 554.2 $ 665.7 $ 251.7 $ 1,471.6 Infectious Disease 172.1 280.5 643.8 1,096.4 Respiratory & Allergy 457.3 351.8 147.7 956.8 Cardiovascular 262.4 443.2 126.6 832.2 Gastroenterology 102.5 448.3 249.3 800.1 Diabetes & Metabolism 318.6 227.9 102.1 648.6 Dermatology 265.7 217.4 70.1 553.2 Women’s Healthcare 261.4 198.1 69.5 529.0 Oncology 382.5 55.4 95.6 533.5 Immunology 36.1 7.3 29.1 72.5 Other (1) 185.6 174.7 379.0 739.3 Total $ 2,998.4 $ 3,070.3 $ 2,164.5 $ 8,233.2 ____________ (1) Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales.
Schedule of Accounts Receivable, Net	Accounts receivable, net was comprised of the following at September 30, 2018 and December 31, 2017 , respectively: (In millions) September 30, December 31, Trade receivables, net $ 2,591.0 $ 3,173.1 Other receivables 357.7 439.3 Accounts receivable, net $ 2,948.7 $ 3,612.4

Acquisitions and Other Transa_2

Acquisitions and Other Transactions (Tables)	9 Months Ended
	Sep. 30, 2018
Apicore [Member]
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The allocation of the $174.9 million purchase price to the assets acquired and liabilities assumed for this business is as follows: (In millions) Current assets (net of cash acquired) $ 6.5 Identified intangible assets 121.0 Goodwill 92.2 Other assets 1.9 Total assets acquired 221.6 Current liabilities (4.1 ) Deferred tax liabilities (40.9 ) Other non-current liabilities (1.7 ) Net assets acquired $ 174.9

Share-Based Incentive Plan (Tab

Share-Based Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Awards Activity	The following table summarizes stock option and SAR (together, “stock awards”) activity: Number of Shares Under Stock Awards Weighted Average Exercise Price per Share Outstanding at December 31, 2017 7,198,684 $ 35.17 Granted 847,590 40.92 Exercised (720,226 ) 21.77 Forfeited (286,473 ) 48.37 Outstanding at September 30, 2018 7,039,575 $ 36.69 Vested and expected to vest at September 30, 2018 6,821,737 $ 36.48 Exercisable at September 30, 2018 5,335,545 $ 34.76
Nonvested Restricted Stock and Restricted Stock Unit Awards Activity	A summary of the status of the Company’s nonvested restricted ordinary shares and restricted stock unit awards, including PSUs (collectively, “restricted stock awards”), as of September 30, 2018 and the changes during the nine months ended September 30, 2018 are presented below: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value per Share Nonvested at December 31, 2017 5,964,207 $ 41.92 Granted 1,542,727 41.03 Released (682,557 ) 50.06 Forfeited (257,208 ) 44.88 Nonvested at September 30, 2018 6,567,169 $ 40.79

Pensions and Other Postretire_2

Pensions and Other Postretirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2018
Retirement Benefits [Abstract]
Net Periodic Benefit Cost	Components of net periodic benefit cost for the three and nine months ended September 30, 2018 and 2017 were as follows: Pension and Other Postretirement Benefits Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Service cost $ 5.0 $ 5.0 $ 15.1 $ 15.1 Interest cost 3.6 3.7 10.9 11.2 Expected return on plan assets (3.6 ) (3.5 ) (10.9 ) (10.6 ) Amortization of prior service costs 0.1 0.1 0.3 0.2 Recognized net actuarial losses 0.1 0.2 0.1 0.5 Net periodic benefit cost $ 5.2 $ 5.5 $ 15.5 $ 16.4

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2018
Balance Sheet Components [Abstract]
Schedule of Cash, cash equivalents, and restricted cash [Table Text Block]	Cash and restricted cash (In millions) September 30, December 31, September 30, Cash and cash equivalents $ 449.2 $ 292.1 $ 614.9 Restricted cash, included in prepaid expenses and other current assets 53.9 77.8 135.9 Cash, cash equivalents and restricted cash $ 503.1 $ 369.9 $ 750.8 The following tables provide a reconciliation of cash and cash equivalents, as reported on our unaudited condensed consolidating balance sheets, to cash, cash equivalents and restricted cash, as reported on our unaudited condensed consolidating statements of cash flows (in millions): September 30, 2018 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 27.1 $ — $ 422.1 $ — $ 449.2 Restricted cash, included in prepaid expenses and other current assets — — — 53.9 — 53.9 Cash, cash equivalents and restricted cash $ — $ 27.1 $ — $ 476.0 $ — $ 503.1 December 31, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Restricted cash, included in prepaid expenses and other current assets — 23.6 — 54.2 — 77.8 Cash, cash equivalents and restricted cash $ — $ 23.8 $ — $ 346.1 $ — $ 369.9 September 30, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 82.2 $ — $ 532.7 $ — $ 614.9 Restricted cash, included in prepaid expenses and other current assets — 73.1 — 62.8 — 135.9 Cash, cash equivalents and restricted cash $ — $ 155.3 $ — $ 595.5 $ — $ 750.8
Inventories	Inventories (In millions) September 30, December 31, Raw materials $ 926.0 $ 895.5 Work in process 369.5 384.7 Finished goods 1,265.1 1,262.5 Inventories $ 2,560.6 $ 2,542.7
Prepaid Expenses and Other Current Assets	Prepaid and other current assets (In millions) September 30, December 31, 2017 Prepaid expenses $ 117.1 $ 119.8 Restricted cash 53.9 77.8 Available-for-sale fixed income securities 25.3 31.5 Fair value of financial instruments 7.1 88.9 Equity securities 36.6 79.1 Other current assets 343.2 369.0 Prepaid expenses and other current assets $ 583.2 $ 766.1
Property, Plant and Equipment	Property, plant and equipment, net (In millions) September 30, December 31, 2017 Machinery and equipment $ 2,365.2 $ 2,414.5 Buildings and improvements 1,170.4 1,191.7 Construction in progress 221.1 252.9 Land and improvements 133.8 143.1 Gross property, plant and equipment 3,890.5 4,002.2 Accumulated depreciation 1,770.9 1,663.1 Property, plant and equipment, net $ 2,119.6 $ 2,339.1
Other Assets	Other assets (In millions) September 30, December 31, 2017 Equity method investments, clean energy investments $ 149.5 $ 226.0 Other long-term assets 95.2 79.6 Other assets $ 244.7 $ 305.6
Trade Accounts Payable	ccounts payable (In millions) September 30, December 31, Trade accounts payable $ 963.7 $ 976.0 Other payables 437.4 476.5 Accounts payable $ 1,401.1 $ 1,452.5
Other Current Liabilities	Other current liabilities (In millions) September 30, December 31, 2017 Accrued sales allowances $ 631.9 $ 818.0 Legal and professional accruals, including litigation accruals 131.4 241.1 Payroll and employee benefit liabilities 372.4 404.6 Contingent consideration 223.3 167.8 Accrued interest 193.8 42.3 Restructuring 80.9 91.5 Equity method investments, clean energy investments 38.1 56.7 Fair value of financial instruments 114.4 31.1 Other 742.2 1,111.4 Other current liabilities $ 2,528.4 $ 2,964.5
Other Noncurrent Liabilities	Other long-term obligations (In millions) September 30, December 31, 2017 Employee benefit liabilities $ 411.7 $ 408.2 Contingent consideration 195.5 285.9 Equity method investments, clean energy investments 151.4 171.8 Tax related items, including contingencies 155.6 237.7 Other 237.4 132.1 Other long-term obligations $ 1,151.6 $ 1,235.7

Equity Method Investments (Tabl

Equity Method Investments (Tables)	9 Months Ended
	Sep. 30, 2018
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis for the three and nine months ended September 30, 2018 and 2017 are as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Total revenues $ 128.6 $ 129.3 $ 376.8 $ 352.0 Gross loss (1.3 ) (2.4 ) (20.0 ) (8.8 ) Operating and non-operating expense 5.9 6.5 16.5 16.9 Net loss $ (7.2 ) $ (8.9 ) $ (36.5 ) $ (25.7 )

Earnings per Ordinary Share (Ta

Earnings per Ordinary Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Basic and Diluted Earnings per Ordinary Share Attributable to Mylan N.V.	Basic and diluted earnings per ordinary share are calculated as follows: Three Months Ended Nine Months Ended September 30, September 30, (In millions, except per share amounts) 2018 2017 2018 2017 Basic earnings (numerator): Net earnings $ 176.7 $ 88.3 $ 301.3 $ 451.7 Shares (denominator): Weighted average ordinary shares outstanding 514.5 535.2 514.4 534.9 Basic earnings per ordinary share $ 0.34 $ 0.17 $ 0.59 $ 0.84 Diluted earnings (numerator): Net earnings $ 176.7 $ 88.3 $ 301.3 $ 451.7 Shares (denominator): Weighted average ordinary shares outstanding 514.5 535.2 514.4 534.9 Share-based awards 2.0 1.8 2.1 2.1 Total dilutive shares outstanding 516.5 537.0 516.5 537.0 Diluted earnings per ordinary share $ 0.34 $ 0.16 $ 0.58 $ 0.84

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2018 are as follows: (In millions) North America Segment Europe Segment Rest of World Segment Total Balance at December 31, 2017: Goodwill $ 3,934.6 $ 4,967.1 $ 1,689.0 $ 10,590.7 Accumulated impairment losses (385.0 ) — — (385.0 ) 3,549.6 4,967.1 1,689.0 10,205.7 Foreign currency translation (16.8 ) (255.1 ) (137.2 ) (409.1 ) $ 3,532.8 $ 4,712.0 $ 1,551.8 $ 9,796.6 Balance at September 30, 2018: Goodwill $ 3,917.8 $ 4,712.0 $ 1,551.8 $ 10,181.6 Accumulated impairment losses (385.0 ) — — (385.0 ) $ 3,532.8 $ 4,712.0 $ 1,551.8 $ 9,796.6
Components of Intangible Assets	Intangible assets consist of the following components at September 30, 2018 and December 31, 2017 : (In millions) Weighted Average Life (Years) Original Cost Accumulated Amortization Net Book Value September 30, 2018 Product rights, licenses and other (1) 15 $ 20,407.7 $ 6,857.5 $ 13,550.2 In-process research and development 688.8 — 688.8 $ 21,096.5 $ 6,857.5 $ 14,239.0 December 31, 2017 Product rights, licenses and other (1) 15 $ 20,338.7 $ 5,906.1 $ 14,432.6 In-process research and development 813.2 — 813.2 $ 21,151.9 $ 5,906.1 $ 15,245.8 ____________ (1) Represents amortizable intangible assets.
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Intangible asset amortization expense $ 412.2 $ 369.4 $ 1,191.9 $ 1,052.6 Intangible asset impairment charges 15.5 — 87.5 13.0 Total Intangible asset amortization expense (including impairment charges) $ 427.7 $ 369.4 $ 1,279.4 $ 1,065.6
Expected Amortization Expense	mortization expense over the remainder of 2018 and for the years ended December 31, 2019 through 2022 is estimated to be as follows: (In millions) 2018 $ 383 2019 1,446 2020 1,283 2021 1,203 2022 1,137

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Tables)	9 Months Ended
	Sep. 30, 2018
Derivatives, Fair Value [Line Items]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2017 to September 30, 2018 is as follows: (In millions) Current Portion (1) Long-Term Portion (2) Total Contingent Consideration Balance at December 31, 2017 $ 167.8 $ 285.9 $ 453.7 Payments (1.1 ) — (1.1 ) Reclassifications 53.6 (53.6 ) — Accretion — 15.1 15.1 Fair value adjustments (3) 3.0 (51.9 ) (48.9 ) Balance at September 30, 2018 $ 223.3 $ 195.5 $ 418.8 ____________ (1) Included in other current liabilities on the Condensed Consolidated Balance Sheets. (2) Included in other long-term obligations on the Condensed Consolidated Balance Sheets. (3) Included in litigation settlements and other contingencies, net in the Condensed Consolidated Statements of Operations.
Financial Assets and Liabilities Carried at Fair Value	Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above: September 30, 2018 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 27.5 $ — $ — $ 27.5 Total cash equivalents 27.5 — — 27.5 Equity securities: Exchange traded funds 35.7 — — 35.7 Marketable securities 0.9 — — 0.9 Total equity securities 36.6 — — 36.6 Available-for-sale fixed income investments: Corporate bonds — 10.4 — 10.4 U.S. Treasuries — 8.7 — 8.7 Agency mortgage-backed securities — 1.7 — 1.7 Asset backed securities — 3.2 — 3.2 Other — 1.3 — 1.3 Total available-for-sale fixed income investments — 25.3 — 25.3 Foreign exchange derivative assets — 7.1 — 7.1 Total assets at recurring fair value measurement $ 64.1 $ 32.4 $ — $ 96.5 Financial Liabilities Interest rate swap derivative liabilities $ — $ 11.1 $ — $ 11.1 Foreign exchange derivative liabilities — 103.3 — 103.3 Contingent consideration — — 418.8 418.8 Total liabilities at recurring fair value measurement $ — $ 114.4 $ 418.8 $ 533.2 December 31, 2017 (In millions) Level 1 Level 2 Level 3 Total Recurring fair value measurements Financial Assets Cash equivalents: Money market funds $ 8.4 $ — $ — $ 8.4 Total cash equivalents 8.4 — — 8.4 Equity securities: Exchange traded funds 33.9 — — 33.9 Marketable securities 45.2 — — 45.2 Total equity securities 79.1 — — 79.1 Available-for-sale fixed income investments: Corporate bonds — 16.5 — 16.5 U.S. Treasuries — 7.4 — 7.4 Agency mortgage-backed securities — 4.1 — 4.1 Asset backed securities — 2.1 — 2.1 Other — 1.4 — 1.4 Total available-for-sale fixed income investments — 31.5 — 31.5 Foreign exchange derivative assets — 72.7 — 72.7 Interest rate swap derivative assets — 16.2 — 16.2 Total assets at recurring fair value measurement $ 87.5 $ 120.4 $ — $ 207.9 Financial Liabilities Foreign exchange derivative liabilities $ — $ 31.1 $ — $ 31.1 Contingent consideration — — 453.7 453.7 Total liabilities at recurring fair value measurement $ — $ 31.1 $ 453.7 $ 484.8
Fair Value Hedging Relationships
Derivatives, Fair Value [Line Items]
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships Location of Gain (Loss) Recognized in Earnings on Derivatives Amount of Gain (Loss) Recognized in Earnings on Derivatives (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Interest rate swaps Interest expense $ (5.0 ) $ (2.5 ) $ (27.3 ) $ (1.0 ) Total $ (5.0 ) $ (2.5 ) $ (27.3 ) $ (1.0 ) Location of Gain (Loss) Recognized in Earnings on Hedged Items Amount of Gain (Loss) Recognized in Earnings on Hedged Items (In millions) Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 2023 Senior Notes (3.125% coupon) Interest expense $ 5.0 $ 2.5 $ 27.3 $ 1.0 Total $ 5.0 $ 2.5 $ 27.3 $ 1.0
Cash Flow Hedging
Derivatives, Fair Value [Line Items]
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency forward contracts $ (33.9 ) $ (8.8 ) $ (87.7 ) $ 7.5 Interest rate swaps — (3.3 ) — (2.0 ) Total $ (33.9 ) $ (12.1 ) $ (87.7 ) $ 5.5 The Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships Location of Gain (Loss) Reclassified from AOCE into Earnings (Effective Portion) Amount of Gain (Loss) Reclassified from AOCE into Earnings Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency forward contracts Net sales $ 0.9 $ 2.0 $ 8.1 $ (3.8 ) Interest rate swaps Interest expense (1.9 ) (1.9 ) (5.7 ) (5.5 ) Total $ (1.0 ) $ 0.1 $ 2.4 $ (9.3 ) Location of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness Amount of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency forward contracts Other expense, net $ — $ 3.3 $ — $ 6.9 Total $ — $ 3.3 $ — $ 6.9
Net Investment Hedging
Derivatives, Fair Value [Line Items]
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationships Amount of Gain (Loss) Recognized in AOCE Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency borrowings and forward contracts $ 17.9 $ (72.1 ) $ 77.7 $ (203.2 ) Total $ 17.9 $ (72.1 ) $ 77.7 $ (203.2 )
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Designated as Hedging Instruments Asset Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Prepaid expenses and other current assets $ — Prepaid expenses and other current assets $ 16.2 Foreign currency forward contracts Prepaid expenses and other current assets — Prepaid expenses and other current assets 63.4 Total $ — $ 79.6 Liability Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Interest rate swaps Other current liabilities $ 11.1 Other current liabilities $ — Foreign currency forward contracts Other current liabilities 76.8 Other current liabilities — Total $ 87.9 $ —
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated as Hedging Instruments Asset Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Prepaid expenses and other current assets $ 7.1 Prepaid expenses and other current assets $ 9.3 Total $ 7.1 $ 9.3 Liability Derivatives September 30, 2018 December 31, 2017 (In millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Foreign currency forward contracts Other current liabilities $ 26.5 Other current liabilities $ 31.1 Total $ 26.5 $ 31.1
Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations	The Effect of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments Location of Gain (Loss) Recognized in Earnings on Derivatives Amount of Gain (Loss) Recognized in Earnings on Derivatives Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2018 2017 2018 2017 Foreign currency option and forward contracts Other expense, net $ (25.1 ) $ (43.0 ) $ 2.5 $ (60.1 ) Total $ (25.1 ) $ (43.0 ) $ 2.5 $ (60.1 )

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Summary of Long-Term Debt	A summary of long-term debt is as follows: (In millions) Interest Rate as of September 30, 2018 September 30, December 31, Current portion of long-term debt: 2018 Senior Notes * 2.600 % $ — $ 649.9 2018 Floating Rate Euro Notes (a) ** 580.2 600.2 2018 Senior Notes ** 3.000 % — 499.8 2019 Senior Notes ** 2.500 % 549.9 — Other 6.3 2.4 Deferred financing fees (0.8 ) (3.1 ) Current portion of long-term debt $ 1,135.6 $ 1,749.2 Non-current portion of long-term debt: 2016 Term Facility (b) ** 3.617 % 100.0 100.0 2019 Senior Notes ** 2.500 % — 999.5 2019 Senior Notes * 2.550 % — 499.7 2020 Floating Rate Euro Notes (c) ** 580.2 600.2 2020 Euro Senior Notes ** 1.250 % 868.4 897.6 2020 Senior Notes ** 3.750 % 499.9 499.9 2021 Senior Notes ** 3.150 % 2,248.5 2,248.2 2023 Senior Notes * 3.125 % 738.2 765.4 2023 Senior Notes * 4.200 % 498.9 498.8 2024 Euro Senior Notes ** 2.250 % 1,158.1 1,197.7 2025 Euro Senior Notes * 2.125 % 578.9 — 2026 Senior Notes ** 3.950 % 2,236.1 2,235.0 2028 Euro Senior Notes ** 3.125 % 862.7 892.0 2028 Senior Notes * 4.550 % 748.2 — 2043 Senior Notes * 5.400 % 497.1 497.1 2046 Senior Notes ** 5.250 % 999.8 999.8 2048 Senior Notes * 5.200 % 747.6 — Other 5.9 6.3 Deferred financing fees (77.1 ) (71.9 ) Long-term debt $ 13,291.4 $ 12,865.3 ____________ (a) Instrument bears interest at a rate of three-month EURIBOR plus 0.870% per annum, reset quarterly. (b) The 2016 Term Facility bears interest at LIBOR plus a base rate, which margins can fluctuate based on the Company’s credit ratings. (c) Instrument bears interest at a rate of three-month EURIBOR plus 0.50% per annum, reset quarterly. * Instrument was issued by Mylan Inc. ** Instrument was issued by Mylan N.V.
Minimum Repayments on Outstanding Borrowings	Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at September 30, 2018 were as follows for each of the periods ending December 31: (In millions) Total 2018 $ 580 2019 650 2020 1,951 2021 2,250 2022 — Thereafter 9,111 Total $ 14,542

Comprehensive Earnings (Tables)

Comprehensive Earnings (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss, as reflected on the Condensed Consolidated Balance Sheets , is comprised of the following: (In millions) September 30, December 31, Accumulated other comprehensive loss: Net unrealized gain on marketable securities, net of tax $ — $ 10.1 Net unrecognized (losses) gains and prior service cost related to defined benefit plans, net of tax (0.5 ) 6.0 Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax (96.9 ) (3.7 ) Net unrecognized losses on derivatives in net investment hedging relationships, net of tax (162.1 ) (239.8 ) Foreign currency translation adjustment (1,231.4 ) (133.8 ) $ (1,490.9 ) $ (361.2 )
Components of Other Comprehensive Loss	Components of accumulated other comprehensive loss, before tax, consist of the following, for the three and nine months ended September 30, 2018 and 2017 : Three Months Ended September 30, 2018 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2018, net of tax $ (63.0 ) $ (180.0 ) $ — $ 4.3 $ (960.6 ) $ (1,199.3 ) Other comprehensive (loss) earnings before reclassifications, before tax (52.9 ) 18.8 — (7.0 ) (270.8 ) (311.9 ) Amounts reclassified from accumulated other comprehensive loss, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (0.9 ) (0.9 ) (0.9 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.9 1.9 1.9 Amortization of prior service costs included in SG&A 0.1 0.1 Amortization of actuarial loss included in SG&A 0.1 0.1 Net other comprehensive (loss) earnings, before tax (51.9 ) 18.8 — (6.8 ) (270.8 ) (310.7 ) Income tax (benefit) provision (18.0 ) 0.9 — (2.0 ) — (19.1 ) Balance at September 30, 2018, net of tax $ (96.9 ) $ (162.1 ) $ — $ (0.5 ) $ (1,231.4 ) $ (1,490.9 ) Nine Months Ended September 30, 2018 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2017, net of tax $ (3.7 ) $ (239.8 ) $ 10.1 $ 6.0 $ (133.8 ) $ (361.2 ) Other comprehensive (loss) earnings before reclassifications, before tax (143.7 ) 78.7 (0.1 ) (8.7 ) (1,097.6 ) (1,171.4 ) Amounts reclassified from accumulated other comprehensive loss, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (8.1 ) (8.1 ) (8.1 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 5.7 5.7 5.7 Amortization of prior service costs included in SG&A 0.3 0.3 Amortization of actuarial loss included in SG&A 0.1 0.1 Net other comprehensive (loss) earnings, before tax (146.1 ) 78.7 (0.1 ) (8.3 ) (1,097.6 ) (1,173.4 ) Income tax (benefit) provision (50.4 ) 1.0 — (1.8 ) — (51.2 ) Cumulative effect of the adoption of new accounting standards 2.5 — (10.0 ) — — (7.5 ) Balance at September 30, 2018, net of tax $ (96.9 ) $ (162.1 ) $ — $ (0.5 ) $ (1,231.4 ) $ (1,490.9 ) Three Months Ended September 30, 2017 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at June 30, 2017, net of tax $ (17.1 ) $ (132.5 ) $ 22.3 $ 0.5 $ (828.8 ) $ (955.6 ) Other comprehensive (loss) earnings before reclassifications, before tax (4.4 ) (72.1 ) (8.9 ) 0.8 423.0 338.4 Amounts reclassified from accumulated other comprehensive loss, before tax: Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales (2.0 ) (2.0 ) (2.0 ) Loss on interest rate swaps classified as cash flow hedges, included in interest expense 1.9 1.9 1.9 Amortization of prior service costs included in SG&A 0.1 0.1 Amortization of actuarial loss included in SG&A 0.2 0.2 Net other comprehensive (loss) earnings, before tax (4.5 ) (72.1 ) (8.9 ) 1.1 423.0 338.6 Income tax (benefit) provision (2.8 ) — (3.2 ) 0.2 — (5.8 ) Balance at September 30, 2017, net of tax $ (18.8 ) $ (204.6 ) $ 16.6 $ 1.4 $ (405.8 ) $ (611.2 ) Nine Months Ended September 30, 2017 Gains and Losses on Derivatives in Cash Flow Hedging Relationships Gains and Losses on Net Investment Hedges Gains and Losses on Marketable Securities Defined Pension Plan Items Foreign Currency Translation Adjustment Totals (In millions) Foreign Currency Forward Contracts Interest Rate Swaps Total Balance at December 31, 2016, net of tax $ (38.6 ) $ (1.4 ) $ 14.5 $ (0.5 ) $ (2,237.7 ) $ (2,263.7 ) Other comprehensive earnings (loss) before reclassifications, before tax 19.9 (203.2 ) 3.5 1.7 1,831.9 1,653.8 Amounts reclassified from accumulated other comprehensive loss, before tax: Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales 3.8 3.8 3.8 Loss on interest rate swaps classified as cash flow hedges, included in interest expense 5.5 5.5 5.5 Amortization of prior service costs included in SG&A 0.2 0.2 Amortization of actuarial gain included in SG&A 0.5 0.5 Net other comprehensive earnings (loss), before tax 29.2 (203.2 ) 3.5 2.4 1,831.9 1,663.8 Income tax provision 9.4 — 1.4 0.5 — 11.3 Balance at September 30, 2017, net of tax $ (18.8 ) $ (204.6 ) $ 16.6 $ 1.4 $ (405.8 ) $ (611.2 )

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Summary of Changes in Shareholders' Equity	A summary of the changes in shareholders’ equity for the nine months ended September 30, 2018 and 2017 is as follows: (In millions) Total December 31, 2017 $ 13,307.6 Net earnings 301.3 Other comprehensive loss, net of tax (1,122.2 ) Stock option activity 15.4 Ordinary share repurchase (432.0 ) Share-based compensation expense (8.6 ) Issuance of restricted stock, net of shares withheld (8.1 ) Cumulative effect of the adoption of new accounting standards 12.8 September 30, 2018 $ 12,066.2 (In millions) Total Noncontrolling Interest Total December 31, 2016 $ 11,116.2 $ 1.4 $ 11,117.6 Net earnings 451.7 — 451.7 Other comprehensive earnings, net of tax 1,652.5 — 1,652.5 Stock option activity 12.8 — 12.8 Share-based compensation expense 64.2 — 64.2 Issuance of restricted stock, net of shares withheld (5.8 ) — (5.8 ) Other — (1.4 ) (1.4 ) September 30, 2017 $ 13,291.6 $ — $ 13,291.6

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Reconciliation of Segment Information to Total Consolidated Information	Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information. (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2018 Net sales $ 1,012.3 $ 1,041.3 $ 773.7 $ — $ 2,827.3 Other revenue 20.9 7.4 6.8 — 35.1 Intersegment revenue 19.5 23.2 97.3 (140.0 ) — Total $ 1,052.7 $ 1,071.9 $ 877.8 $ (140.0 ) $ 2,862.4 Segment profitability $ 446.0 $ 310.5 $ 194.6 $ — $ 951.1 Intangible asset amortization expense (412.2 ) Intangible asset impairment charges (15.5 ) Globally managed research and development costs (61.9 ) Corporate costs and special items (143.7 ) Litigation settlements & other contingencies 20.4 Earnings from operations $ 338.2 Nine Months Ended September 30, 2018 Net sales $ 2,998.4 $ 3,070.3 $ 2,164.5 $ — $ 8,233.2 Other revenue 84.5 19.8 17.7 — 122.0 Intersegment revenue 55.5 74.2 287.1 (416.8 ) — Total $ 3,138.4 $ 3,164.3 $ 2,469.3 $ (416.8 ) $ 8,355.2 Segment profitability $ 1,281.3 $ 806.8 $ 475.2 $ — $ 2,563.3 Intangible asset amortization expense (1,191.9 ) Intangible asset impairment charges (87.5 ) Globally managed research and development costs (213.6 ) Corporate costs and special items (448.1 ) Litigation settlements & other contingencies 50.6 Earnings from operations $ 672.8 (In millions) North America Europe Rest of World Eliminations Consolidated Three Months Ended September 30, 2017 Net sales $ 1,172.2 $ 1,040.8 $ 743.3 $ — $ 2,956.3 Other revenue 20.0 8.9 1.9 — 30.8 Intersegment revenue 15.5 18.4 87.7 (121.6 ) — Total $ 1,207.7 $ 1,068.1 $ 832.9 $ (121.6 ) $ 2,987.1 Segment profitability $ 575.8 $ 290.3 $ 133.9 $ — $ 1,000.0 Intangible asset amortization expense (369.4 ) Globally managed research and development costs (76.8 ) Corporate costs and special items (222.1 ) Litigation settlements & other contingencies (15.2 ) Earnings from operations $ 316.5 Nine Months Ended September 30, 2017 Net sales $ 3,666.7 $ 2,887.1 $ 2,016.4 $ — $ 8,570.2 Other revenue 67.3 25.0 6.3 — 98.6 Intersegment revenue 60.5 87.6 275.4 (423.5 ) — Total $ 3,794.5 $ 2,999.7 $ 2,298.1 $ (423.5 ) $ 8,668.8 Segment profitability $ 1,810.5 $ 776.8 $ 358.9 $ — $ 2,946.2 Intangible asset amortization expense (1,052.6 ) Intangible asset impairment charges (13.0 ) Globally managed research and development costs (269.0 ) Corporate costs and special items (619.4 ) Litigation settlements & other contingencies 25.8 Earnings from operations $ 1,018.0

Subsidiary Guarantors (Tables)

Subsidiary Guarantors (Tables)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Income Statement	UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 2,827.3 $ — $ 2,827.3 Other revenues — — — 35.1 — 35.1 Total revenues — — — 2,862.4 — 2,862.4 Cost of sales — — — 1,823.2 — 1,823.2 Gross profit — — — 1,039.2 — 1,039.2 Operating expenses: Research and development — — — 144.1 — 144.1 Selling, general and administrative 11.5 117.6 — 448.2 — 577.3 Litigation settlements and other contingencies, net — 0.1 — (20.5 ) — (20.4 ) Total operating expenses 11.5 117.7 — 571.8 — 701.0 (Loss) earnings from operations (11.5 ) (117.7 ) — 467.4 — 338.2 Interest expense 84.0 42.9 — 9.3 — 136.2 Other (income) expense, net (47.9 ) (79.0 ) — 136.7 — 9.8 (Loss) earnings before income taxes (47.6 ) (81.6 ) — 321.4 — 192.2 Income tax (benefit) provision (8.0 ) 18.1 — 5.4 — 15.5 Earnings of equity interest subsidiaries 216.3 143.3 — — (359.6 ) — Net earnings $ 176.7 $ 43.6 $ — $ 316.0 $ (359.6 ) $ 176.7 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 8,233.2 $ — $ 8,233.2 Other revenues — — — 122.0 — 122.0 Total revenues — — — 8,355.2 — 8,355.2 Cost of sales — — — 5,369.2 — 5,369.2 Gross profit — — — 2,986.0 — 2,986.0 Operating expenses: Research and development — — — 555.7 — 555.7 Selling, general and administrative 31.0 367.7 — 1,409.4 — 1,808.1 Litigation settlements and other contingencies, net — 7.1 — (57.7 ) — (50.6 ) Total operating expenses 31.0 374.8 — 1,907.4 — 2,313.2 (Loss) earnings from operations (31.0 ) (374.8 ) — 1,078.6 — 672.8 Interest expense 266.1 110.9 — 30.1 — 407.1 Other (income) expense, net (211.5 ) (205.0 ) — 460.8 — 44.3 (Loss) earnings before income taxes (85.6 ) (280.7 ) — 587.7 — 221.4 Income tax (benefit) provision (23.3 ) 13.5 — (70.1 ) — (79.9 ) Earnings of equity interest subsidiaries 363.6 217.2 — — (580.8 ) — Net earnings (loss) $ 301.3 $ (77.0 ) $ — $ 657.8 $ (580.8 ) $ 301.3 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 2,956.3 $ — $ 2,956.3 Other revenues — — — 30.8 — 30.8 Total revenues — — — 2,987.1 — 2,987.1 Cost of sales — — — 1,809.0 — 1,809.0 Gross profit — — — 1,178.1 — 1,178.1 Operating expenses: Research and development — — — 182.3 — 182.3 Selling, general and administrative 6.5 184.3 — 473.3 — 664.1 Litigation settlements and other contingencies, net — 17.0 — (1.8 ) — 15.2 Total operating expenses 6.5 201.3 — 653.8 — 861.6 (Loss) earnings from operations (6.5 ) (201.3 ) — 524.3 — 316.5 Interest expense 93.3 26.7 — 11.8 — 131.8 Other (income) expense, net (122.3 ) (44.7 ) — 172.1 — 5.1 Earnings (loss) before income taxes 22.5 (183.3 ) — 340.4 — 179.6 Income tax provision (benefit) 2.4 (0.6 ) — 89.5 — 91.3 Earnings of equity interest subsidiaries 68.2 129.9 — — (198.1 ) — Net earnings (loss) $ 88.3 $ (52.8 ) $ — $ 250.9 $ (198.1 ) $ 88.3 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Revenues: Net sales $ — $ — $ — $ 8,570.2 $ — $ 8,570.2 Other revenues — — — 98.6 — 98.6 Total revenues — — — 8,668.8 — 8,668.8 Cost of sales — — — 5,180.3 — 5,180.3 Gross profit — — — 3,488.5 — 3,488.5 Operating expenses: Research and development — — — 580.9 — 580.9 Selling, general and administrative 32.4 477.6 — 1,405.4 — 1,915.4 Litigation settlements and other contingencies, net — 17.0 — (42.8 ) — (25.8 ) Total operating expenses 32.4 494.6 — 1,943.5 — 2,470.5 (Loss) earnings from operations (32.4 ) (494.6 ) — 1,545.0 — 1,018.0 Interest expense 285.6 77.8 — 42.9 — 406.3 Other (income) expense, net (331.3 ) (161.5 ) — 528.6 — 35.8 Earnings (loss) before income taxes 13.3 (410.9 ) — 973.5 — 575.9 Income tax provision 1.4 5.1 — 117.7 — 124.2 Earnings of equity interest subsidiaries 439.8 788.8 — — (1,228.6 ) — Net earnings $ 451.7 $ 372.8 $ — $ 855.8 $ (1,228.6 ) $ 451.7
Condensed Consolidating Statement of Comprehensive Earnings	UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Three Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 176.7 $ 43.6 $ — $ 316.0 $ (359.6 ) $ 176.7 Other comprehensive (loss) earnings, before tax: Foreign currency translation adjustment (270.8 ) — — (270.8 ) 270.8 (270.8 ) Change in unrecognized (loss) gain and prior service cost related to defined benefit plans (6.8 ) 0.1 — (6.9 ) 6.8 (6.8 ) Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (51.9 ) 1.9 — (53.8 ) 51.9 (51.9 ) Net unrecognized gain on derivatives in net investment hedging relationships 18.8 4.0 — — (4.0 ) 18.8 Other comprehensive (loss) earnings, before tax (310.7 ) 6.0 — (331.5 ) 325.5 (310.7 ) Income tax benefit (19.1 ) (1.6 ) — (17.5 ) 19.1 (19.1 ) Other comprehensive (loss) earnings, net of tax (291.6 ) 7.6 — (314.0 ) 306.4 (291.6 ) Comprehensive (loss) earnings $ (114.9 ) $ 51.2 $ — $ 2.0 $ (53.2 ) $ (114.9 ) UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Nine Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings (loss) $ 301.3 $ (77.0 ) $ — $ 657.8 $ (580.8 ) $ 301.3 Other comprehensive (loss) earnings, before tax: Foreign currency translation adjustment (1,097.6 ) — — (1,097.6 ) 1,097.6 (1,097.6 ) Change in unrecognized (loss) gain and prior service cost related to defined benefit plans (8.3 ) 0.2 — (8.5 ) 8.3 (8.3 ) Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (146.1 ) 5.7 — (151.8 ) 146.1 (146.1 ) Net unrecognized gain on derivatives in net investment hedging relationships 78.7 4.6 — — (4.6 ) 78.7 Net unrealized loss on marketable securities (0.1 ) — — (0.1 ) 0.1 (0.1 ) Other comprehensive (loss) earnings, before tax (1,173.4 ) 10.5 — (1,258.0 ) 1,247.5 (1,173.4 ) Income tax benefit (51.2 ) (2.4 ) — (48.8 ) 51.2 (51.2 ) Other comprehensive (loss) earnings, net of tax (1,122.2 ) 12.9 — (1,209.2 ) 1,196.3 (1,122.2 ) Comprehensive loss $ (820.9 ) $ (64.1 ) $ — $ (551.4 ) $ 615.5 $ (820.9 ) UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Three Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings (loss) $ 88.3 $ (52.8 ) $ — $ 250.9 $ (198.1 ) $ 88.3 Other comprehensive earnings (loss), before tax: Foreign currency translation adjustment 423.0 — — 423.0 (423.0 ) 423.0 Change in unrecognized gain and prior service cost related to defined benefit plans 1.1 0.1 — 1.2 (1.3 ) 1.1 Net unrecognized (loss) gain on derivatives in cash flow hedging relationships (4.5 ) 1.9 — (6.4 ) 4.5 (4.5 ) Net unrecognized loss on derivatives in net investment hedging relationships (72.1 ) — — — — (72.1 ) Net unrealized loss on marketable securities (8.9 ) (8.9 ) — — 8.9 (8.9 ) Other comprehensive earnings (loss), before tax 338.6 (6.9 ) — 417.8 (410.9 ) 338.6 Income tax (benefit) provision (5.8 ) 2.5 — (8.0 ) 5.5 (5.8 ) Other comprehensive earnings (loss), net of tax 344.4 (9.4 ) — 425.8 (416.4 ) 344.4 Comprehensive earnings (loss) $ 432.7 $ (62.2 ) $ — $ 676.7 $ (614.5 ) $ 432.7 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE EARNINGS Nine Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net earnings $ 451.7 $ 372.8 $ — $ 855.8 $ (1,228.6 ) $ 451.7 Other comprehensive earnings, before tax: Foreign currency translation adjustment 1,831.9 — — 1,831.9 (1,831.9 ) 1,831.9 Change in unrecognized gain and prior service cost related to defined benefit plans 2.4 0.3 — 2.1 (2.4 ) 2.4 Net unrecognized gain on derivatives in cash flow hedging relationships 29.2 5.5 — 23.7 (29.2 ) 29.2 Net unrecognized loss on derivatives in net investment hedging relationships (203.2 ) — — — — (203.2 ) Net unrealized gain (loss) on marketable securities 3.5 3.7 — (0.2 ) (3.5 ) 3.5 Other comprehensive earnings, before tax 1,663.8 9.5 — 1,857.5 (1,867.0 ) 1,663.8 Income tax provision (benefit) 11.3 (3.5 ) — 14.8 (11.3 ) 11.3 Other comprehensive earnings, net of tax 1,652.5 13.0 — 1,842.7 (1,855.7 ) 1,652.5 Comprehensive earnings $ 2,104.2 $ 385.8 $ — $ 2,698.5 $ (3,084.3 ) $ 2,104.2
Condensed Consolidating Balance Sheet	UNAUDITED CONDENSED CONSOLIDATING BALANCE SHEET As of September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 27.1 $ — $ 422.1 $ — $ 449.2 Accounts receivable, net — 5.0 — 2,943.7 — 2,948.7 Inventories — — — 2,560.6 — 2,560.6 Intercompany receivables 446.0 572.8 — 11,946.6 (12,965.4 ) — Prepaid expenses and other current assets 4.9 67.9 — 510.4 — 583.2 Total current assets 450.9 672.8 — 18,383.4 (12,965.4 ) 6,541.7 Property, plant and equipment, net — 263.7 — 1,855.9 — 2,119.6 Investments in subsidiaries 18,939.5 12,829.4 — — (31,768.9 ) — Intercompany notes and interest receivable 6,479.2 10,615.5 — 2,932.3 (20,027.0 ) — Intangible assets, net — — — 14,239.0 — 14,239.0 Goodwill — 17.1 — 9,779.5 — 9,796.6 Other assets 0.3 58.3 — 700.1 — 758.7 Total assets $ 25,869.9 $ 24,456.8 $ — $ 47,890.2 $ (64,761.3 ) $ 33,455.6 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 55.8 $ — $ 1,345.3 $ — $ 1,401.1 Short-term borrowings — — — 0.4 — 0.4 Income taxes payable — 4.5 — 71.2 — 75.7 Current portion of long-term debt and other long-term obligations 1,129.3 0.2 — 46.9 — 1,176.4 Intercompany payables 875.5 12,019.3 — 70.6 (12,965.4 ) — Other current liabilities 138.1 315.2 — 2,075.1 — 2,528.4 Total current liabilities 2,142.9 12,395.0 — 3,609.5 (12,965.4 ) 5,182.0 Long-term debt 9,507.9 3,777.8 — 5.7 — 13,291.4 Intercompany notes payable 2,152.9 3,127.2 — 14,746.9 (20,027.0 ) — Other long-term obligations — 50.7 — 2,865.3 — 2,916.0 Total liabilities 13,803.7 19,350.7 — 21,227.4 (32,992.4 ) 21,389.4 Total equity 12,066.2 5,106.1 — 26,662.8 (31,768.9 ) 12,066.2 Total liabilities and equity $ 25,869.9 $ 24,456.8 $ — $ 47,890.2 $ (64,761.3 ) $ 33,455.6 UNAUDITED CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated ASSETS Assets Current assets: Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Accounts receivable, net — 1.0 — 3,611.4 — 3,612.4 Inventories — — — 2,542.7 — 2,542.7 Intercompany receivables 317.2 462.1 — 11,828.5 (12,607.8 ) — Prepaid expenses and other current assets 5.6 171.1 — 589.4 — 766.1 Total current assets 322.8 634.4 — 18,863.9 (12,607.8 ) 7,213.3 Property, plant and equipment, net — 294.1 — 2,045.0 — 2,339.1 Investments in subsidiaries 19,736.5 13,683.3 — — (33,419.8 ) — Intercompany notes and interest receivable 7,822.6 10,271.2 — 2,186.3 (20,280.1 ) — Intangible assets, net — — — 15,245.8 — 15,245.8 Goodwill — 17.1 — 10,188.6 — 10,205.7 Other assets 4.9 56.5 — 741.0 — 802.4 Total assets $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3 LIABILITIES AND EQUITY Liabilities Current liabilities: Accounts payable $ — $ 45.3 $ — $ 1,407.2 $ — $ 1,452.5 Short-term borrowings — — — 46.5 — 46.5 Income taxes payable — — — 112.9 — 112.9 Current portion of long-term debt and other long-term obligations 1,097.8 649.1 — 62.0 — 1,808.9 Intercompany payables 664.7 11,911.5 — 31.6 (12,607.8 ) — Other current liabilities 35.5 397.0 — 2,532.0 — 2,964.5 Total current liabilities 1,798.0 13,002.9 — 4,192.2 (12,607.8 ) 6,385.3 Long-term debt 10,614.3 2,244.5 — 6.5 — 12,865.3 Intercompany notes payable 2,166.9 3,312.7 — 14,800.5 (20,280.1 ) — Other long-term obligations — 57.3 — 3,190.8 — 3,248.1 Total liabilities 14,579.2 18,617.4 — 22,190.0 (32,887.9 ) 22,498.7 Total equity 13,307.6 6,339.2 — 27,080.6 (33,419.8 ) 13,307.6 Total liabilities and equity $ 27,886.8 $ 24,956.6 $ — $ 49,270.6 $ (66,307.7 ) $ 35,806.3
Condensed Consolidating Statement of Cash Flows	UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Nine Months Ended September 30, 2018 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (68.6 ) $ (1,201.6 ) $ — $ 2,975.8 $ — $ 1,705.6 Cash flows from investing activities: Capital expenditures — (17.8 ) — (119.6 ) — (137.4 ) Purchase of available for sale securities and other investments — — — (49.4 ) — (49.4 ) Proceeds from the sale of marketable securities — 36.3 — 35.8 — 72.1 Cash paid for acquisitions, net — — — (65.9 ) — (65.9 ) Investments in affiliates — (22.0 ) — — 22.0 — Dividends from affiliates 65.3 — — — (65.3 ) — Loans to affiliates (470.6 ) — — (4,577.1 ) 5,047.7 — Repayments of loans from affiliates 1,810.8 — — 3,205.0 (5,015.8 ) — Payments for product rights and other, net — (0.4 ) — (853.8 ) — (854.2 ) Net cash provided by (used in) investing activities 1,405.5 (3.9 ) — (2,425.0 ) (11.4 ) (1,034.8 ) Cash flows from financing activities: Payments of financing fees (0.5 ) (20.2 ) — (0.1 ) — (20.8 ) Purchase of ordinary shares (432.0 ) — — — — (432.0 ) Change in short-term borrowings, net — — — (45.9 ) — (45.9 ) Proceeds from issuance of long-term debt 496.5 2,079.2 — 2.0 — 2,577.7 Payments of long-term debt (1,446.5 ) (1,150.0 ) — (2.1 ) — (2,598.6 ) Proceeds from exercise of stock options 15.6 — — — — 15.6 Taxes paid related to net share settlement of equity awards (10.1 ) — — — — (10.1 ) Contingent consideration payments — — — (0.2 ) — (0.2 ) Capital contribution from affiliates — — — 22.0 (22.0 ) — Capital payments to affiliates — — — (65.3 ) 65.3 — Payments on borrowings from affiliates (1,273.9 ) (3,010.1 ) — (731.8 ) 5,015.8 — Proceeds from borrowings from affiliates 1,314.0 3,309.9 — 423.8 (5,047.7 ) — Other items, net — — — (0.4 ) — (0.4 ) Net cash (used in) provided by financing activities (1,336.9 ) 1,208.8 — (398.0 ) 11.4 (514.7 ) Effect on cash of changes in exchange rates — — — (22.9 ) — (22.9 ) Net increase in cash, cash equivalents and restricted cash — 3.3 — 129.9 — 133.2 Cash, cash equivalents and restricted cash — beginning of period — 23.8 — 346.1 — 369.9 Cash, cash equivalents and restricted cash — end of period $ — $ 27.1 $ — $ 476.0 $ — $ 503.1 UNAUDITED CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Nine Months Ended September 30, 2017 (In millions) Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash flows from operating activities: Net cash (used in) provided by operating activities $ (175.1 ) $ (338.8 ) $ — $ 2,083.2 $ — $ 1,569.3 Cash flows from investing activities: Capital expenditures — (31.4 ) — (125.0 ) — (156.4 ) Purchase of available for sale securities and other investments — — — (8.9 ) — (8.9 ) Proceeds from the sale of assets — — — 31.1 — 31.1 Proceeds from the sale of marketable securities — — — 8.9 — 8.9 Cash paid for acquisitions, net (71.6 ) — — — — (71.6 ) Investments in affiliates — (21.1 ) — — 21.1 — Dividends from affiliates 168.1 — — — (168.1 ) — Loans to affiliates (143.7 ) (364.1 ) — (2,558.0 ) 3,065.8 — Repayments of loans from affiliates 1,066.4 0.3 — 943.6 (2,010.3 ) — Payments for product rights and other, net — (0.3 ) — (558.5 ) — (558.8 ) Net cash provided by (used in) investing activities 1,019.2 (416.6 ) — (2,266.8 ) 908.5 (755.7 ) Cash flows from financing activities: Payments of financing fees (8.3 ) (0.4 ) — — — (8.7 ) Change in short-term borrowings, net — — — (48.3 ) — (48.3 ) Proceeds from issuance of long-term debt 554.5 — — 1.3 — 555.8 Payments of long-term debt (1,500.0 ) — — (247.3 ) — (1,747.3 ) Proceeds from exercise of stock options 12.8 — — — — 12.8 Taxes paid related to net share settlement of equity awards (7.4 ) — — — — (7.4 ) Contingent consideration payments — — — (10.1 ) — (10.1 ) Capital contribution from affiliates — — — 21.1 (21.1 ) — Capital payments to affiliates — — — (168.1 ) 168.1 — Payments on borrowings from affiliates — (1,664.4 ) — (345.9 ) 2,010.3 — Proceeds from borrowings from affiliates 104.0 2,497.5 — 464.3 (3,065.8 ) — Other items, net — (7.4 ) — 6.7 — (0.7 ) Net cash (used in) provided by financing activities (844.4 ) 825.3 — (326.3 ) (908.5 ) (1,253.9 ) Effect on cash of changes in exchange rates — — — 44.1 — 44.1 Net (decrease) increase in cash, cash equivalents and restricted cash (0.3 ) 69.9 — (465.8 ) — (396.2 ) Cash, cash equivalents and restricted cash — beginning of period 0.3 85.4 — 1,061.3 — 1,147.0 Cash, cash equivalents and restricted cash — end of period $ — $ 155.3 $ — $ 595.5 $ — $ 750.8
Schedule of Cash, cash equivalents, and restricted cash [Table Text Block]	Cash and restricted cash (In millions) September 30, December 31, September 30, Cash and cash equivalents $ 449.2 $ 292.1 $ 614.9 Restricted cash, included in prepaid expenses and other current assets 53.9 77.8 135.9 Cash, cash equivalents and restricted cash $ 503.1 $ 369.9 $ 750.8 The following tables provide a reconciliation of cash and cash equivalents, as reported on our unaudited condensed consolidating balance sheets, to cash, cash equivalents and restricted cash, as reported on our unaudited condensed consolidating statements of cash flows (in millions): September 30, 2018 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 27.1 $ — $ 422.1 $ — $ 449.2 Restricted cash, included in prepaid expenses and other current assets — — — 53.9 — 53.9 Cash, cash equivalents and restricted cash $ — $ 27.1 $ — $ 476.0 $ — $ 503.1 December 31, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 0.2 $ — $ 291.9 $ — $ 292.1 Restricted cash, included in prepaid expenses and other current assets — 23.6 — 54.2 — 77.8 Cash, cash equivalents and restricted cash $ — $ 23.8 $ — $ 346.1 $ — $ 369.9 September 30, 2017 Mylan N.V. Mylan Inc. Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash and cash equivalents $ — $ 82.2 $ — $ 532.7 $ — $ 614.9 Restricted cash, included in prepaid expenses and other current assets — 73.1 — 62.8 — 135.9 Cash, cash equivalents and restricted cash $ — $ 155.3 $ — $ 595.5 $ — $ 750.8

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring - employee related [Table Text Block]	The following table summarizes the restructuring charges and the reserve activity from December 31, 2017 to September 30, 2018 : (In millions) Employee Related Costs Other Exit Costs Total Balance at December 31, 2017: $ 92.9 $ 14.1 $ 107.0 Charges (1) 15.1 30.3 45.4 Cash payment (28.7 ) (2.8 ) (31.5 ) Utilization — (30.8 ) (30.8 ) Foreign currency translation 0.6 — 0.6 Balance at March 31, 2018: $ 79.9 $ 10.8 $ 90.7 Charges (1) 35.1 41.0 76.1 Cash payment (31.1 ) (8.2 ) (39.3 ) Utilization — (28.0 ) (28.0 ) Foreign currency translation (2.7 ) (0.6 ) (3.3 ) Balance at June 30, 2018: $ 81.2 $ 15.0 $ 96.2 Charges (1) 16.2 64.6 80.8 Cash payment (19.3 ) (7.5 ) (26.8 ) Utilization — (54.6 ) (54.6 ) Foreign currency translation (0.3 ) 0.2 (0.1 ) Balance at September 30, 2018: $ 77.8 $ 17.7 $ 95.5 ____________ (1) For the three months ended September 30, 2018 , total restructuring charges in North America, Europe, and Rest of World were approximately $49.7 million , $28.5 million , and $2.6 million , respectively. For the nine months ended September 30, 2018 , total restructuring charges in North America, Europe, Rest of World and corporate were approximately $108.1 million , $79.9 million , $13.3 million and $1.0 million , respectively.

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Revenue Recognition And Accounts Receivable [Line Items]
Sales allowances, current	$ 1,640	$ 1,980
Accrued sales allowances and other adjustments	631.9	818
Total Current Allowances	2,274.1	2,795.2
Securitized accounts receivable	464	$ 1,040
Receivables Facility
Revenue Recognition And Accounts Receivable [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 400

Revenue Recognition and Accou_4

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Net sales	$ 2,827.3	$ 2,956.3	$ 8,233.2	$ 8,570.2
Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	466.7		1,471.6
Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	444.1		1,096.4
Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	304		956.8
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	284.1		832.2
Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	265.6		800.1
Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	212.6		648.6
Dermatology
Disaggregation of Revenue [Line Items]
Net sales	167.5		553.2
Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	172.5		529
Oncology
Disaggregation of Revenue [Line Items]
Net sales	221.1		533.5
Immunology
Disaggregation of Revenue [Line Items]
Net sales	20.3		72.5
Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	268.8		739.3
North America Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	154.7		554.2
North America Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	63.1		172.1
North America Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	161.8		457.3
North America Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	95.9		262.4
North America Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	24.5		102.5
North America Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	94.9		318.6
North America Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	86.7		265.7
North America Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	83.1		261.4
North America Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	171		382.5
North America Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	8		36.1
North America Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	68.6		185.6
Europe Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	219.6		665.7
Europe Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	157.8		280.5
Europe Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	94.8		351.8
Europe Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	147.3		443.2
Europe Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	150		448.3
Europe Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	73.9		227.9
Europe Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	62.8		217.4
Europe Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	61.3		198.1
Europe Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	18.2		55.4
Europe Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	2.3		7.3
Europe Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	53.3		174.7
Rest of World Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	92.4		251.7
Rest of World Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	223.2		643.8
Rest of World Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	47.4		147.7
Rest of World Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	40.9		126.6
Rest of World Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	91.1		249.3
Rest of World Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	43.8		102.1
Rest of World Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	18		70.1
Rest of World Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	28.1		69.5
Rest of World Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	31.9		95.6
Rest of World Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	10		29.1
Rest of World Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	146.9		379
Operating Segment | North America Segment
Disaggregation of Revenue [Line Items]
Net sales	1,012.3	1,172.2	2,998.4	3,666.7
Operating Segment | Europe Segment
Disaggregation of Revenue [Line Items]
Net sales	1,041.3	1,040.8	3,070.3	2,887.1
Operating Segment | Rest of World Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 773.7	$ 743.3	$ 2,164.5	$ 2,016.4

Revenue Recognition and Accou_5

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Gross sales	$ 4,861.4		$ 14,419
Chargebacks	(835.7)		(2,524.2)
Rebates, promotional programs and other sales allowances	(1,025.6)		(3,144.2)
Returns	(59.4)		(160.5)
Medicaid and other governmental rebates	(113.4)		(356.9)
Sales Revenue, Gross to net adjustments	2,034.1		6,185.8
Net sales	$ 2,827.3	$ 2,956.3	$ 8,233.2	$ 8,570.2

Revenue Recognition and Accou_6

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Revenue from Contract with Customer [Abstract]
Trade receivables, net	$ 2,591	$ 3,173.1
Other receivables	357.7	439.3
Accounts receivable, net	$ 2,948.7	$ 3,612.4

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements Recent Accounting Pronouncements (Impact of Adoption - ASU 2014-09) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Item Effected [Line Items]
Cost of sales	$ 1,823.2	$ 1,809	$ 5,369.2	$ 5,180.3
Income tax provision (benefit)	15.5	91.3	(79.9)	124.2
Net earnings	176.7	88.3	301.3	451.7
Revenues	2,862.4	$ 2,987.1	8,355.2	$ 8,668.8
Prepaid expenses and other current assets	583.2		583.2			$ 784.6	$ 766.1
Deferred income tax liability	1,764.4		1,764.4			2,018.1	2,012.4
Income taxes payable	75.7		75.7				112.9
Retained earnings	5,965.8		5,965.8			5,664.8	5,644.5
Accumulated other comprehensive loss	(1,490.9)		(1,490.9)		$ (1,199.3)	$ (368.7)	(361.2)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Item Effected [Line Items]
Cost of sales	1,876.4		5,475.5
Income tax provision (benefit)	15		(82.3)
Net earnings	175.6		296.2
Revenues	2,914		8,454
Prepaid expenses and other current assets	575.7		575.7
Income taxes payable	73.3		73.3
Retained earnings	5,960.7		5,960.7
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Item Effected [Line Items]
Cost of sales	(53.2)		(106.3)
Income tax provision (benefit)	0.5		2.4
Net earnings	1.1		5.1
Revenues	(51.6)		(98.8)
Prepaid expenses and other current assets	7.5		7.5
Income taxes payable	2.4		2.4
Retained earnings	$ 5.1		$ 5.1
Accounting Standards Update 2014-09 [Member]
Item Effected [Line Items]
Prepaid expenses and other current assets							18.5
Deferred income tax liability							5.7
Retained earnings							12.8
Accounting Standards Update 2016-01 [Member]
Item Effected [Line Items]
Retained earnings							10
Accumulated other comprehensive loss							(10)
Accounting Standards Update 2017-12 [Member]
Item Effected [Line Items]
Retained earnings							(2.5)
Accumulated other comprehensive loss							$ 2.5

Acquisitions and Other Transa_3

Acquisitions and Other Transactions (Meda) (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill		$ 9,796.6	$ 10,205.7
Meda
Business Acquisition [Line Items]
Amortization of fair value inventory step-up	$ 107
Europe Segment
Business Acquisition [Line Items]
Goodwill		4,712	4,967.1
North America Segment
Business Acquisition [Line Items]
Goodwill		3,532.8	3,549.6
Rest of World Segment
Business Acquisition [Line Items]
Goodwill		$ 1,551.8	$ 1,689

Acquisitions and Other Transa_4

Acquisitions and Other Transactions (Meda Schedule of Purchase Price Allocation) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 9,796.6	$ 10,205.7

Acquisitions and Other Transa_5

Acquisitions and Other Transactions (Renaissance Topicals Business) (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Contingent consideration	$ 418.8	$ 453.7
Goodwill	$ 9,796.6	$ 10,205.7

Acquisitions and Other Transa_6

Acquisitions and Other Transactions (Renaissance Topicals Business Schedule of Purchase Price Allocation) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Business Combinations [Abstract]
Goodwill	$ 9,796.6	$ 10,205.7

Acquisitions and Other Transa_7

Acquisitions and Other Transactions (Pro Forma Financial Information) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Basic	514.5	535.2	514.4	534.9
Diluted	516.5	537	516.5	537

Acquisitions and Other Transa_8

Acquisitions and Other Transactions Acquisitions and Other Transactions (Apicore Inc) (Narrative) (Details) - USD ($) $ in Millions	Oct. 03, 2017	Sep. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill		$ 9,796.6	$ 10,205.7
Contingent consideration		$ 418.8	$ 453.7
Apicore [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 121
Acquired intangible assets, weighted average useful life, in years	7 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	7 years
In-process research and development	$ 9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	9
Goodwill	92.2
Amount of goodwill expected to be tax deductible	0
Business Acquisition, Goodwill, Expected Tax Deductible Amount	0
Contingent consideration	4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	174.9
Maximum | Apicore [Member]
Business Acquisition [Line Items]
Purchase consideration, contingent consideration arrangements	15
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset	$ 15

Acquisitions and Other Transa_9

Acquisitions and Other Transactions Acquisitions and Other Transactions (Apicore Inc Schedule of Purchase Price Allocation) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017	Oct. 03, 2017
Business Acquisition [Line Items]
Goodwill	$ 9,796.6	$ 10,205.7
Apicore [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			$ 6.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			121
Goodwill			92.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			1.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			221.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			4.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent			40.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other			1.7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 174.9

Acquisitions and Other Trans_10

Acquisitions and Other Transactions (Other Transactions) (Details) - USD ($) $ in Millions	Feb. 28, 2018	Dec. 25, 2017	Oct. 03, 2017	Sep. 30, 2018	Sep. 30, 2018	Aug. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Payment for Contingent Consideration Liability, Financing Activities				$ 20
Contingent consideration				418.8	$ 418.8		$ 453.7
Apicore [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 174.9
Acquired intangible assets, weighted average useful life, in years			7 years
Contingent consideration			$ 4
TOBI [Member]
Business Acquisition [Line Items]
Cash consideration				463
Payments to Acquire Businesses, Gross				240
Business Acquisition, expected future payments, next twelve months						$ 130
Business Acquisition, expected future payment, year two				$ 93
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Assets						574.8
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						$ 91
Acquired intangible assets, weighted average useful life, in years				10 years
Product rights and licenses | Other Companies [Member]
Business Acquisition [Line Items]
Cash consideration		$ 90			220
Acquired intangible assets, weighted average useful life, in years		5 years
Payments To Acquire Collaborative Agreement					160
Revance [Member]
Business Acquisition [Line Items]
Payments To Acquire Collaborative Agreement	$ 25
Fujifilm Kyowa Kirin Biologics [Member]
Business Acquisition [Line Items]
Payments To Acquire Collaborative Agreement					$ 53.7
Maximum | Revance [Member]
Business Acquisition [Line Items]
Development Milestone Payments	100
Sales Milestone Payments	$ 225

Share-Based Incentive Plan (Nar

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reduction in Share-based Compensation Expense	$ 47.1	$ 23.5
Accrued Bonuses	$ 20		$ 20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	7,039,575		7,039,575		7,198,684
Long-Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ordinary shares reserved for issuance	55,300,000		55,300,000
Total unrecognized compensation expense, net of estimated forfeitures	$ 99.1		$ 99.1
Weighted-average period over which total unrecognized compensation expense expected to be recognized, in years			1 year 7 months 16 days
Intrinsic value of stock-based awards exercised and restricted stock units converted			$ 42.8	$ 34.7
Long-Term Incentive Plan 2003 | Stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award expiration period, in years			10 years
Average remaining contractual term for stock awards outstanding, in years			5 years 5 months 20 days
Average remaining contractual term for stock awards vested and expected to vest, in years			5 years 4 months 15 days
Average remaining contractual term for stock awards exercisable, in years			4 years 5 months 5 days
Aggregate intrinsic value for stock awards outstanding	41.1		$ 41.1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	41.1		41.1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 40.9		$ 40.9
Long-Term Incentive Plan 2003 | Stock awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years			3 years
Long-Term Incentive Plan 2003 | Stock awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years			4 years
One-Time Special Performance-Based Five-Year Realizable Value Incentive Program [Domain]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,600,000		2,600,000
One-Time Special Performance-Based Five-Year Realizable Value Incentive Program [Domain] | Stock awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years			2 years
One-Time Special Performance-Based Five-Year Realizable Value Incentive Program [Domain] | Stock awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years			6 years

Share-Based Incentive Plan (Sto

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 36.69	$ 35.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	847,590
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 40.92
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(720,226)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 21.77
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(286,473)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 48.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	6,821,737
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 36.48
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	5,335,545
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 34.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	7,039,575	7,198,684

Share-Based Incentive Plan (Non

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted stock awards	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning of period | shares	5,964,207
Weighted average grant-date fair value per share, nonvested beginning of period | $ / shares	$ 41.92
Number of restricted stock awards, granted | shares	1,542,727
Weighted average grant-date fair value per share, granted | $ / shares	$ 41.03
Number of restricted stock awards, released | shares	(682,557)
Weighted average grant-date fair value per share, released | $ / shares	$ 50.06
Number of restricted stock awards, forfeited | shares	(257,208)
Weighted average grant-date fair value per share, forfeited | $ / shares	$ 44.88
Number of restricted stock awards, nonvested end of period | shares	6,567,169
Weighted average grant-date fair value per share, nonvested end of period | $ / shares	$ 40.79

Pension and Other Postretiremen

Pension and Other Postretirement Benefit (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2018USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Number of Frozen Plans	2
Defined benefit plans, estimated benefit payments, in current fiscal year	$ 31.1
Estimated employer contributions in current year	$ 29.9

Pensions and Other Postretire_3

Pensions and Other Postretirement Benefits (Net Periodic Benefit Costs) (Details) - Pension and other postretirement benefits - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 5	$ 5	$ 15.1	$ 15.1
Interest cost	3.6	3.7	10.9	11.2
Expected return on plan assets	(3.6)	(3.5)	(10.9)	(10.6)
Amortization of prior service costs	0.1	0.1	0.3	0.2
Recognized net actuarial losses	0.1		0.1
Net periodic benefit cost	$ 5.2	$ 5.5	$ 15.5	$ 16.4

Balance Sheet Components Balanc

Balance Sheet Components Balance Sheet Components (Cash, cash equivalents, and restricted cash) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 503.1	$ 369.9	$ 750.8	$ 1,147	$ 750.8
Cash and cash equivalents	449.2	292.1	614.9
Restricted cash	$ 53.9	$ 77.8	$ 135.9

Balance Sheet Components (Inven

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Balance Sheet Components [Abstract]
Raw materials	$ 926	$ 895.5
Work in process	369.5	384.7
Finished goods	1,265.1	1,262.5
Inventories	$ 2,560.6	$ 2,542.7

Balance Sheet Components (Prepa

Balance Sheet Components (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	Sep. 30, 2017
Prepaid Expense and Other Assets [Abstract]
Prepaid expenses	$ 117.1		$ 119.8
Restricted cash	53.9		77.8	$ 135.9
Fair value of financial instruments	7.1		88.9
Equity securities	36.6		79.1
Other current assets	343.2		369
Prepaid expenses and other current assets	$ 583.2	$ 784.6	$ 766.1

Balance Sheet Components (Prope

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 3,890.5	$ 4,002.2
Accumulated depreciation	1,770.9	1,663.1
Property, plant and equipment, net	2,119.6	2,339.1
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,365.2	2,414.5
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,170.4	1,191.7
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	221.1	252.9
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 133.8	$ 143.1

Balance Sheet Components (Other

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Schedule of Other Assets [Line Items]
Equity method investments	$ 0	$ 0
Other long-term assets	95.2	79.6
Other assets	244.7	305.6
Other assets | Clean energy investments
Schedule of Other Assets [Line Items]
Equity method investments	$ 149.5	$ 226

Balance Sheet Components (Trade

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Accounts Payable, Current [Abstract]
Accounts Payable, Trade	$ 963.7	$ 976
Accounts Payable, Other	437.4	476.5
Accounts Payable, Trade, Current	$ 1,401.1	$ 1,452.5

Balance Sheet Components (Oth_2

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Schedule of other current liabilities [Line Items]
Opioid Assessment	$ 100
Payments for Legal Settlements	472.7
Accrued sales allowances	631.9	$ 818
Legal and professional accruals, including litigation accruals	131.4	241.1
Payroll and employee benefit liabilities	372.4	404.6
Contingent consideration	418.8	453.7
Restructuring	80.9	91.5
Other Accrued Liabilities, Current	742.2	1,111.4
Accrued interest	193.8	42.3
Fair value of financial instruments	114.4	31.1
Other current liabilities	2,528.4	2,964.5
Clean energy investments
Schedule of other current liabilities [Line Items]
Other current liabilities	38.1	56.7
Prepaid expenses and other current assets
Schedule of other current liabilities [Line Items]
Contingent consideration	$ 223.3	$ 167.8

Balance Sheet Components (Oth_3

Balance Sheet Components (Other Long-term Obligations) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Schedule of Other Noncurrent Liabilities [Line Items]
Employee benefit liabilities	$ 411.7	$ 408.2
Contingent consideration	418.8	453.7
Tax related items, including contingencies	155.6	237.7
Other	237.4	132.1
Other long-term obligations	1,151.6	1,235.7
Clean energy investments
Schedule of Other Noncurrent Liabilities [Line Items]
Other long-term obligations	151.4	171.8
Other long-term obligations
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration	$ 195.5	$ 285.9

Equity Method Investments (Narr

Equity Method Investments (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Schedule of Equity Method Investments [Line Items]
Loss from equity method investments	$ 12.6	$ 22.4	$ 58.6	$ 77.2
Equity method investments summarized financial data basis			100.00%
Equity Method Investment, Other than Temporary Impairment	39
Reduction in Equity Method Investment Long-Term Obligation	40		$ 40
Equity Method Investment, Realized Gain (Loss) on Disposal	$ 1
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Number of equity method investments	3		3

Equity Method Investments (Inco

Equity Method Investments (Income Statement) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
Total revenues	$ 128.6	$ 129.3	$ 376.8	$ 352
Gross loss	(1.3)	(2.4)	(20)	(8.8)
Operating and non-operating expense	5.9	6.5	16.5	16.9
Net loss	$ (7.2)	$ (8.9)	$ (36.5)	$ (25.7)

Earnings per Ordinary Share (Na

Earnings per Ordinary Share (Narrative) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Anti-dilutive stock options or restricted stock awards excluded from computation of earnings per share	9.3	8.9	8.9	8.6

Earnings per Ordinary Share (Ba

Earnings per Ordinary Share (Basic and Diluted Earnings Per Ordinary Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Net earnings	$ 176.7	$ 88.3	$ 301.3	$ 451.7
Weighted average ordinary shares outstanding	514.5	535.2	514.4	534.9
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	2	1.8	2.1	2.1
Total dilutive shares outstanding	516.5	537	516.5	537
Basic earnings per ordinary share	$ 0.34	$ 0.17	$ 0.59	$ 0.84
Diluted earnings (loss) per ordinary share	$ 0.34	$ 0.16	$ 0.58	$ 0.84

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Apr. 01, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
In-process research and development		$ 688.8		$ 688.8			$ 813.2
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	[1]			(48.9)
Contingent consideration		418.8		418.8			453.7
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		15.5	$ 0	87.5	$ 13
Goodwill		385		$ 385			385
Goodwill, Impaired, Change in Estimate Description				5
Fair Value Inputs, Earnings before Interest, Taxes, Depreciation, and Amortization Multiple				0.15
Fair Value Inputs, Long-term Revenue Growth Rate				3.50%
Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year				2.00%
Respiratory delivery platform [Member]
Finite-Lived Intangible Assets [Line Items]
In-process research and development		347.2		$ 347.2
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings		19.3		49.3
Contingent consideration		326.6		326.6
North America Generics [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill						$ 2,890
North America Specialty [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill						660
Europe Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill		0		0		4,970	0
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount						$ 800
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount						6.00%
Rest of World Segment
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 0		$ 0		$ 1,800	$ 0
Minimum
Finite-Lived Intangible Assets [Line Items]
Fair Value Inputs, Earnings before Interest, Taxes, Depreciation, and Amortization Multiple				9
Maximum
Finite-Lived Intangible Assets [Line Items]
Goodwill, Impaired, Change in Estimate Description				0.24
Fair Value Inputs, Earnings before Interest, Taxes, Depreciation, and Amortization Multiple				10.5
Goodwill [Member] | Maximum
Finite-Lived Intangible Assets [Line Items]
Rate used to discount net cash inflows to present value				9.00%
Reduction in Terminal Value Growth Rate [Domain]
Finite-Lived Intangible Assets [Line Items]
Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year				2.00%
Increased Discount Rate [Domain]
Finite-Lived Intangible Assets [Line Items]
Rate used to discount net cash inflows to present value				1.50%
[1]	Included in litigation settlements and other contingencies, net in the Condensed Consolidated Statements of Operations.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Changes in Carrying Amount of Goodwill) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Goodwill [Line Items]
Goodwill, gross, beginning balance	$ 10,590.7
Accumulated impairment losses, beginning balance	(385)
Foreign currency translation	(409.1)
Goodwill, net, beginning balance	10,205.7
Goodwill, gross, ending balance	10,181.6
Accumulated impairment losses, ending balance	(385)
Goodwill, net, ending balance	10,205.7	$ 9,796.6
North America Segment
Goodwill [Line Items]
Goodwill, gross, beginning balance	3,934.6
Accumulated impairment losses, beginning balance	(385)
Foreign currency translation	(16.8)
Goodwill, net, beginning balance	3,549.6
Goodwill, gross, ending balance	3,917.8
Accumulated impairment losses, ending balance	(385)
Goodwill, net, ending balance	3,549.6	3,532.8
Europe Segment
Goodwill [Line Items]
Goodwill, gross, beginning balance	4,967.1
Accumulated impairment losses, beginning balance	0
Foreign currency translation	(255.1)
Goodwill, net, beginning balance	4,967.1
Goodwill, gross, ending balance	4,712
Accumulated impairment losses, ending balance	0
Goodwill, net, ending balance	4,967.1	4,712
Rest of World Segment
Goodwill [Line Items]
Goodwill, gross, beginning balance	1,689
Accumulated impairment losses, beginning balance	0
Foreign currency translation	(137.2)
Goodwill, net, beginning balance	1,689
Goodwill, gross, ending balance	1,551.8
Accumulated impairment losses, ending balance	0
Goodwill, net, ending balance	$ 1,689	$ 1,551.8

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2017
Intangible Assets by Major Class [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 15.5	$ 0	$ 87.5	$ 13
Finite-lived intangible assets, original cost	20,407.7		20,407.7			$ 20,338.7
Finite-lived intangible assets, accumulated amortization	6,857.5		6,857.5			5,906.1
Finite-lived intangible assets, net book value	13,550.2		13,550.2			14,432.6
In-process research and development	688.8		688.8			813.2
Intangible assets, gross, excluding goodwill	21,096.5		21,096.5			21,151.9
Intangible assets, net book value, excluding goodwill	$ 14,239		$ 14,239			$ 15,245.8
Patents and technologies
Intangible Assets by Major Class [Line Items]
Finite-lived intangible assets, estimated useful life, in years			15 years		15 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 412.2	$ 369.4	$ 1,191.9	$ 1,052.6
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	15.5	0	87.5	13
Total Intangible asset amortization expense (including impairment charges)	$ 427.7	$ 369.4	$ 1,279.4	$ 1,065.6

Goodwill and Intangibles Assets

Goodwill and Intangibles Assets (Expected Amortization Expense) (Details) $ in Millions	Sep. 30, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Expected amortization expense, remainder of 2018	$ 383
Expected amortization expense, 2019	1,446
Expected amortization expense, 2020	1,283
Expected amortization expense, 2021	1,203
Expected amortization expense, 2022	$ 1,137

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2018USD ($)	Sep. 30, 2018EUR (€)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018EUR (€)	May 23, 2018	Dec. 31, 2017EUR (€)	Nov. 22, 2016	Jun. 09, 2016
Derivative [Line Items]
Document Fiscal Year Focus					2,018
Unrealized Gain (Loss) on Securities | $		$ 1.3		$ (7.8)	$ 2	$ 6.6
Long-term Debt, Gross | $		14,542			14,542
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months | $					(85)
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings | $	[1]				48.9
Business Combination Contingent Consideration Liability Payments | $					$ (1.1)
Contingent consideration | Minimum
Derivative [Line Items]
Rate used to discount net cash inflows to present value					2.10%
Contingent consideration | Maximum
Derivative [Line Items]
Rate used to discount net cash inflows to present value					10.50%
Prepaid expenses and other current assets
Derivative [Line Items]
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings | $	[1],[2]				$ (3)
Business Combination Contingent Consideration Liability Payments | $	[2]				(1.1)
Senior Notes | 2020 Euro Senior Notes
Derivative [Line Items]
Stated percentage rate										1.25%
Senior Notes | 2024 Euro Senior Notes
Derivative [Line Items]
Stated percentage rate										2.25%
Senior Notes | 2026 Senior Notes (3.950% coupon)
Derivative [Line Items]
Stated percentage rate											3.95%
Senior Notes | 2028 Euro Senior Notes
Derivative [Line Items]
Stated percentage rate										3.125%
Senior Notes | 2025 Euro Senior Notes [Member]
Derivative [Line Items]
Long-term debt | $		500			500
Stated percentage rate								2.125%
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative							€ 2,354		€ 1,854
Amount of Ineffectiveness on Net Investment Hedges			€ 0
Long-term debt							4,000
Net Investment Hedging | 2020 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative							104		104
Long-term debt							750
Net Investment Hedging | 2024 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative							1,000		1,000
Long-term debt							1,000
Net Investment Hedging | 2028 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative							750		750
Long-term debt							750
Net Investment Hedging | 2018 Floating Rate Euro Notes
Derivative [Line Items]
Notional amount of derivative							0		0
Long-term debt							500
Net Investment Hedging | 2020 Floating Rate Euro Notes [Domain]
Derivative [Line Items]
Notional amount of derivative							0		0
Long-term debt							500
Net Investment Hedging | 2025 Euro Senior Notes [Member]
Derivative [Line Items]
Notional amount of derivative							500		€ 0
Long-term debt							€ 500
Respiratory delivery platform [Member]
Derivative [Line Items]
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings | $		$ (19.3)			$ (49.3)
[1]	Included in litigation settlements and other contingencies, net in the Condensed Consolidated Statements of Operations.
[2]	Included in other current liabilities on the Condensed Consolidated Balance Sheets.

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Value of Derivative Instruments Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 7.1	$ 88.9
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	0	79.6
Fair value of financial instruments	87.9	0
Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest rate swaps
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	0	16.2
Designated as Hedging Instrument | Prepaid expenses and other current assets | Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	0	63.4
Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest rate swaps
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	11.1	0
Designated as Hedging Instrument | Prepaid expenses and other current assets | Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 76.8	$ 0

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Balance Sheets Fair Values of Derivative Instruments Derivatives Not Designated As Hedging Instrument) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 7.1	$ 88.9
Fair value of financial instruments	26.5	31.1
Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	7.1	9.3
Not Designated as Hedging Instruments | Prepaid expenses and other current assets | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	7.1	9.3
Not Designated as Hedging Instruments | Other current liabilities | Foreign currency forward contracts
Derivatives, Fair Value [Line Items]
Fair value of financial instruments	$ 26.5	$ 31.1

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Document Fiscal Year Focus			2,018
Fair Value Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	$ (5)	$ (2.5)	$ (27.3)	$ (1)
Amount of Gain (Loss) Recognized in Earnings on Hedged Items	5	2.5	27.3	1
Fair Value Hedging Relationships | Interest expense | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	(5)	(2.5)	(27.3)	(1)
Fair Value Hedging Relationships | Interest expense | 2023 Senior Notes (3.125% coupon)
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Hedged Items	$ 5	$ 2.5	$ 27.3	$ 1

Financial Instruments and Ris_8

Financial Instruments and Risk Management Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) (Details) - Cash Flow Hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative	$ (33.9)	$ (12.1)	$ (87.7)	$ 5.5
Foreign currency forward contracts
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative	(33.9)	(8.8)	(87.7)	7.5
Interest rate swaps
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCE (Net of Tax) on Derivative	$ 0	$ (3.3)	$ 0	$ (2)

Financial Instruments and Ris_9

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationships (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Document Fiscal Year Focus			2,018
Gains and Losses on Derivatives | Net Investment Hedging | Foreign currency borrowings and forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in AOCE (Net of Tax) on Derivative (Effective Portion)	$ 17.9	$ (72.1)	$ 77.7	$ (203.2)

Financial Instruments and Ri_10

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Document Fiscal Year Focus			2,018
Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from AOCE into Earnings	$ (1)	$ 0.1	$ 2.4	$ (9.3)
Amount of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness	0	3.3	0	6.9
Cash Flow Hedging | Foreign currency forward contracts | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from AOCE into Earnings	0.9	2	8.1	(3.8)
Cash Flow Hedging | Foreign currency forward contracts | Other income
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness	0	3.3		6.9
Cash Flow Hedging | Foreign currency forward contracts | Other expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Excluded from the Assessment of Hedge Effectiveness			0
Cash Flow Hedging | Interest rate swaps | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from AOCE into Earnings	$ (1.9)	$ (1.9)	$ (5.7)	$ (5.5)

Financial Instruments and Ri_11

Financial Instruments and Risk Management (Effect Of Derivative Instruments on the Condensed Consolidated Statements of Operations, Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Document Fiscal Year Focus			2,018
Amount of Gain (Loss) Recognized in Earnings on Derivatives	$ (25.1)	$ (43)	$ 2.5	$ (60.1)
Foreign currency forward contracts | Other expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Earnings on Derivatives	$ (25.1)	$ (43)	$ 2.5	$ (60.1)

Financial Instruments and Ri_12

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Securities	$ 1.3	$ (7.8)	$ 2	$ 6.6
Cash equivalents	27.5		27.5		$ 8.4
Equity securities	36.6		36.6		79.1
Total assets at recurring fair value measurement	96.5		96.5		207.9
Fair value of financial instruments	7.1		7.1		88.9
Total liabilities at recurring fair value measurement	533.2		533.2		484.8
Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	7.1		7.1		72.7
Foreign exchange derivative liabilities					31.1
Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative liabilities	103.3		103.3
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	418.8		418.8		453.7
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	27.5		27.5		8.4
Exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	35.7		35.7		33.9
Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale fixed income securities	25.3		25.3		31.5
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	10.4		10.4		16.5
U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	8.7		8.7		7.4
Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.7		1.7		4.1
Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	3.2		3.2		2.1
Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.3		1.3		1.4
Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.9		0.9
Available-for-sale securities					45.2
Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap derivative assets					16.2
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	27.5		27.5		8.4
Equity securities	36.6		36.6		79.1
Total assets at recurring fair value measurement	64.1		64.1		87.5
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	27.5		27.5		8.4
Level 1 | Exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	35.7		35.7		33.9
Level 1 | Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.9		0.9
Available-for-sale securities					45.2
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	32.4		32.4		120.4
Total liabilities at recurring fair value measurement	114.4		114.4		31.1
Level 2 | Foreign currency forward contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	7.1		7.1		72.7
Foreign exchange derivative liabilities	103.3		103.3		31.1
Level 2 | Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	25.3		25.3		31.5
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	10.4		10.4		16.5
Level 2 | U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	8.7		8.7		7.4
Level 2 | Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.7		1.7		4.1
Level 2 | Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	3.2		3.2		2.1
Level 2 | Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	1.3		1.3		1.4
Level 2 | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap derivative assets					16.2
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at recurring fair value measurement	418.8		418.8		453.7
Level 3 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	418.8		418.8		453.7
Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial instruments	87.9		87.9		0
Fair value of financial instruments	0		0		79.6
Prepaid expenses and other current assets | Designated as Hedging Instrument | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial instruments	$ 11.1		$ 11.1		$ 0

Financial Instruments and Ri_13

Financial Instruments and Risk Management Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions		Oct. 22, 2018	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accretion expense				$ 15.1
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	[1]			(48.9)
Business Combination Contingent Consideration Liability Payments				(1.1)
Business Combination, Contingent Consideration Arrangements, Reclassifications				0
Contingent consideration			$ 418.8	418.8	$ 453.7
Payment for Contingent Consideration Liability, Financing Activities			20
Prepaid expenses and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accretion expense	[2]			0
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	[1],[2]			3
Business Combination Contingent Consideration Liability Payments	[2]			(1.1)
Business Combination, Contingent Consideration Arrangements, Reclassifications				53.6
Contingent consideration			223.3	223.3	167.8
Other long-term obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accretion expense	[3]			15.1
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings	[1],[3]			(51.9)
Business Combination Contingent Consideration Liability Payments	[3]			0
Business Combination, Contingent Consideration Arrangements, Reclassifications				(53.6)
Contingent consideration			195.5	195.5	$ 285.9
Respiratory delivery platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings			19.3	49.3
Contingent consideration			$ 326.6	$ 326.6
Subsequent Event [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment for Contingent Consideration Liability, Financing Activities		$ 30
[1]	Included in litigation settlements and other contingencies, net in the Condensed Consolidated Statements of Operations.
[2]	Included in other current liabilities on the Condensed Consolidated Balance Sheets.
[3]	Included in other long-term obligations on the Condensed Consolidated Balance Sheets.

Debt (Short-Term Borrowings) (D

Debt (Short-Term Borrowings) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Short-term Debt [Line Items]
Short-term borrowings	$ 0.4	$ 46.5
Receivables Facility
Short-term Debt [Line Items]
Short-term borrowings	0	45
Other Short Term Debt [Member]
Short-term Debt [Line Items]
Short-term borrowings	$ 0.4	$ 1.5

Debt (Summary of Long-Term Debt

Debt (Summary of Long-Term Debt) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Jun. 15, 2018	May 23, 2018	Apr. 28, 2018	Apr. 09, 2018	Dec. 31, 2017	Nov. 22, 2016	Jun. 09, 2016	Dec. 09, 2015	Dec. 24, 2013	Nov. 13, 2013	Jun. 18, 2013
Debt Instrument [Line Items]
Current portion of long-term debt	$ 1,135.6					$ 1,749.2
Unamortized debt issuance expense	(77.1)					(71.9)
Long-term debt	13,291.4				$ 1,500	12,865.3
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Current portion of long-term debt	6.3					2.4
2016 Term Loans
Debt Instrument [Line Items]
Long-term debt	$ 100					100
Long-term Debt, Weighted Average Interest Rate, at Point in Time	3.617%
Other
Debt Instrument [Line Items]
Long-term debt	$ 5.9					6.3
Senior Notes | 2018 Senior Notes (2.600% coupon)
Debt Instrument [Line Items]
Stated percentage rate												2.60%
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.30%
Senior Notes | 2018 Senior Notes (3.000% coupon)
Debt Instrument [Line Items]
Stated percentage rate									3.00%
Current portion of long-term debt	$ 0					499.8
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.30%
Senior Notes | 2019 Senior Notes (2.500% coupon)
Debt Instrument [Line Items]
Stated percentage rate								2.50%
Long-term debt		$ 1,000
Long-term debt	$ 0					999.5
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.25%
Senior Notes | 2019 Senior Notes (2.550% coupon)
Debt Instrument [Line Items]
Stated percentage rate											2.55%
Long-term debt	$ 549.9			$ 500		0
Long-term debt	$ 0					499.7
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.20%
Senior Notes | 2020 Floating Rate Euro Notes [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 580.2					600.2
Basis spread on variable rate	0.50%
Senior Notes | 2020 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate							1.25%
Long-term debt	$ 868.4					897.6
Senior Notes | 2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Stated percentage rate									3.75%
Long-term debt	$ 499.9					499.9
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.35%
Senior Notes | 2021 Senior Notes (3.150% coupon)
Debt Instrument [Line Items]
Stated percentage rate								3.15%
Long-term debt	$ 2,248.5					2,248.2
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.30%
Senior Notes | 2023 Senior Notes (3.125% coupon)
Debt Instrument [Line Items]
Stated percentage rate										3.125%
Long-term debt	$ 738.2					765.4
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.20%
Senior Notes | 2023 Senior Notes (4.200% coupon)
Debt Instrument [Line Items]
Stated percentage rate											4.20%
Long-term debt	$ 498.9					498.8
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.25%
Senior Notes | 2024 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate							2.25%
Long-term debt	$ 1,158.1					1,197.7
Senior Notes | 2025 Euro Senior Notes [Member]
Debt Instrument [Line Items]
Stated percentage rate			2.125%
Long-term debt	500
Long-term debt	$ 578.9					0
Basis spread on variable rate	0.30%
Senior Notes | 2026 Senior Notes (3.950% coupon)
Debt Instrument [Line Items]
Stated percentage rate								3.95%
Long-term debt	$ 2,236.1					2,235
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.35%
Senior Notes | 2028 Euro Senior Notes
Debt Instrument [Line Items]
Stated percentage rate							3.125%
Long-term debt	$ 862.7					892
Senior Notes | 2028 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	748.2					0
Senior Notes | 2043 Senior Notes (5.400% coupon)
Debt Instrument [Line Items]
Stated percentage rate								5.40%
Long-term debt	$ 497.1					497.1
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.25%
Senior Notes | 2046 Senior Notes (5.250% coupon)
Debt Instrument [Line Items]
Stated percentage rate								5.25%
Long-term debt	$ 999.8					999.8
Equivalent percentage of redeemed amount	100.00%
Basis spread on variable rate	0.40%
Senior Notes | 2018 Floating Rate Euro Notes
Debt Instrument [Line Items]
Current portion of long-term debt	$ 580.2					600.2
Basis spread on variable rate	0.87%
Senior Notes | 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	$ 747.6					0
Current Portion of Long-Term Debt
Debt Instrument [Line Items]
Unamortized debt issuance expense	(0.8)					(3.1)
Senior Notes | 2018 Senior Notes (2.600% coupon)
Debt Instrument [Line Items]
Current portion of long-term debt	$ 0					$ 649.9

Debt (Commercial Paper Program)

Debt (Commercial Paper Program) (Details) - Commercial Paper [Member] $ in Millions	9 Months Ended
	Sep. 30, 2018USD ($)
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,650
Debt Instrument, Redemption, Description	P364D

Debt (Receivables Facility) (Na

Debt (Receivables Facility) (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Short-term Debt [Line Items]
Short-term borrowings	$ 0.4	$ 46.5
Receivables Facility
Short-term Debt [Line Items]
Short-term borrowings	$ 0	$ 45

Debt (2016 Revolving Credit Agr

Debt (2016 Revolving Credit Agreement) (Narrative) (Details) - USD ($) $ in Billions	9 Months Ended
	Sep. 30, 2018	Nov. 22, 2016
2016 Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2
2018 Senior Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2
Three Full Fiscal Quarters Following Qualifying Acquisition [Member] | 2016 Term Loans
Debt Instrument [Line Items]
Debt Instrument, Covenant Description	4.25 to 1.00
Three Full Fiscal Quarters Following Qualifying Acquisition [Member] | 2018 Senior Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Description	4.25 to 1.00
Trailing Four Quarters [Member] | Line of Credit [Member] | 2016 Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Covenant Terms	3.75 to 1.00
Trailing Four Quarters [Member] | Line of Credit [Member] | 2018 Senior Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Covenant Terms	3.75 to 1.00

Debt (2016 Term Credit Agreemen

Debt (2016 Term Credit Agreement) (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Apr. 09, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Long-term debt	$ 13,291.4	$ 1,500	$ 12,865.3
2016 Term Loans
Debt Instrument [Line Items]
Long-term debt	$ 100		$ 100

Debt (Euro Notes) (Narrative) (

Debt (Euro Notes) (Narrative) (Details) - USD ($) $ in Millions	Jun. 15, 2018	Apr. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 14,542
Repayments of Long-term Debt			$ 2,598.6	$ 1,747.3
Senior Notes | 2025 Euro Senior Notes [Member]
Debt Instrument [Line Items]
Basis spread on variable rate			0.30%
Long-term Debt			$ 500
Senior Notes | 2018 Floating Rate Euro Notes
Debt Instrument [Line Items]
Basis spread on variable rate			0.87%
Senior Notes | 2020 Floating Rate Euro Notes [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
Senior Notes | 2019 Senior Notes (2.550% coupon)
Debt Instrument [Line Items]
Basis spread on variable rate			0.20%
Equivalent percentage of redeemed amount			100.00%
Long-term Debt		$ 500	$ 549.9		$ 0
Repayments of Long-term Debt	$ 150	$ 350
Senior Notes | 2019 Senior Notes (2.500% coupon)
Debt Instrument [Line Items]
Basis spread on variable rate			0.25%
Equivalent percentage of redeemed amount			100.00%
Long-term Debt	1,000
Repayments of Long-term Debt	$ 450

Debt (Fair Value) (Narrative) (

Debt (Fair Value) (Narrative) (Details) - Senior Notes - USD ($) $ in Millions	Sep. 30, 2018	Jun. 15, 2018	May 23, 2018	Apr. 28, 2018	Dec. 31, 2017	Jun. 09, 2016	Dec. 09, 2015	Dec. 24, 2013	Nov. 13, 2013	Jun. 18, 2013
Debt Instrument [Line Items]
Fair value of long-term debt	$ 14,100				$ 14,900
2025 Euro Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	500
Stated percentage rate			2.125%
2018 Senior Notes (2.600% coupon)
Debt Instrument [Line Items]
Stated percentage rate										2.60%
2018 Senior Notes (3.000% coupon)
Debt Instrument [Line Items]
Stated percentage rate							3.00%
2019 Senior Notes (2.500% coupon)
Debt Instrument [Line Items]
Long-term Debt		$ 1,000
Stated percentage rate						2.50%
2019 Senior Notes (2.550% coupon)
Debt Instrument [Line Items]
Long-term Debt	$ 549.9			$ 500	$ 0
Stated percentage rate									2.55%
2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Stated percentage rate							3.75%
2021 Senior Notes (3.150% coupon)
Debt Instrument [Line Items]
Stated percentage rate						3.15%
2023 Senior Notes (3.125% coupon)
Debt Instrument [Line Items]
Stated percentage rate								3.125%
2023 Senior Notes (4.200% coupon)
Debt Instrument [Line Items]
Stated percentage rate									4.20%
2026 Senior Notes (3.950% coupon)
Debt Instrument [Line Items]
Stated percentage rate						3.95%
2043 Senior Notes (5.400% coupon)
Debt Instrument [Line Items]
Stated percentage rate						5.40%
2046 Senior Notes (5.250% coupon)
Debt Instrument [Line Items]
Stated percentage rate						5.25%

Debt (Minimum Repayments on Out

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Sep. 30, 2018USD ($)
Debt Disclosure [Abstract]
2,018	$ 580
2,019	650
2,020	1,951
2,021	2,250
2,022	0
Thereafter	9,111
Total	$ 14,542

Debt Debt (Subsequent Issuance

Debt Debt (Subsequent Issuance Table) (Details) - USD ($) $ in Millions	Jun. 15, 2018	Apr. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	May 23, 2018	Apr. 09, 2018	Dec. 31, 2017	Jun. 09, 2016	Dec. 09, 2015	Nov. 13, 2013	Jun. 18, 2013
Debt Instrument [Line Items]
Repayments of Long-term Debt			$ 2,598.6	$ 1,747.3
Current portion of long-term debt			1,135.6				$ 1,749.2
Long-term debt			13,291.4			$ 1,500	12,865.3
Senior Notes | SeniorNotesTwoThousandTwentyEight [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					4.55%
Long-term Debt			750
Senior Notes | SeniorNotesTwoThousandFortyEight [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					5.20%
Long-term Debt			$ 750
Senior Notes | 2028 Senior Notes [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate			0.30%
Senior Notes | 2020 Floating Rate Euro Notes [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
Long-term debt			$ 580.2				600.2
Senior Notes | 2048 Senior Notes [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate			0.35%
Senior Notes | 2018 Senior Notes (2.600% coupon)
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage											2.60%
Basis spread on variable rate			0.30%
Senior Notes | 2018 Senior Notes (3.000% coupon)
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									3.00%
Repayments of Long-term Debt		$ 500
Basis spread on variable rate			0.30%
Current portion of long-term debt			$ 0				499.8
Senior Notes | 2019 Senior Notes (2.550% coupon)
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage										2.55%
Repayments of Long-term Debt	$ 150	350
Long-term Debt		500	$ 549.9				0
Basis spread on variable rate			0.20%
Long-term debt			$ 0				499.7
Senior Notes | 2019 Senior Notes (2.500% coupon)
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								2.50%
Repayments of Long-term Debt	450
Long-term Debt	$ 1,000
Basis spread on variable rate			0.25%
Long-term debt			$ 0				999.5
Senior Notes | 2018 Senior Notes (2.600% coupon)
Debt Instrument [Line Items]
Repayments of Long-term Debt		$ 650
Current portion of long-term debt			$ 0				$ 649.9

Comprehensive Earnings (Accumul

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	$ 15.5	$ 91.3	$ (79.9)	$ 124.2
Net unrealized gain on marketable securities, net of tax	0		0		$ 0		$ 10.1
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	(0.5)		(0.5)		4.3		6
Foreign currency translation adjustment	(1,231.4)		(1,231.4)		(960.6)		(133.8)
Accumulated other comprehensive loss	(1,490.9)		(1,490.9)		(1,199.3)	$ (368.7)	(361.2)
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Net unrealized (loss) gain on marketable securities	0	(8.9)	(0.1)	3.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	6.8	(1.1)	8.3	(2.4)
Sales Revenue, Goods, Net	2,827.3	2,956.3	8,233.2	8,570.2
Interest expense	136.2	131.8	407.1	406.3
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	(51.9)	(4.5)	(146.1)	29.2
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx	(162.1)		(162.1)		(180)		(239.8)
Net unrecognized gain (loss) on derivatives	18.8	(72.1)	78.7	(203.2)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)		(5.8)		11.3
Accumulated other comprehensive loss		(611.2)		(611.2)				$ (955.6)	$ (2,263.7)
Other comprehensive earnings (loss) before reclassifications, before tax	(311.9)	338.4	(1,171.4)	1,653.8
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)		(2.8)		9.4
Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax		(18.8)		(18.8)				(17.1)	(38.6)
Other comprehensive earnings (loss) before reclassifications, before tax		(4.4)		19.9
Gains and Losses on Derivatives | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	(18)		(50.4)
Cumulative Effect of New Accounting Principle in Period of Adoption	2.5		2.5
Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax	(96.9)		(96.9)		$ (63)		$ (3.7)
Other comprehensive earnings (loss) before reclassifications, before tax	(52.9)		(143.7)
Gains and Losses on Derivatives | Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	0.9	0	1	0
Cumulative Effect of New Accounting Principle in Period of Adoption	0		0
Net unrecognized losses on derivatives in cash flow hedging relationships, net of tax		(204.6)		(204.6)				(132.5)	(1.4)
Other comprehensive earnings (loss) before reclassifications, before tax		(72.1)		(203.2)
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)		(3.2)		1.4
Net unrealized gain on marketable securities, net of tax		16.6		16.6				22.3	14.5
Other comprehensive earnings (loss) before reclassifications, before tax		(8.9)		3.5
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)		0.2		(0.5)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		1.4		1.4				(0.5)	(0.5)
Other comprehensive earnings (loss) before reclassifications, before tax	(7)	0.8	(8.7)	1.7
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)		0		0
Foreign currency translation adjustment		(405.8)		(405.8)				$ (828.8)	$ (2,237.7)
Other comprehensive earnings (loss) before reclassifications, before tax	(270.8)		(1,097.6)
Reclassification out of Accumulated Other Comprehensive Earnings | AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	(19.1)		(51.2)
Cumulative Effect of New Accounting Principle in Period of Adoption	(7.5)		(7.5)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.1)	0.1	(0.3)	(0.2)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax	(0.1)	0.2	(0.1)	(0.5)
Reclassification out of Accumulated Other Comprehensive Earnings | Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives		(4.5)		29.2
Reclassification out of Accumulated Other Comprehensive Earnings | Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	0		0
Cumulative Effect of New Accounting Principle in Period of Adoption	(10)		(10)
Net unrealized (loss) gain on marketable securities		(8.9)		3.5
Reclassification out of Accumulated Other Comprehensive Earnings | Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	(2)		(1.8)
Cumulative Effect of New Accounting Principle in Period of Adoption	0		0
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax		1.1		(2.4)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax		0.1		0.2
Reclassification out of Accumulated Other Comprehensive Earnings | Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	0		0
Cumulative Effect of New Accounting Principle in Period of Adoption	0		0
Other comprehensive (loss) earnings, before tax		423		1,831.9
Mylan N.V.
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax provision (benefit)	(8)	2.4	(23.3)	1.4
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Net unrealized (loss) gain on marketable securities		(8.9)	(0.1)	3.5
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	6.8	(1.1)	8.3	(2.4)
Sales Revenue, Goods, Net	0	0	0	0
Interest expense	84	93.3	266.1	285.6
Mylan N.V. | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	(51.9)	(4.5)	(146.1)	29.2
Mylan N.V. | Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gain (loss) on derivatives	18.8	(72.1)	78.7	(203.2)
Foreign currency forward contracts | Gains and Losses on Derivatives | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(0.9)		(8.1)
Foreign currency forward contracts | Reclassification out of Accumulated Other Comprehensive Earnings | AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(0.9)	(2)	(8.1)	3.8
Foreign currency forward contracts | Reclassification out of Accumulated Other Comprehensive Earnings | Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales Revenue, Goods, Net	(0.9)	(2)	(8.1)	3.8
Interest rate swaps | Gains and Losses on Derivatives | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.9		5.7
Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Earnings | AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.9	1.9	5.7	5.5
Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Earnings | Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.9	1.9	5.7	5.5
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	(0.1)	(0.1)	(0.3)	(0.2)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	(0.1)		(0.1)
Pension and other postretirement benefits | Reclassification out of Accumulated Other Comprehensive Earnings | Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax	$ (0.1)		$ (0.3)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement		$ (0.2)		$ (0.5)

Comprehensive Earnings (Compone

Comprehensive Earnings (Components Of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period			$ 10.1
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax	$ (0.5)		(0.5)		$ (0.5)	$ 4.3	$ 6
Foreign currency translation adjustment, beginning of period			(133.8)
Accumulated other comprehensive loss, net of tax, beginning of period			(361.2)
Net sales	2,827.3	$ 2,956.3	8,233.2	$ 8,570.2
Interest expense	136.2	131.8	407.1	406.3
Other comprehensive earnings (loss), available-for-sale securities adjustment, before tax	0	(8.9)	(0.1)	3.5
Change in unrecognized gain and prior service cost related to defined benefit plans	(6.8)	1.1	(8.3)	2.4
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Income tax provision (benefit)	15.5	91.3	(79.9)	124.2
Net unrealized gain (loss) on marketable securities, net of tax, end of period	0		0
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period	(0.5)		(0.5)
Foreign currency translation adjustment, end of period	(1,231.4)		(1,231.4)
Accumulated other comprehensive loss, net of tax, end of period	(1,490.9)		(1,490.9)
Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period				(38.6)
Other comprehensive earnings (loss) before reclassifications, before tax		(4.4)		19.9
Income tax provision (benefit)		(2.8)		9.4
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(18.8)		(18.8)
Gains and Losses on Derivatives | Reclassification out of Accumulated Other Comprehensive Earnings
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax		(4.5)		29.2
Gains and Losses on Derivatives | Reclassification out of Accumulated Other Comprehensive Earnings | Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(0.9)	(2)	(8.1)	3.8
Gains and Losses on Derivatives | Reclassification out of Accumulated Other Comprehensive Earnings | Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.9	1.9	5.7	5.5
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gain (loss) on marketable securities, net of tax, beginning of period				14.5
Other comprehensive earnings (loss) before reclassifications, before tax		(8.9)		3.5
Income tax provision (benefit)		(3.2)		1.4
Net unrealized gain (loss) on marketable securities, net of tax, end of period		16.6		16.6
Gains and Losses on Marketable Securities | Reclassification out of Accumulated Other Comprehensive Earnings
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive earnings (loss), available-for-sale securities adjustment, before tax		(8.9)		3.5
Income tax provision (benefit)	0		0
Cumulative Effect of New Accounting Principle in Period of Adoption					(10)
Defined Benefit Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax		1.4		1.4				$ (0.5)	$ (0.5)
Other comprehensive earnings (loss) before reclassifications, before tax	(7)	0.8	(8.7)	1.7
Income tax provision (benefit)		0.2		(0.5)
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, end of period		1.4		1.4
Defined Benefit Plan Items | Reclassification out of Accumulated Other Comprehensive Earnings
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs		(0.1)		(0.2)
Change in unrecognized gain and prior service cost related to defined benefit plans		(1.1)		2.4
Income tax provision (benefit)	(2)		(1.8)
Cumulative Effect of New Accounting Principle in Period of Adoption					0
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period				(2,237.7)
Other comprehensive earnings (loss) before reclassifications, before tax	(270.8)		(1,097.6)
Income tax provision (benefit)		0		0
Foreign currency translation adjustment, end of period		(405.8)		(405.8)
Foreign Currency Translation Adjustment | Reclassification out of Accumulated Other Comprehensive Earnings
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive (loss) earnings, before tax		423		1,831.9
Income tax provision (benefit)	0		0
Cumulative Effect of New Accounting Principle in Period of Adoption					0
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax, beginning of period				(2,263.7)
Other comprehensive earnings (loss) before reclassifications, before tax	(311.9)	338.4	(1,171.4)	1,653.8
Income tax provision (benefit)		(5.8)		11.3
Accumulated other comprehensive loss, net of tax, end of period		(611.2)		(611.2)
AOCI Attributable to Parent [Member] | Reclassification out of Accumulated Other Comprehensive Earnings
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.1	(0.1)	0.3	0.2
Other comprehensive earnings (loss), reclassification adjustment from AOCE, pension and other postretirement benefit plans, for net gain (loss), before tax	0.1	(0.2)	0.1	0.5
Income tax provision (benefit)	(19.1)		(51.2)
Cumulative Effect of New Accounting Principle in Period of Adoption					(7.5)
AOCI Attributable to Parent [Member] | Reclassification out of Accumulated Other Comprehensive Earnings | Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(0.9)	(2)	(8.1)	3.8
AOCI Attributable to Parent [Member] | Reclassification out of Accumulated Other Comprehensive Earnings | Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.9	1.9	5.7	5.5
Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	(51.9)	(4.5)	(146.1)	29.2
Cash Flow Hedging | Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period			(3.7)
Other comprehensive earnings (loss) before reclassifications, before tax	(52.9)		(143.7)
Income tax provision (benefit)	(18)		(50.4)
Net unrecognized gains (losses) on derivatives, net of tax, end of period	(96.9)		(96.9)
Cumulative Effect of New Accounting Principle in Period of Adoption					2.5
Cash Flow Hedging | Gains and Losses on Derivatives | Foreign currency forward contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(0.9)		(8.1)
Cash Flow Hedging | Gains and Losses on Derivatives | Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	1.9		5.7
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulate Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Taxx					(162.1)	$ (180)	$ (239.8)
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	18.8	(72.1)	78.7	(203.2)
Net Investment Hedging | Gains and Losses on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period				(1.4)
Other comprehensive earnings (loss) before reclassifications, before tax		(72.1)		(203.2)
Income tax provision (benefit)	0.9	0	1	0
Net unrecognized gains (losses) on derivatives, net of tax, end of period		(204.6)		(204.6)
Cumulative Effect of New Accounting Principle in Period of Adoption					$ 0
Mylan N.V.
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	0	0	0	0
Interest expense	84	93.3	266.1	285.6
Other comprehensive earnings (loss), available-for-sale securities adjustment, before tax		(8.9)	(0.1)	3.5
Change in unrecognized gain and prior service cost related to defined benefit plans	(6.8)	1.1	(8.3)	2.4
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Income tax provision (benefit)	(8)	2.4	(23.3)	1.4
Mylan N.V. | Cash Flow Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	(51.9)	(4.5)	(146.1)	29.2
Mylan N.V. | Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses on derivatives in net investment hedging relationships, net of tax	18.8	(72.1)	78.7	(203.2)
Pension and other postretirement benefits
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	0.1	0.1	0.3	0.2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	(0.1)		(0.1)
Pension and other postretirement benefits | Defined Benefit Plan Items | Reclassification out of Accumulated Other Comprehensive Earnings
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs	$ 0.1		$ 0.3
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement		$ (0.2)		$ (0.5)

Shareholders' Equity (Summary O

Shareholders' Equity (Summary Of Change In Shareholders' Equity) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Shareholders' equity, beginning balance			$ 13,307.6	$ 11,117.6
Net earnings (loss)			301.3	451.7
Other comprehensive loss, net of tax	$ (291.6)	$ 344.4	(1,122.2)	1,652.5
Stock option activity			15.4	12.8
Ordinary Share Repurchase			(432)
Share-based compensation expense			(8.6)	64.2
Issuance of restricted stock, net of shares withheld			(8.1)	5.8
Cumulative effect of the adoption			12.8
Other				(1.4)
Shareholders' equity, ending balance	$ 12,066.2	13,291.6	$ 12,066.2	13,291.6
Total Mylan N.V. Shareholders' Equity
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Shareholders' equity, beginning balance				11,116.2
Net earnings (loss)				451.7
Other comprehensive loss, net of tax				1,652.5
Stock option activity				12.8
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition				64.2
Issuance of restricted stock, net of shares withheld				(5.8)
Other				0
Shareholders' equity, ending balance		13,291.6		13,291.6
Noncontrolling Interest
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Shareholders' equity, beginning balance				1.4
Net earnings (loss)				0
Other				(1.4)
Shareholders' equity, ending balance		$ 0		$ 0

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions		9 Months Ended
		Sep. 30, 2018USD ($)country	Sep. 30, 2017USD ($)
Segment Reporting Information [Line Items]
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings | $	[1]	$ (48.9)
Europe Segment
Segment Reporting Information [Line Items]
Number of Countries in which Entity Operates | country		35
Rest of World Segment
Segment Reporting Information [Line Items]
Number of Countries in which Entity Operates | country		120
Contingent consideration
Segment Reporting Information [Line Items]
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings | $			$ 78.2
[1]	Included in litigation settlements and other contingencies, net in the Condensed Consolidated Statements of Operations.

Segment Information (Reconcilia

Segment Information (Reconciliation Of Segment Information To Total Consolidated Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$ 2,827.3	$ 2,956.3	$ 8,233.2	$ 8,570.2
Revenues	2,862.4	2,987.1	8,355.2	8,668.8
Segment profitability	951.1	1,000
Amortization of Intangible Assets	(412.2)	(369.4)	(1,191.9)	(1,052.6)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	(15.5)	0	(87.5)	(13)
Research and development	(144.1)	(182.3)	(555.7)	(580.9)
Litigation settlements and other contingencies, net	20.4	(15.2)	50.6	25.8
Earnings from operations	338.2	316.5	672.8	1,018
Other revenue
Segment Reporting Information [Line Items]
Segment profitability			2,563.3	2,946.2
Amortization of Intangible Assets	(412.2)	(369.4)	(1,191.9)	(1,052.6)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	(15.5)		(87.5)	(13)
Research and development	(61.9)	(76.8)	(213.6)	(269)
Corporate costs	(143.7)	(222.1)	(448.1)	(619.4)
Litigation settlements and other contingencies, net	20.4	(15.2)	50.6	25.8
Intersegment revenue
Segment Reporting Information [Line Items]
Revenues			(416.8)	(423.5)
Corporate / Other
Segment Reporting Information [Line Items]
Revenues	(140)	(121.6)	(416.8)	(423.5)
Segment profitability	0	0	0	0
North America Segment
Segment Reporting Information [Line Items]
Revenues	1,052.7	1,207.7	3,138.4	3,794.5
North America Segment | Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	1,012.3	1,172.2	2,998.4	3,666.7
Segment profitability	446	575.8	1,281.3	1,810.5
North America Segment | Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	19.5	15.5	55.5	60.5
Europe Segment
Segment Reporting Information [Line Items]
Revenues	1,071.9	1,068.1	3,164.3	2,999.7
Europe Segment | Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	1,041.3	1,040.8	3,070.3	2,887.1
Segment profitability	310.5	290.3	806.8	776.8
Europe Segment | Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	23.2	18.4	74.2	87.6
Rest of World Segment
Segment Reporting Information [Line Items]
Revenues	877.8	832.9	2,469.3	2,298.1
Rest of World Segment | Operating Segment
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	773.7	743.3	2,164.5	2,016.4
Segment profitability	194.6	133.9	475.2	358.9
Rest of World Segment | Intersegment revenue
Segment Reporting Information [Line Items]
Revenues	97.3	87.7	287.1	275.4
Other Revenues
Segment Reporting Information [Line Items]
Revenues	35.1	30.8	122	98.6
Other Revenues | North America Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues	20.9	20	84.5	67.3
Other Revenues | Europe Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues	7.4	8.9	19.8	25
Other Revenues | Rest of World Segment | Other revenue
Segment Reporting Information [Line Items]
Revenues	$ 6.8	$ 1.9	$ 17.7	$ 6.3

Subsidiary Guarantors (Narrativ

Subsidiary Guarantors (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	May 23, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 09, 2016	Dec. 09, 2015	Dec. 24, 2013	Nov. 13, 2013	Jun. 18, 2013
Cash and cash equivalents	$ 449.2		$ 292.1	$ 614.9
Restricted Cash and Cash Equivalents	53.9		77.8	135.9
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	503.1		369.9	750.8	$ 1,147	$ 750.8
Equity method investments	0		0
2021 Senior Notes (3.150% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage							3.15%
2026 Senior Notes (3.950% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage							3.95%
2046 Senior Notes (5.250% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage							5.25%
2018 Senior Notes (2.600% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage											2.60%
2019 Senior Notes (2.550% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage										2.55%
2023 Senior Notes (3.125% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage									3.125%
2023 Senior Notes (4.200% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage										4.20%
SeniorNotesTwoThousandTwentyEight [Member] | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage		4.55%
2043 Senior Notes (5.400% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage							5.40%
2018 Senior Notes (3.000% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage								3.00%
2019 Senior Notes (2.500% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage							2.50%
2020 Senior Notes (3.750% coupon) | Senior Notes
Debt Instrument, Interest Rate, Stated Percentage								3.75%
Mylan N.V.
Cash and cash equivalents	0		0	0
Restricted Cash and Cash Equivalents	0		0	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	0		0	0	0.3
Equity method investments	18,939.5		19,736.5
Mylan Inc.
Cash and cash equivalents	27.1		0.2	82.2
Restricted Cash and Cash Equivalents	0		23.6	73.1
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	27.1		23.8	155.3	85.4
Equity method investments	12,829.4		13,683.3
Guarantor Subsidiaries
Cash and cash equivalents	0		0	0
Restricted Cash and Cash Equivalents	0		0	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	0		0	0	0
Equity method investments	0		0
Non-Guarantor Subsidiaries
Cash and cash equivalents	422.1		291.9	532.7
Restricted Cash and Cash Equivalents	53.9		54.2	62.8
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	476		346.1	595.5	1,061.3
Equity method investments	0		0
Eliminations
Cash and cash equivalents	0		0	0
Restricted Cash and Cash Equivalents	0		0	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	0		0	$ 0	$ 0
Equity method investments	$ (31,768.9)		(33,419.8)
Previously Reported | Mylan Inc.
Equity method investments			$ 15,288.3

Subsidiary Guarantors Condensed

Subsidiary Guarantors Condensed Consolidating Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Income Statements, Captions [Line Items]
Net sales	$ 2,827.3	$ 2,956.3	$ 8,233.2	$ 8,570.2
Revenues	2,862.4	2,987.1	8,355.2	8,668.8
Cost of sales	1,823.2	1,809	5,369.2	5,180.3
Gross profit	1,039.2	1,178.1	2,986	3,488.5
Research and development	144.1	182.3	555.7	580.9
Selling, general and administrative	577.3	664.1	1,808.1	1,915.4
Litigation settlements and other contingencies, net	(20.4)	15.2	(50.6)	(25.8)
Total operating expenses	701	861.6	2,313.2	2,470.5
Earnings from operations	338.2	316.5	672.8	1,018
Interest expense	136.2	131.8	407.1	406.3
Other expense (income), net	9.8	5.1	44.3	35.8
Earnings before income taxes	192.2	179.6	221.4	575.9
Income tax provision (benefit)	15.5	91.3	(79.9)	124.2
Earnings (losses) of equity interest subsidiaries	0	0	0	0
Net earnings	176.7	88.3	301.3	451.7
Other Revenues
Condensed Income Statements, Captions [Line Items]
Revenues	35.1	30.8	122	98.6
Eliminations
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0	0
Revenues	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	0	0	0	0
Litigation settlements and other contingencies, net	0	0	0	0
Total operating expenses	0	0	0	0
Earnings from operations	0	0	0	0
Interest expense	0	0	0	0
Other expense (income), net	0	0	0	0
Earnings before income taxes	0	0	0	0
Income tax provision (benefit)	0	0	0	0
Earnings (losses) of equity interest subsidiaries	(359.6)	(198.1)	(580.8)	(1,228.6)
Net earnings	(359.6)	(198.1)	(580.8)	(1,228.6)
Eliminations | Other Revenues
Condensed Income Statements, Captions [Line Items]
Revenues	0	0	0	0
Mylan N.V.
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0	0
Revenues	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	11.5	6.5	31	32.4
Litigation settlements and other contingencies, net	0	0	0	0
Total operating expenses	11.5	6.5	31	32.4
Earnings from operations	(11.5)	(6.5)	(31)	(32.4)
Interest expense	84	93.3	266.1	285.6
Other expense (income), net	(47.9)	(122.3)	(211.5)	(331.3)
Earnings before income taxes	(47.6)	22.5	(85.6)	13.3
Income tax provision (benefit)	(8)	2.4	(23.3)	1.4
Earnings (losses) of equity interest subsidiaries	216.3	68.2	363.6	439.8
Net earnings	176.7	88.3	301.3	451.7
Mylan N.V. | Other Revenues
Condensed Income Statements, Captions [Line Items]
Revenues	0	0	0	0
Mylan Inc.
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0	0
Revenues	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	117.6	184.3	367.7	477.6
Litigation settlements and other contingencies, net	0.1	17	7.1	17
Total operating expenses	117.7	201.3	374.8	494.6
Earnings from operations	(117.7)	(201.3)	(374.8)	(494.6)
Interest expense	42.9	26.7	110.9	77.8
Other expense (income), net	(79)	(44.7)	(205)	(161.5)
Earnings before income taxes	(81.6)	(183.3)	(280.7)	(410.9)
Income tax provision (benefit)	18.1	(0.6)	13.5	5.1
Earnings (losses) of equity interest subsidiaries	143.3	129.9	217.2	788.8
Net earnings	43.6	(52.8)	(77)	372.8
Mylan Inc. | Other Revenues
Condensed Income Statements, Captions [Line Items]
Revenues	0	0	0	0
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net sales	0	0	0	0
Revenues	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	0	0	0	0
Litigation settlements and other contingencies, net	0	0	0	0
Total operating expenses	0	0	0	0
Earnings from operations	0	0	0	0
Interest expense	0	0	0	0
Other expense (income), net	0	0	0	0
Earnings before income taxes	0	0	0	0
Income tax provision (benefit)	0	0	0	0
Earnings (losses) of equity interest subsidiaries	0	0	0	0
Net earnings	0	0	0	0
Guarantor Subsidiaries | Other Revenues
Condensed Income Statements, Captions [Line Items]
Revenues	0	0	0	0
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net sales	2,827.3	2,956.3	8,233.2	8,570.2
Revenues	2,862.4	2,987.1	8,355.2	8,668.8
Cost of sales	1,823.2	1,809	5,369.2	5,180.3
Gross profit	1,039.2	1,178.1	2,986	3,488.5
Research and development	144.1	182.3	555.7	580.9
Selling, general and administrative	448.2	473.3	1,409.4	1,405.4
Litigation settlements and other contingencies, net	(20.5)	(1.8)	(57.7)	(42.8)
Total operating expenses	571.8	653.8	1,907.4	1,943.5
Earnings from operations	467.4	524.3	1,078.6	1,545
Interest expense	9.3	11.8	30.1	42.9
Other expense (income), net	136.7	172.1	460.8	528.6
Earnings before income taxes	321.4	340.4	587.7	973.5
Income tax provision (benefit)	5.4	89.5	(70.1)	117.7
Earnings (losses) of equity interest subsidiaries	0	0	0	0
Net earnings	316	250.9	657.8	855.8
Non-Guarantor Subsidiaries | Other Revenues
Condensed Income Statements, Captions [Line Items]
Revenues	$ 35.1	$ 30.8	$ 122	$ 98.6

Subsidiary Guarantors Condens_2

Subsidiary Guarantors Condensed Consolidating Statement of Comprehensive Earnings (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Statement of Income Captions [Line Items]
Net earnings	$ 176.7	$ 88.3	$ 301.3	$ 451.7
Earnings (losses) of equity interest subsidiaries	0	0	0	0
Net earnings (loss)			301.3	451.7
Foreign currency translation adjustment	(270.8)	423	(1,097.6)	1,831.9
Change in unrecognized gain and prior service cost related to defined benefit plans	(6.8)	1.1	(8.3)	2.4
Net unrealized (loss) gain on marketable securities	0	(8.9)	(0.1)	3.5
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Income tax (benefit) provision	(19.1)	(5.8)	(51.2)	11.3
Other comprehensive (loss) earnings, net of tax	(291.6)	344.4	(1,122.2)	1,652.5
Comprehensive (loss) earnings	(114.9)	432.7	(820.9)	2,104.2
Cash Flow Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	(51.9)	(4.5)	(146.1)	29.2
Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	18.8	(72.1)	78.7	(203.2)
Eliminations
Condensed Statement of Income Captions [Line Items]
Net earnings	(359.6)	(198.1)	(580.8)	(1,228.6)
Earnings (losses) of equity interest subsidiaries	(359.6)	(198.1)	(580.8)	(1,228.6)
Foreign currency translation adjustment	270.8	(423)	1,097.6	(1,831.9)
Change in unrecognized gain and prior service cost related to defined benefit plans	6.8	(1.3)	8.3	(2.4)
Net unrealized (loss) gain on marketable securities		8.9	0.1	(3.5)
Other comprehensive (loss) earnings, before tax	325.5	(410.9)	1,247.5	(1,867)
Income tax (benefit) provision	19.1	5.5	51.2	(11.3)
Other comprehensive (loss) earnings, net of tax	306.4	(416.4)	1,196.3	(1,855.7)
Comprehensive (loss) earnings	(53.2)	(614.5)	615.5	(3,084.3)
Eliminations | Cash Flow Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	51.9	4.5	146.1	(29.2)
Eliminations | Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	(4)	0	(4.6)	0
Mylan N.V.
Condensed Statement of Income Captions [Line Items]
Net earnings	176.7	88.3	301.3	451.7
Earnings (losses) of equity interest subsidiaries	216.3	68.2	363.6	439.8
Foreign currency translation adjustment	(270.8)	423	(1,097.6)	1,831.9
Change in unrecognized gain and prior service cost related to defined benefit plans	(6.8)	1.1	(8.3)	2.4
Net unrealized (loss) gain on marketable securities		(8.9)	(0.1)	3.5
Other comprehensive (loss) earnings, before tax	(310.7)	338.6	(1,173.4)	1,663.8
Income tax (benefit) provision	(19.1)	(5.8)	(51.2)	11.3
Other comprehensive (loss) earnings, net of tax	(291.6)	344.4	(1,122.2)	1,652.5
Comprehensive (loss) earnings	(114.9)	432.7	(820.9)	2,104.2
Mylan N.V. | Cash Flow Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	(51.9)	(4.5)	(146.1)	29.2
Mylan N.V. | Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	18.8	(72.1)	78.7	(203.2)
Mylan Inc.
Condensed Statement of Income Captions [Line Items]
Net earnings	43.6	(52.8)	(77)	372.8
Earnings (losses) of equity interest subsidiaries	143.3	129.9	217.2	788.8
Foreign currency translation adjustment	0	0	0	0
Change in unrecognized gain and prior service cost related to defined benefit plans	0.1	0.1	0.2	0.3
Net unrealized (loss) gain on marketable securities		(8.9)	0	3.7
Other comprehensive (loss) earnings, before tax	6	(6.9)	10.5	9.5
Income tax (benefit) provision	(1.6)	2.5	(2.4)	(3.5)
Other comprehensive (loss) earnings, net of tax	7.6	(9.4)	12.9	13
Comprehensive (loss) earnings	51.2	(62.2)	(64.1)	385.8
Mylan Inc. | Cash Flow Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	1.9	1.9	5.7	5.5
Mylan Inc. | Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	4	0	4.6	0
Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net earnings	0	0	0	0
Earnings (losses) of equity interest subsidiaries	0	0	0	0
Foreign currency translation adjustment	0	0	0	0
Change in unrecognized gain and prior service cost related to defined benefit plans	0	0	0	0
Net unrealized (loss) gain on marketable securities		0	0	0
Other comprehensive (loss) earnings, before tax	0	0	0	0
Income tax (benefit) provision	0	0	0	0
Other comprehensive (loss) earnings, net of tax	0	0	0	0
Comprehensive (loss) earnings	0	0	0	0
Guarantor Subsidiaries | Cash Flow Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	0	0	0	0
Guarantor Subsidiaries | Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	0	0	0	0
Non-Guarantor Subsidiaries
Condensed Statement of Income Captions [Line Items]
Net earnings	316	250.9	657.8	855.8
Earnings (losses) of equity interest subsidiaries	0	0	0	0
Foreign currency translation adjustment	(270.8)	423	(1,097.6)	1,831.9
Change in unrecognized gain and prior service cost related to defined benefit plans	(6.9)	1.2	(8.5)	2.1
Net unrealized (loss) gain on marketable securities		0	(0.1)	(0.2)
Other comprehensive (loss) earnings, before tax	(331.5)	417.8	(1,258)	1,857.5
Income tax (benefit) provision	(17.5)	(8)	(48.8)	14.8
Other comprehensive (loss) earnings, net of tax	(314)	425.8	(1,209.2)	1,842.7
Comprehensive (loss) earnings	2	676.7	(551.4)	2,698.5
Non-Guarantor Subsidiaries | Cash Flow Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	(53.8)	(6.4)	(151.8)	23.7
Non-Guarantor Subsidiaries | Net Investment Hedging
Condensed Statement of Income Captions [Line Items]
Net unrecognized (loss) gain on derivatives	$ 0	$ 0	$ 0	$ 0

Subsidiary Guarantors Condens_3

Subsidiary Guarantors Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2018	Apr. 09, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 449.2		$ 292.1	$ 614.9
Accounts receivable, net	2,948.7		3,612.4
Inventories	2,560.6		2,542.7
Intercompany receivables	0		0
Prepaid expenses and other current assets	583.2		766.1
Total current assets	6,541.7		7,213.3
Property, plant and equipment, net	2,119.6		2,339.1
Investments in subsidiaries	0		0
Intercompany notes and interest receivable	0		0
Intangible assets, net	14,239		15,245.8
Goodwill	9,796.6		10,205.7
Other assets	758.7		802.4
Total assets	33,455.6		35,806.3
Current liabilities:
Accounts payable	1,401.1		1,452.5
Short-term borrowings	0.4		46.5
Income taxes payable	75.7		112.9
Current portion of long-term debt and other long-term obligations	1,176.4		1,808.9
Intercompany payables	0		0
Other current liabilities	2,528.4		2,964.5
Total current liabilities	5,182		6,385.3
Long-term debt	13,291.4	$ 1,500	12,865.3
Intercompany notes payable	0		0
Other long-term obligations	2,916		3,248.1
Total liabilities	21,389.4		22,498.7
Equity [Abstract]
Total equity	12,066.2		13,307.6	13,291.6	$ 11,117.6
Total liabilities and equity	33,455.6		35,806.3
Eliminations
Current assets:
Cash and cash equivalents	0		0	0
Accounts receivable, net	0		0
Inventories	0		0
Intercompany receivables	(12,965.4)		(12,607.8)
Prepaid expenses and other current assets	0		0
Total current assets	(12,965.4)		(12,607.8)
Property, plant and equipment, net	0		0
Investments in subsidiaries	(31,768.9)		(33,419.8)
Intercompany notes and interest receivable	(20,027)		(20,280.1)
Intangible assets, net	0		0
Goodwill	0		0
Other assets	0		0
Total assets	(64,761.3)		(66,307.7)
Current liabilities:
Accounts payable	0		0
Short-term borrowings	0		0
Income taxes payable	0		0
Current portion of long-term debt and other long-term obligations	0		0
Intercompany payables	(12,965.4)		(12,607.8)
Other current liabilities	0		0
Total current liabilities	(12,965.4)		(12,607.8)
Long-term debt	0		0
Intercompany notes payable	(20,027)		(20,280.1)
Other long-term obligations	0		0
Total liabilities	(32,992.4)		(32,887.9)
Equity [Abstract]
Total equity	(31,768.9)		(33,419.8)
Total liabilities and equity	(64,761.3)		(66,307.7)
Mylan N.V.
Current assets:
Cash and cash equivalents	0		0	0
Accounts receivable, net	0		0
Inventories	0		0
Intercompany receivables	446		317.2
Prepaid expenses and other current assets	4.9		5.6
Total current assets	450.9		322.8
Property, plant and equipment, net	0		0
Investments in subsidiaries	18,939.5		19,736.5
Intercompany notes and interest receivable	6,479.2		7,822.6
Intangible assets, net	0		0
Goodwill	0		0
Other assets	0.3		4.9
Total assets	25,869.9		27,886.8
Current liabilities:
Accounts payable	0		0
Short-term borrowings	0		0
Income taxes payable	0		0
Current portion of long-term debt and other long-term obligations	1,129.3		1,097.8
Intercompany payables	875.5		664.7
Other current liabilities	138.1		35.5
Total current liabilities	2,142.9		1,798
Long-term debt	9,507.9		10,614.3
Intercompany notes payable	2,152.9		2,166.9
Other long-term obligations	0		0
Total liabilities	13,803.7		14,579.2
Equity [Abstract]
Total equity	12,066.2		13,307.6
Total liabilities and equity	25,869.9		27,886.8
Mylan Inc.
Current assets:
Cash and cash equivalents	27.1		0.2	82.2
Accounts receivable, net	5		1
Inventories	0		0
Intercompany receivables	572.8		462.1
Prepaid expenses and other current assets	67.9		171.1
Total current assets	672.8		634.4
Property, plant and equipment, net	263.7		294.1
Investments in subsidiaries	12,829.4		13,683.3
Intercompany notes and interest receivable	10,615.5		10,271.2
Intangible assets, net	0		0
Goodwill	17.1		17.1
Other assets	58.3		56.5
Total assets	24,456.8		24,956.6
Current liabilities:
Accounts payable	55.8		45.3
Short-term borrowings	0		0
Income taxes payable	4.5		0
Current portion of long-term debt and other long-term obligations	0.2		649.1
Intercompany payables	12,019.3		11,911.5
Other current liabilities	315.2		397
Total current liabilities	12,395		13,002.9
Long-term debt	3,777.8		2,244.5
Intercompany notes payable	3,127.2		3,312.7
Other long-term obligations	50.7		57.3
Total liabilities	19,350.7		18,617.4
Equity [Abstract]
Total equity	5,106.1		6,339.2
Total liabilities and equity	24,456.8		24,956.6
Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	0		0	0
Accounts receivable, net	0		0
Inventories	0		0
Intercompany receivables	0		0
Prepaid expenses and other current assets	0		0
Total current assets	0		0
Property, plant and equipment, net	0		0
Investments in subsidiaries	0		0
Intercompany notes and interest receivable	0		0
Intangible assets, net	0		0
Goodwill	0		0
Other assets	0		0
Total assets	0		0
Current liabilities:
Accounts payable	0		0
Short-term borrowings	0		0
Income taxes payable	0		0
Current portion of long-term debt and other long-term obligations	0		0
Intercompany payables	0		0
Other current liabilities	0		0
Total current liabilities	0		0
Long-term debt	0		0
Intercompany notes payable	0		0
Other long-term obligations	0		0
Total liabilities	0		0
Equity [Abstract]
Total equity	0		0
Total liabilities and equity	0		0
Non-Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	422.1		291.9	$ 532.7
Accounts receivable, net	2,943.7		3,611.4
Inventories	2,560.6		2,542.7
Intercompany receivables	11,946.6		11,828.5
Prepaid expenses and other current assets	510.4		589.4
Total current assets	18,383.4		18,863.9
Property, plant and equipment, net	1,855.9		2,045
Investments in subsidiaries	0		0
Intercompany notes and interest receivable	2,932.3		2,186.3
Intangible assets, net	14,239		15,245.8
Goodwill	9,779.5		10,188.6
Other assets	700.1		741
Total assets	47,890.2		49,270.6
Current liabilities:
Accounts payable	1,345.3		1,407.2
Short-term borrowings	0.4		46.5
Income taxes payable	71.2		112.9
Current portion of long-term debt and other long-term obligations	46.9		62
Intercompany payables	70.6		31.6
Other current liabilities	2,075.1		2,532
Total current liabilities	3,609.5		4,192.2
Long-term debt	5.7		6.5
Intercompany notes payable	14,746.9		14,800.5
Other long-term obligations	2,865.3		3,190.8
Total liabilities	21,227.4		22,190
Equity [Abstract]
Total equity	26,662.8		27,080.6
Total liabilities and equity	$ 47,890.2		$ 49,270.6

Subsidiary Guarantors Condens_4

Subsidiary Guarantors Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidating Cash Flow Statements [Line Items]
Cash and cash equivalents			$ 449.2	$ 292.1	$ 614.9
Restricted Cash and Cash Equivalents			53.9	77.8	135.9
Cash flows from operating activities:
Net cash (used in) provided by operating activities	$ 1,705.6	$ 1,569.3
Cash flows from investing activities:
Capital expenditures	(137.4)	(156.4)
Purchase of available for sale securities and other investments	(49.4)	(8.9)
Proceeds from the sale of assets	0	31.1
Proceeds from the sale of marketable securities	72.1	8.9
Cash paid for acquisitions, net	(65.9)	(71.6)
Investments in affiliates	0	0
Dividends from affiliates	0	0
Loans to affiliates	0	0
Repayments of loans from affiliates	0	0
Payments for product rights and other, net	(854.2)	(558.8)
Net cash used in investing activities	(1,034.8)	(755.7)
Cash flows from financing activities:
Payments of financing fees	(20.8)	(8.7)
Purchase of ordinary shares	(432)	0
Change in short-term borrowings, net	(45.9)	(48.3)
Proceeds from issuance of long-term debt	2,577.7	555.8
Payments of long-term debt	(2,598.6)	(1,747.3)
Proceeds from exercise of stock options	15.6	12.8
Taxes paid related to net share settlement of equity awards	(10.1)	(7.4)
Contingent consideration payments	(0.2)	(10.1)
Capital contribution from affiliates	0	0
Capital payments to affiliates	0	0
Payments on borrowings from affiliates	0	0
Proceeds from borrowings from affiliates	0	0
Other items, net	(0.4)	(0.7)
Net cash used in financing activities	(514.7)	(1,253.9)
Effect on cash of changes in exchange rates	(22.9)	44.1
Net increase (decrease) in cash, cash equivalents and restricted cash	133.2	(396.2)
Cash, cash equivalents and restricted cash — beginning of period	369.9	1,147
Cash, cash equivalents and restricted cash — end of period	503.1	750.8
Supplemental Cash Flow Elements [Abstract]
Cash, cash equivalents and restricted cash	369.9	1,147	503.1	369.9	750.8	$ 750.8
Eliminations
Condensed Consolidating Cash Flow Statements [Line Items]
Cash and cash equivalents			0	0	0
Restricted Cash and Cash Equivalents			0	0	0
Cash flows from operating activities:
Net cash (used in) provided by operating activities	0	0
Cash flows from investing activities:
Capital expenditures	0	0
Purchase of available for sale securities and other investments	0	0
Proceeds from the sale of assets		0
Proceeds from the sale of marketable securities	0	0
Cash paid for acquisitions, net	0	0
Investments in affiliates	22	21.1
Dividends from affiliates	(65.3)	(168.1)
Loans to affiliates	5,047.7	3,065.8
Repayments of loans from affiliates	(5,015.8)	(2,010.3)
Payments for product rights and other, net	0	0
Net cash used in investing activities	(11.4)	908.5
Cash flows from financing activities:
Payments of financing fees	0	0
Purchase of ordinary shares	0
Change in short-term borrowings, net	0	0
Proceeds from issuance of long-term debt	0	0
Payments of long-term debt	0	0
Proceeds from exercise of stock options	0	0
Taxes paid related to net share settlement of equity awards	0	0
Contingent consideration payments	0	0
Capital contribution from affiliates	(22)	(21.1)
Capital payments to affiliates	65.3	168.1
Payments on borrowings from affiliates	(5,047.7)	2,010.3
Proceeds from borrowings from affiliates	5,015.8	(3,065.8)
Other items, net	0	0
Net cash used in financing activities	11.4	(908.5)
Effect on cash of changes in exchange rates	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash — beginning of period	0	0
Cash, cash equivalents and restricted cash — end of period	0	0
Supplemental Cash Flow Elements [Abstract]
Cash, cash equivalents and restricted cash	0	0	0	0	0
Mylan N.V.
Condensed Consolidating Cash Flow Statements [Line Items]
Cash and cash equivalents			0	0	0
Restricted Cash and Cash Equivalents			0	0	0
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(68.6)	(175.1)
Cash flows from investing activities:
Capital expenditures	0	0
Purchase of available for sale securities and other investments	0	0
Proceeds from the sale of assets		0
Proceeds from the sale of marketable securities	0	0
Cash paid for acquisitions, net	0	(71.6)
Investments in affiliates	0	0
Dividends from affiliates	65.3	168.1
Loans to affiliates	(470.6)	(143.7)
Repayments of loans from affiliates	1,810.8	1,066.4
Payments for product rights and other, net	0	0
Net cash used in investing activities	1,405.5	1,019.2
Cash flows from financing activities:
Payments of financing fees	(0.5)	(8.3)
Purchase of ordinary shares	(432)
Change in short-term borrowings, net	0	0
Proceeds from issuance of long-term debt	496.5	554.5
Payments of long-term debt	(1,446.5)	(1,500)
Proceeds from exercise of stock options	15.6	12.8
Taxes paid related to net share settlement of equity awards	(10.1)	(7.4)
Contingent consideration payments	0	0
Capital contribution from affiliates	0	0
Capital payments to affiliates	0	0
Payments on borrowings from affiliates	1,314	0
Proceeds from borrowings from affiliates	(1,273.9)	104
Other items, net	0	0
Net cash used in financing activities	(1,336.9)	(844.4)
Effect on cash of changes in exchange rates	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash	0	(0.3)
Cash, cash equivalents and restricted cash — beginning of period	0	0.3
Cash, cash equivalents and restricted cash — end of period	0	0
Supplemental Cash Flow Elements [Abstract]
Cash, cash equivalents and restricted cash	0	0.3	0	0	0
Mylan Inc.
Condensed Consolidating Cash Flow Statements [Line Items]
Cash and cash equivalents			27.1	0.2	82.2
Restricted Cash and Cash Equivalents			0	23.6	73.1
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(1,201.6)	(338.8)
Cash flows from investing activities:
Capital expenditures	(17.8)	(31.4)
Purchase of available for sale securities and other investments	0	0
Proceeds from the sale of assets		0
Proceeds from the sale of marketable securities	36.3	0
Cash paid for acquisitions, net	0	0
Investments in affiliates	(22)	(21.1)
Dividends from affiliates	0	0
Loans to affiliates	0	(364.1)
Repayments of loans from affiliates	0	0.3
Payments for product rights and other, net	(0.4)	(0.3)
Net cash used in investing activities	(3.9)	(416.6)
Cash flows from financing activities:
Payments of financing fees	(20.2)	(0.4)
Purchase of ordinary shares	0
Change in short-term borrowings, net	0	0
Proceeds from issuance of long-term debt	2,079.2	0
Payments of long-term debt	(1,150)	0
Proceeds from exercise of stock options	0	0
Taxes paid related to net share settlement of equity awards	0	0
Contingent consideration payments	0	0
Capital contribution from affiliates	0	0
Capital payments to affiliates	0	0
Payments on borrowings from affiliates	3,309.9	(1,664.4)
Proceeds from borrowings from affiliates	(3,010.1)	2,497.5
Other items, net	0	(7.4)
Net cash used in financing activities	1,208.8	825.3
Effect on cash of changes in exchange rates	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash	3.3	69.9
Cash, cash equivalents and restricted cash — beginning of period	23.8	85.4
Cash, cash equivalents and restricted cash — end of period	27.1	155.3
Supplemental Cash Flow Elements [Abstract]
Cash, cash equivalents and restricted cash	23.8	85.4	27.1	23.8	155.3
Guarantor Subsidiaries
Condensed Consolidating Cash Flow Statements [Line Items]
Cash and cash equivalents			0	0	0
Restricted Cash and Cash Equivalents			0	0	0
Cash flows from operating activities:
Net cash (used in) provided by operating activities	0	0
Cash flows from investing activities:
Capital expenditures	0	0
Purchase of available for sale securities and other investments	0	0
Proceeds from the sale of assets		0
Proceeds from the sale of marketable securities	0	0
Cash paid for acquisitions, net	0	0
Investments in affiliates	0	0
Dividends from affiliates	0	0
Loans to affiliates	0	0
Repayments of loans from affiliates	0	0
Payments for product rights and other, net	0	0
Net cash used in investing activities	0	0
Cash flows from financing activities:
Payments of financing fees	0	0
Purchase of ordinary shares	0
Change in short-term borrowings, net	0	0
Proceeds from issuance of long-term debt	0	0
Payments of long-term debt	0	0
Proceeds from exercise of stock options	0	0
Taxes paid related to net share settlement of equity awards	0	0
Contingent consideration payments	0	0
Capital contribution from affiliates	0	0
Capital payments to affiliates	0	0
Payments on borrowings from affiliates	0	0
Proceeds from borrowings from affiliates	0	0
Other items, net	0	0
Net cash used in financing activities	0	0
Effect on cash of changes in exchange rates	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash — beginning of period	0	0
Cash, cash equivalents and restricted cash — end of period	0	0
Supplemental Cash Flow Elements [Abstract]
Cash, cash equivalents and restricted cash	0	0	0	0	0
Non-Guarantor Subsidiaries
Condensed Consolidating Cash Flow Statements [Line Items]
Cash and cash equivalents			422.1	291.9	532.7
Restricted Cash and Cash Equivalents			53.9	54.2	62.8
Cash flows from operating activities:
Net cash (used in) provided by operating activities	2,975.8	2,083.2
Cash flows from investing activities:
Capital expenditures	(119.6)	(125)
Purchase of available for sale securities and other investments	(49.4)	(8.9)
Proceeds from the sale of assets		31.1
Proceeds from the sale of marketable securities	35.8	8.9
Cash paid for acquisitions, net	(65.9)	0
Investments in affiliates	0	0
Dividends from affiliates	0	0
Loans to affiliates	(4,577.1)	(2,558)
Repayments of loans from affiliates	3,205	943.6
Payments for product rights and other, net	(853.8)	(558.5)
Net cash used in investing activities	(2,425)	(2,266.8)
Cash flows from financing activities:
Payments of financing fees	(0.1)	0
Purchase of ordinary shares	0
Change in short-term borrowings, net	(45.9)	(48.3)
Proceeds from issuance of long-term debt	2	1.3
Payments of long-term debt	(2.1)	(247.3)
Proceeds from exercise of stock options	0	0
Taxes paid related to net share settlement of equity awards	0	0
Contingent consideration payments	(0.2)	(10.1)
Capital contribution from affiliates	22	21.1
Capital payments to affiliates	(65.3)	(168.1)
Payments on borrowings from affiliates	423.8	(345.9)
Proceeds from borrowings from affiliates	(731.8)	464.3
Other items, net	(0.4)	6.7
Net cash used in financing activities	(398)	(326.3)
Effect on cash of changes in exchange rates	(22.9)	44.1
Net increase (decrease) in cash, cash equivalents and restricted cash	129.9	(465.8)
Cash, cash equivalents and restricted cash — beginning of period	346.1	1,061.3
Cash, cash equivalents and restricted cash — end of period	476	595.5
Supplemental Cash Flow Elements [Abstract]
Cash, cash equivalents and restricted cash	$ 346.1	$ 1,061.3	$ 476	$ 346.1	$ 595.5

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 80.8	$ 76.1	$ 45.4
Through fiscal year 2018 | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				$ 500
Through fiscal year 2018 | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				600
Corporate / Other
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				1
Rest of World Segment
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 2.6			$ 13.3

Restructuring (Restructuring Ch

Restructuring (Restructuring Charges) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 95.5	$ 96.2	$ 90.7	$ 95.5	$ 107
Restructuring Charges	80.8	76.1	45.4
Document Fiscal Year Focus				2,018
Payments for Restructuring	(26.8)	(39.3)	(31.5)
Restructuring and Related Cost, Incurred Cost	(54.6)	(28)	(30.8)
Restructuring Reserve, Translation and Other Adjustment	(0.1)	(3.3)	0.6
Restructuring Reserve, Current	80.9			$ 80.9	91.5
North America Segment
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	49.7			108.1
Europe Segment
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	28.5			79.9
Rest of World Segment
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	2.6			13.3
Corporate / Other
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				1
Employee Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	77.8	81.2	79.9	77.8	92.9
Restructuring Charges	16.2	35.1	15.1
Payments for Restructuring	(19.3)	(31.1)	(28.7)
Restructuring and Related Cost, Incurred Cost	0	0	0
Restructuring Reserve, Translation and Other Adjustment	(0.3)	(2.7)	0.6
Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	17.7	15	10.8	$ 17.7	$ 14.1
Restructuring Charges	64.6	41	30.3
Payments for Restructuring	(7.5)	(8.2)	(2.8)
Restructuring and Related Cost, Incurred Cost	(54.6)	(28)	(30.8)
Restructuring Reserve, Translation and Other Adjustment	$ 0.2	$ (0.6)	$ 0

Income Taxes Income Taxes Discl

Income Taxes Income Taxes Disclosure (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2018	Dec. 31, 2025
Income Tax Contingency [Line Items]
Deduction limit of GILTI tax			50.00%
Net tax provision due to enactment of the Tax Cuts and Jobs Act			$ 128.6
Expense on remeasurement of deferred taxes under Tax Act 2017			15
Transition tax expense recognized on enactment of U.S. Tax Act 2017		$ 113.6	92.3
Other Tax Expense (Benefit)	$ 21.3
Reduction in liability for Unrecognized Tax Benefits	85		85
Net Benefit to the Income Tax Provision	$ 52		$ 52
Scenario, Forecast [Member]
Income Tax Contingency [Line Items]
Deduction limit of GILTI tax				37.50%

Litigation (Lorazepam and Clora

Litigation (Lorazepam and Clorazepate) (Narrative) (Details) $ in Millions	Aug. 30, 2017USD ($)	May 30, 2012USD ($)	Jun. 01, 2005USD ($)Insurer	Sep. 30, 2018USD ($)
Loss Contingencies [Line Items]
Payments for Legal Settlements				$ 472.7
Lorazepam and Clorazepate
Loss Contingencies [Line Items]
Loss Contingency Accrual			$ 12
Judgment issued	$ 67
Payments for Legal Settlements				$ 34.5
Lorazepam and Clorazepate | Health insurers
Loss Contingencies [Line Items]
Number of plaintiffs | Insurer			4
Lorazepam and Clorazepate | Surety bond
Loss Contingencies [Line Items]
Bond		$ 66.6

Litigation (Pricing and Medicai

Litigation (Pricing and Medicaid Litigation) (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Payments for Legal Settlements	$ 472.7
Other current liabilities	2,528.4	$ 2,964.5
Pricing and Medicaid Litigation
Loss Contingencies [Line Items]
Payments for Legal Settlements	23.5
Pricing and Medicaid Litigation | Mylan Specialty | Indemnification agreement
Loss Contingencies [Line Items]
Other current liabilities	$ 42.2

Litigation (Modafinil Antitrust

Litigation (Modafinil Antitrust Litigation and FTC Inquiry) (Narrative) (Details) $ in Millions	Jul. 28, 2016	Jul. 10, 2015other_drug_manufacturers	Apr. 27, 2006other_drug_manufacturers	Apr. 30, 2018USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2018USD ($)	Dec. 14, 2016
Loss Contingencies [Line Items]
Number of states							20
Payments for Legal Settlements						$ 472.7
Modafinil Antitrust Litigation and FTC Inquiry
Loss Contingencies [Line Items]
Loss Contingency Accrual					$ 16	$ 16
Modafinil Antitrust Litigation and FTC Inquiry | Other drug manufacturers
Loss Contingencies [Line Items]
Number of defendants	4	3	4
Modafinil Antitrust Litigation Settlement [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount (Deprecated 2017-01-31)				$ 89	$ 165

Litigation (MDRP Classification

Litigation (MDRP Classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Oct. 07, 2016
Loss Contingencies [Line Items]
Payments for Legal Settlements	$ 472.7
Prepaid expenses and other current assets
Loss Contingencies [Line Items]
Loss Contingency Accrual		$ 465
Estimated litigation liability	$ 10

Litigation (Drug Pricing Matter

Litigation (Drug Pricing Matters) (Details)	Dec. 14, 2016
Loss Contingencies [Line Items]
Number of states	20

Litigation (European Commission

Litigation (European Commission Proceedings) (Narrative) (Details) € in Millions, $ in Millions	Jul. 09, 2014EUR (€)	Jun. 19, 2013EUR (€)	Dec. 31, 2014USD ($)	Dec. 31, 2017USD ($)
European Commission Proceedings - Perindorpril | Antitrust Proceedings | Mylan Laboratories Limited
Loss Contingencies [Line Items]
Damages to be paid	€ 17.2
European Commission Proceedings - Perindorpril | Antitrust Proceedings | Mylan
Loss Contingencies [Line Items]
Damages to be paid	€ 8		$ 21.7
European Union Commission Proceedings - Citalopram
Loss Contingencies [Line Items]
Damages awarded		€ 7.8
Loss Contingency Accrual | $				$ 7.4

Litigation (U.K. Competition an

Litigation (U.K. Competition and Markets Authority) (Narrative) (Details) - U.K. Competition and Markets Authority Proceedings Paroxetine £ in Millions	Feb. 12, 2016GBP (£)
Loss Contingencies [Line Items]
Damages awarded	£ 5.8
Mylan
Loss Contingencies [Line Items]
Damages awarded	£ 2.7

Litigation (Product Liability)

Litigation (Product Liability) (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Product Liability
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 9.6	$ 8.4

Litigation (Intellectual Proper

Litigation (Intellectual Property) (Narrative) (Details)	2 Months Ended	9 Months Ended
	Mar. 31, 2015patent	Sep. 30, 2018increase
Loss Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number | patent	3
Intellectual Property
Loss Contingencies [Line Items]
Number of times damages may be increased in cases of willful infringement | increase		3

Litigation (Other Litigation) (

Litigation (Other Litigation) (Narrative) (Details) $ in Millions	Sep. 30, 2018USD ($)
Other Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 5